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ABSTRACT OF DISSERTATION

NOVEL ROLE OF PROSTATE APOPTOSIS RESPONSE-4 TUMOR SUPPRESSOR
IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic Lymphocytic Leukemia (CLL) is defined by the accumulation of clonally
expanded CD5+ and CD19+ B lymphocytes in blood and secondary lymphoid organs with
impaired apoptotic mechanisms. CLL represents one third of all leukemia cases with an average
age of 72 years at diagnosis making it the most common adult leukemia. The Eµ-Tcl1 mouse
serves as an excellent model to study the development of CLL as they progress to a CLL like
disease by 9-14 months of age, due to overexpression of an oncogene, T cell Leukemia 1(Tcl1),
specifically in B cells through the Ig VH promoter and Eµ enhancer (Bichi et al. PNAS. 2002). In an
adoptive transfer model, intravenous or intraperitoneal injection of primary CD5+CD19+ CLL
cells from the Eµ-Tcl1 CLL mouse into recipient syngeneic mice leads to the development of a
CLL like disease within 3-8 weeks of transfer. We have characterized the growth of CLL cells in
these mice by periodic submandibular bleeding, spleen ultrasonography and flow cytometry.
We find that Eµ-Tcl1 CLL cells express more Prostate apoptosis response-4 protein (Par-4), a
known pro-apoptotic tumor suppressor protein, than normal B-1 or B-2 cells in mice. Par-4 is
silenced by promoter methylation in more than 30% of all cancers and has been shown to be
secreted and to induce apoptosis selectively in various types of cancer cells but not in normal
cells. We found that CLL cells have constitutively active B-cell receptor signaling (BCR) and that
inhibition of BCR signaling with FDA approved drugs causes a decrease in Par-4 protein, mRNA
levels, and an increase in apoptosis. In particular, activities of Src family kinases, spleen tyrosine
kinase and Bruton’s tyrosine kinase are required for Par-4 expression in CLL cells, suggesting a
novel regulation of Par-4 through BCR signaling in both Eµ-Tcl1 CLL cells and primary human
CLLsamples. Consistent with this, lenti-viral shRNA mediated knockdown of Lyn kinase leads to a
decrease in Par-4 expression in MEC-1 cells, a human CLL derived cell line. Igα (CD79a) silencing
in primary human CLL cells also results in down regulation of Par-4 expression. Additionally, we
knocked down expression of Par-4 in MEC-1 cells which resulted in a decrease in cell growth
that could be attributed to an increase in p21 expression and a reduction in the G1/S cell cycle
transition. We have also observed this phenomenon by crossing mice deficient in Par-4 with the
Eµ-Tcl1 mouse where lack of Par-4 delays CLL growth in the mouse significantly (time to
euthanization due to poor body condition - Eµ-Tcl1: 8.9mo vs Par4-/-EµTcl1: 11.97 mo, p =
0.0472) and splenic B-CLL cells from these mice also have increased expression of p21. Since

mice in this cohort are whole body knockout for Par-4, the difference in survival times
between the Par-4 +ve and Par-4 –ve EµTcl1 mice could be due to the influence of Par-4 on CLL
cells as well as the effect of Par-4 secreted by the CLL cells on the microenvironment. There
could be other potential roles for Par-4 in the context of CLL which are under further
investigation. We have also investigated the site of CLL growth in mouse models to determine
that the spleen is the primary organ to accumulate the CLL tumor burden. We have found that
splenectomy significantly delays the development of CLL in the primary Eμ-Tcl1 mouse model
and prevents growth and development in the adoptive transfer model. Interestingly,
splenectomy did not delay CLL development as significantly in animals deficient for Par-4
compared to C57BL/6 wild type mice. Par-4 appears to regulate a specific microenvironment
required for CLL growth. Current studies are investigating the role of Par-4 in the
microenvironment and the cell types that are critical for CLL growth within the splenic niche.
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CHAPTER 1
Introduction
Cancer is defined as the abnormal growth of cells that have the ability to spread into
surrounding tissues of the body[1]. It is a very heterogeneous disease with over 100 different
types of cancers currently defined; some forming solid tumors and others derived from the
blood, known as leukemias. Cancer is one of the leading causes of death worldwide and it is
projected that from 2012 to 2030 cancer incidence will increase 50% with 22 million new cancer
cases diagnosed [2]. This increase will lead to approximately 40% of the population being
diagnosed with cancer during their lifetime and attribute to nearly 1 in 6 deaths [3]. In the
United States, the overall cancer rate has declined in last several years but it is estimated that in
2017 there will still be 1,688,780 new cancer cases diagnosed [4]. While dramatic progress has
been made over the last few decades in cancer research, these numbers are still astronomical
and continue to support the need for innovative new research in cancer biology.
Since 1960, the number of cancer related articles that are available on the NCBI PubMed
data base has grown significantly each decade indicating the increased research efforts to
further understand this disease. More peer reviewed articles have focused on cancer research
which in turn is helping to decrease cancer related deaths in the United States as reported by
the NCI SEER database (Figure 1.1)[2]. While cancer mortality has decreased, the American
Cancer Society predicts that about 1,650 people will die per day in 2017 due to cancer, making it
an incurable disease [5].
Extensive research has allowed us to understand the mechanisms that underlie the
development of cancer which led to definition of the now famous “six hallmarks of cancer” by
Hanahan and Weinberg. These include 1)sustaining proliferative signaling 2)evading growth
suppressors 3) activating invasion and metastasis 4) enabling replicative immortality 5) inducing
1

angiogenesis and 6) resisting cell death [6]. With the addition of two emerging hallmarks that
include the reprogramming of energy metabolism and immune evasion, these acquired
biological functions allow for the persistence of malignant cells and metastasis[7]. Furthermore,
the tumor microenvironment has been found to play a role in sustaining the growth of both
solid tumors and hematological malignancies which introduces other supportive factors that
provide survival signals for cancer cells [8, 9]. All cancers have the hallmarks of self-replication
and avoidance of cell death mechanisms, or apoptosis, which leads to an increased tumor
burden. Specifically, Chronic Lymphocytic Leukemia (CLL) is characterized to have a defect in
apoptosis that facilitates the accumulation of malignant cells in the secondary lymphoid organs
and peripheral blood. This dissertation will focus on understanding the survival pathways
supporting CLL and specific regulatory proteins, such as Prostate Apoptosis Response-4 (Par-4)
that we have found to promote the growth of this malignancy.
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Figure 1.1: Number of cancer related articles published and cancer mortality in the
United States. Article values generated through PubMed search via “cancer” for each
decade (Left Y-axis). Number of cancer related deaths per 100,000 reported in SEER
database per year (Right Y-axis).
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1.1 B cells and B cell Malignancies
1.1a Normal B cells
A B cell is a type of lymphocyte that is derived from a hematopoietic precursor in the
bone marrow [10]. B cells function primarily within the adaptive immune system, specifically
humoral immunity, to secrete antibodies and present antigen to other effector cells such as T
cells in order to provide protection against infectious agents. B cells develop from stem cells
within the adult bone marrow, but are also derived from fetal liver precursors within the
embryo [11]. B cells can be subdivided into two populations known as B1 and B2 cells. B1 cells
are unique and thought to mainly play a role in the innate immune system by producing
immunoglobulins (primarily IgM) that recognize self-antigen and are therefore self-reactive,
although they also recognize evolutionarily conserved epitopes on pathogens [12]. B1 cells can
be classified into two subgroups based on surface marker expression: B1-a are defined as IgM+
CD11b+ CD5+ and B1-b are defined as IgM+CD11b+CD5- [13]. B1 cells were first described in
mice around 1983 by the Herzenberg group and originally called Ly-1 B cells based on the
expression of CD5, a pan T cell marker [14]. B1 cells are abundantly located in the peritoneal
cavity of mice making up nearly 70% of the B cell population [15, 16]. In humans, B1 cells are
more prominently found in the tonsils, mucosal sites, and pleural cavity [17]. B1 cells are
thought to derive from the fetal liver providing evidence for the “layered immune system” or
“lineage hypothesis” suggested by Herzenberg et al. This hypothesis suggests that B1 and B2
cells are from separate lineages derived from different time points in development [18]. The
more conventional B2 cells originate from the bone marrow and then migrate to secondary
lymphoid organs such as the lymph node and spleen, where they complete maturation. Within
the bone marrow, B cell development is tightly regulated with the functional rearrangement of
the immunoglobulin gene segments [19]. During this stage of development, B cells begin to
3

express a κ or λ light chain associated with the μ heavy chain to make up the B cell receptor
(BCR) and express surface IgM; they then begin to egress from the bone marrow as immature B
cells. If these cells come in contact with antigen during the immature state, the B cell undergoes
anergy and apoptosis (clonal deletion) rather than clonal expansion. It is important for B cells to
express an additional immunoglobulin, IgD, on the surface of their membrane to become
mature as they progress through a transitional state in the spleen. Depending on the strength
of BCR derived signals, B cells become either marginal zone (MZ) or follicular (FO) B cells. Once
MZ B cells come in contact with antigen, these cells develop into short lived plasma cells that
secrete antibody in order to neutralize the pathogen. Follicular B cells form germinal centers
with T helper cells that result in B cells becoming memory B cells or plasma cells as they undergo
somatic hypermutation and class switching, but may also participate in an extrafollicular
response that does not involve somatic hypermutation [20]. B cells are reliant on tonic signals
through the BCR for their survival in the periphery [21]. These steps are strictly controlled in
order for B cell activation to occur correctly and to generate a primary or secondary immune
responses. If B cell development is dysregulated during VDJ rearrangement or if B cells escape
self-antigen recognition and clonal deletion, autoimmunity may develop resulting in
overproduction of auto-antibody secretion. Additionally, if dysregulation occurs during gene
arrangement resulting in chromosomal translocations, oncogenic transformations may occur
and therefore lead to the development of B cell malignancies [22].
1.1b B Cell Malignancies
B cell malignancies encompass both lymphomas and leukemia. Lymphoma is a cancer of
white blood cells that develops in the lymphatic system and is the 7th most common cancer in
the US [23]. There are two primary types of lymphoma classified as Hodgkin’s (HL) and nonHodgkin’s lymphoma (NHL). Hodgkin’s lymphoma is characterized by large abnormal Reed4

Sternberg cells that accumulate in the lymph nodes and is one of the most curable forms of
cancer with more than 75% of cases entering remission after chemotherapy and radiation[24].
There are over 30 different subtypes of NHL that originate from B, T, and NK cells but 85% of
NHL is B cell in origin [25]. NHL is considered a very aggressive disease or slow growing,
depending on the subtype. Diffuse large B cell lymphomas (DLBCL) account for about 60% of
NHL and are aggressive in nature while follicular lymphomas are more indolent and slow
progressing. Some of these subtypes can be classified according to chromosomal translocations
that potentially result in enhanced expression of proliferative and survival genes under the
control of the Ig loci regulatory regions. For example, mantle cell lymphoma (MCL) results from
a translocation between chromosomes 11 and 14 allowing for overexpression of cyclin D1, a cell
cycle regulator, by being brought under the control of the IgH promoter [22].
According to the SEER database, leukemia is the 9th most common cancer in the US and
contributed to 4.1% of all reported cancer deaths [23]. The word leukemia originated in the mid19th century from the Greek words “leukos” (≈white) and “haima” (≈blood), further designating
an accumulation of white blood cells [26]. As a cancer of the blood, abnormal leukemic cells
accumulate and do not die, suppress the function of normal immune cells, and eventually out
populate other hematopoietic cell types resulting in anemia. Leukemia may be classified as
chronic (slow progression of mature cells) or acute (rapid growth of primarily immature cells)
and can affect both the myeloid or lymphoid white blood cells. Patients that are diagnosed with
acute leukemia will normally start treatment as soon as possible while patients with chronic
leukemia may be placed under a “watch and wait” status until symptoms progress. Subtypes of
leukemia include: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL),
Acute Myelogenous Leukemia (AML), and Chronic Myelogenous Leukemia (CML). Both AML and
CML are more common in adults than children and have distinct cytogenetic abnormalities,
5

especially the aberration noted in CML known as the Philadelphia Chromosome. Many CML
patients respond well to imatinib, a small molecule targeting the kinase resulting from fusion of
the BCR/ABL genes located on the Philadelphia chromosome [27]. Patients with AML have
almost a 70% chance to attain a complete response after chemotherapy treatment with a
traditional regimen of cytarabine and anthracycline [28]. ALL is more commonly seen in children
and young adults. Recent advances in treatment have led to nearly a 98% remission rate and an
overall 5-year survival of 90% in ALL patients [29, 30]. CLL is the most common adult leukemia in
the Western world and like all leukemia, patients are grouped into fast or slow progressing
disease based on prognostic indicators. Many patients with CLL may live a relatively normal life
without symptoms, while others may only survive months to years after diagnosis or treatment
initiation. Patients with CLL do have an 82% 5-year survival rate but experts in the field classify
CLL as incurable [31].
1.2 Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is defined by the accumulation of clonally
expanded CD5+ CD19+ B lymphocytes with impaired apoptotic mechanisms in the blood, bone
marrow, and secondary lymphoid organs [32]. In 2017, it is estimated that there will be 20,110
newly diagnosed cases of CLL leading to 4,660 deaths in the United States [31]. According the
national SEER database, CLL contributes to 1.2% of all new cancer cases but of the over 3.5
million cancer articles available on PubMed, only 0.6% are related to CLL (Figure 1.2A) further
substantiating the need to better understand the mechanisms of this disease to serve the
population of patients. Additionally, it is predicted that 4.7people per 100,000 will be diagnosed
with CLL per year (Figure 1.2B) with an estimated 1.3 deaths per 100,000[23].
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Figure 1.2: Comparing the number of new CLL cases in the US to the number of total
articles published on PubMed covering CLL. A) Left: CLL represents 1.2% of all new
cancer cases diagnosed in the US as reported to the NIH SEER registry. Right: CLL
publications only comprise 0.63% of the total 3.5 million cancer articles available on
PubMed. Values obtained by “Leukemia” and “Chronic Lymphocytic Leukemia” searches
on PubMed. B) Number of new cases of CLL reported per 100,000 people is 4.7 per year.
Adapted from SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia. National Cancer
Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/clyl.html

The median age of diagnosis for CLL is 72, primarily affecting the older population and very
rarely seen in patients under the age of 40 [31]. The incidence in men is almost twice that as
observed in women[33]. CLL is classified within the Non-Hodgkin’s Lymphoma family of
diseases. Leukemia is primarily characterized by an increase in the absolute lymphocyte count in
the peripheral blood with ≥ 5000 lymphocytes per microliter of blood, and in many cases CLL is
diagnosed through incidental blood counts [32]. Immunophenotyping is required to successfully
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diagnose CLL to distinguish it from other unknown lymphocytosis or different types of
lymphomas. Specifically, CLL cells are a distinct population of B cells which express CD19, CD20lo,
CD5, CD23 and low levels of surface IgM/IgD molecules, as well as a clonal light chain restriction
(kappa or lambda) [34]. These cell number requirements and surface markers help distinguish
CLL cells from related diseases such as small lymphocytic lymphoma (SLL), B-cell prolymphocytic
leukemia (PLL), monoclonal B cell lymphocytosis (MBL), and various B cell lymphomas such as
Marginal Zone Lymphoma that also express CD5 (MZL).
CLL is a highly heterogeneous disease in terms of clinical course as some patients may
live decades past initial diagnosis and likely die from other complications such as infections,
while others may progress more rapidly. This heterogeneity can be attributed to mutations
found within the variable gene segments of the BCR [35]. CLL can be classified into mutated (MCLL) and un-mutated (U-CLL) forms, the latter resulting in increased BCR signaling, more
aggressive disease, and worse prognosis. This BCR signaling pathway is a desirable target as it is
required for the survival of malignant B cells and is constitutively activated in many CLL cases
[36, 37]. Additionally, the microenvironment has been found to play a key role in promoting the
growth of B cell malignancies, including CLL, by providing proliferative signals and promoting
drug resistance [9, 38]. BCR signaling and microenvironment make CLL a very complex disease to
study and treat but also allows for new targets to be explored for therapeutic potential.
1.2a History, Staging, and Etiology
Leukemia was first described by Rudolph Virchow in 1845 after a 50-year old cook
presented with an enlarged spleen and “pigmented to colourless corpuscles” found in her blood
[39]. Chronic lymphocytic leukemia was not characterized until 1903 by Turk who differentiated
CLL from lymphosarcoma [40] and in 1924, Minot and Issacs characterized the clinical features
of CLL predicting a median survival time of 40 months post diagnosis [41]. In the mid-1970s
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Galton and Dameshek defined CLL as a disease of progressive accumulation of lymphocytes that
are not rapidly proliferating and are functionally inert [42]. This definition has been refined since
then as Hamblin et al. discovered the mutational status of the Ig variable region genes to play a
prognostic role in classifying aggressive and indolent CLL cases [43]. Some patients may remain
symptom free for the majority of their disease while others may experience fatigue, weight loss,
night sweats, abdominal fullness, increased frequency of infections, anemia, or
thrombocytopenia [44]. Additionally, aggressive disease may result in enlarged lymph nodes,
splenomegaly, and hepatomegaly. Two types of disease staging are accepted in the medical field
including the Rai System and Binet System. A summary of the staging is provided in Table 1 [4547].
Table 1: Staging of CLL.

Two classifications used include Rai (typically used in US) and Binet (Europe).
Information adapted from Rai et. al. 1975, Binet et. al. 1981, and Hallek et. al. 2008. (Hb
indicates hemoglobin, normal levels are 13.8-17.2g/dL)
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The etiology of CLL is not precisely known, but genetic factors are thought to contribute
to the development of disease as 9% of patients with CLL also have a diagnosed relative [48]. It
is important to note that multiple genome wide association studies (GWAS) have identified
various single nucleotide polymorphisms (SNPs) within loci that are associated with heritable
CLL risk [49]. Many of the biological pathways associated with the SNPs involve apoptosis and
enhance the resistance to cell death [50]. SNPs and chromosomal deletions are common among
CLL cases even though the genome is considered relatively stable in CLL compared to other
cancers [51]. Some identified mutations have been excellent prognostic indicators; for example,
deletion of 13q14 is a frequent genetic aberration that is associated with a more favorable
outcome in patients but it is also the site of microRNAs 15a and 16-1 that work to suppress ZAP70 and Bcl-2 [48, 52]. Some of the more frequent chromosome abnormalities include Trisomy
12, 13q deletion, 13q14 translocation, 17p deletion, and 11q22/23 band deletions [34]. In a
study examining 325 cases of CLL, 82% of patients had detectable chromosomal aberrations,
some of which led to worse prognosis and decreased median survival times (Figure 1.3) [53]. On
average, patients with the 17p deletion only live 32 months past their point of diagnosis making
it a very aggressive disease with splenomegaly and extensive lymphoadenopathy. The 17p
deletion is associated with loss of the tumor suppressor p53 in CLL and other lymphoid
malignancies [54]. p53 is well-known for its role as guardian of the genome by its ability to
regulate cell cycle, and its loss in CLL cases leads to rapid disease progression [55]. Patients with
loss of 11q are associated with defects in the ATM (ataxia telangiectasia mutated) gene which is
a key kinase that is recruited to recognize DNA double strand breaks in order to repair damage
[56]. The addition of chromosome 12 is the third most common genetic aberration in CLL and
has been linked to a variety of genetic irregularities [51]. A recent GWAS study also identified
multiple loci aberrations in CLL compared to other B cell malignancies, including multiple
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myeloma and Hodgkin’s Lymphoma, and found pleiotropic associations at 3q22.2. This region is
associated with T cell activation and the PI3K/Akt pathway. Additional polymorphisms were
identified in HLA regions that are critical for antigen presentation and T cell receptor binding
[57]. There are currently 33 common loci genetic variations that influence the risk of CLL
development but with the recent GWAS studies, more are being identified that include SNPs
involved in B cell immune response and signaling[58].

Figure 1.3 Adapted from Dohner et. al. 2008, NEJM 344(26): 1910-1916, Figure 1 with
permission: Survival of patients with various cytogenetic abnormalities. 17p deletion is
the most aggressive aberration resulting in a decreased life expectancy comparted to
other mutations. Reproduced with permission from New England Journal of Medicine,
Copyright Massachusetts Medical Society.
Next generation sequencing has revealed alterations in the NOTCH1, SF3B1, and BIRC3
genes along with the previously known alteration in the ATM gene associated with the 11q22
deletion [59]. NOTCH signaling is constitutively activated in CLL cells compared to normal B cells,
leading to apoptosis resistance [60]. NOTCH is a cell surface receptor that responds to Delta-like
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and Jagged ligands leading to nuclear translocation of an intracellular subunit that regulates
DNA binding proteins and transcriptional complexes [61]. This pathway is known to regulate cell
proliferation, differentiation and some mechanisms of cell death. In CLL, NOTCH has been found
to promote the expression of Mcl-1, an anti-apoptotic protein, leading to increased CLL survival
[62]. NOTCH overexpression is associated an intermediate survival risk and is also found to be
expressed in unmutated IGHV patients with trisomy 12 [63, 64]. SF3B1, which encodes a
component of the spliceosome that plays a key role in pre-mRNA splicing [65], has been found
to be associated with intermediate risk patients and 11q deletions [63]. Loss of BIRC3, located
within the 11q deleted region, is linked to high risk patients [66]. BIRC3 negatively regulates NFκB and loss of BIRC3 is very common in patients that are refractory to chemotherapy treatments
[63, 67]. Many of these mutations are associated with a shorter time to treatment and used as
prognostic indicators [68].
Interestingly, other than age and gender, no other lifestyle or dietary factors have been
associated with the increased incidence of CLL. Of note, a few studies found that exposure to
Agent Orange and insecticides increased the risk of developing CLL [48, 69, 70].
1.2b Cell of Origin
Even with the incredible discoveries made in the field of Chronic Lymphocytic Leukemia
over the last few decades, the cellular origin of the disease is still debated today. CLL cells
distinctively express CD19, CD5, CD23, as well as surface Ig molecules [71]. CD19 is a surface
antigen that is expressed on both normal and neoplastic B cells and is critical for intrinsic B cell
signaling through BCR interactions as well as BCR independent signaling [72]. CD5 is also a cell
surface molecule that is expressed on thymocytes, mature T cells, and differentiates B1 cells
from the conventional B2 population [73]. Previous studies have also indicated that CD5 is found
on some activated human B cells that are autoreactive [74]. CD5 is thought to be a negative
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regulator to mitigate signaling in order to prevent over activation of signaling downstream of
the TCR or BCR [75]. CD23 is a reliable marker for CLL cells to differentiate between other
lymphomas that also express CD5 (mantle cell lymphomas). CD23 is an IgE receptor that is
normally expressed on mature resting B cells and some activated B cells [76].
The co-expression of low IgM and IgD levels on the surface of CLL cells originally
suggested that these cells arise from naïve antigen-inexperienced B cells [77]. After Hamblin and
colleagues classified CLL into two subgroups, M-CLL and U-CLL defined by mutations in the
variable gene segments of the BCR indicating that 50-60% of CLL cells had undergone somatic
hypermutation (M-CLL), hypotheses arose that CLL cells are derived from two cellular origins
[43, 78]. Seifert and colleagues suggest that U-CLL cells are derived from unmutated mature
CD5+ B cells as their IgV sequence is less than 2% different from germline, whereas M-CLL cells
are derived from a distinct CD5+CD27+ post germinal center B cell [79]. An additional study
investigating phenotypic markers found that CLL cells express more of an activated state
(CD69+CD25+CD71+) independent of their Ig mutational status when compared to normal CD5+
B cells in humans, suggesting that CLL cells are mature antigen experienced cells [77]. Antigen
experienced cells can be derived from cells that undergo somatic hypermutation within a
germinal center but may also develop in a T cell-independent manner which may account for
CLL cells that have unmutated Ig variable regions [78, 80]. Further support for antigen
experienced B cells to be CLL precursors comes from studies that have examined the BCR
repertoire in multiple CLL samples. It is well accepted that CLL cells have constitutive BCR
signaling, but CLL cells also respond to antigen [81, 82]. Recent studies have found that 30% of
BCR immunoglobulins within the CLL patient population are quasi-identical resulting in a
stereotypy of BCRs [81, 83, 84]. This indicates that these malignant B cells from unrelated
patients recognize similar antigens suggesting that are a few common epitopes which activate
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CLL cells. Not many antigens have been identified to stimulate CLL cells, but one potential
candidate is non-muscle myosin heavy chain IIA which is an intracellular protein that interacts
with actin to provide cellular movement and therefore is considered a self-antigen [85]. This is
interesting as B1 cells are thought to be self-reactive and respond to autoantigens supporting
the idea that CLL cells are derived from B1 cells[78].
B1 cells are primarily found within the peritoneal cavity of mice but are also present in
the spleen, albeit at a lower level [16]. As mentioned before, B1 cells express self-reactive BCRs
but respond poorly to BCR cross-linking to prevent against self-activation that is suggested to be
mediated through CD5 [75, 86]. B1 B cells also express restricted BCRs with a predominance of
VH12 promoting B1 phenotype [87] and are known to produce antibody quickly in response to
infection, primarily IgM, independent of T cell help (similar to U-CLL) [88]. Additionally, B1 cells
are divided into B1a (CD5+) and B1b (CD5-)subsets where B1a cells are the primary source of
natural IgM production and B1b cells respond to antigen in mice [16, 89, 90]. It has been
suggested that B1a cells serve as the normal counterpart for CLL cells. Adoptive transfer studies
of young/early B1a populations into immunocompromised recipient mice led to development of
CLL like disease [91]. CLL development in this study was independent of oncogene expression
but a follow-up study was able to confirm that early B1a cells expressing the oncogene, Tcl1,
also led to the development of CLL in recipient mice [92]. These authors did note that not all B1a
cells result in CLL development, but were restricted to specific BCRs that were later identified in
promoting CLL growth [91, 92]. Additional studies favoring the B1a population serving as CLL
normal counterpart provide evidence that both B1a cells and CLL cells secrete significant
amounts of the cytokine Interleukin-10 that works to suppress the immune response [86].
Controversy regarding the normal counterpart of CLL has been focused on the inability
to identify a human B1 population that is similar to mouse B1 cells [93]. Recently, reverse
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engineering has allowed researchers to identify a human B1 cell population within the umbilical
cord blood and adult peripheral blood [94]. Rothstein et al summarized evidence showing that
mouse and human B1 cells share similar phenotypes and also express autoreactive antibodies
that protect against infections. Seifert and colleagues compared normal CD5+ B cells from
healthy human donors with both populations of CLL cells, M-CLL and U-CLL, and confirmed that
CD5+ B cells are the normal B cell subset that are most similar to CLL [79].
Besides B1 cells, other hypotheses for the CLL precursor include marginal zone B cells as
well as immature pre-B cells and transitional B cells [35, 93]. While the data indicating CD5+ B
cells is strong in supporting the normal counterpart of CLL, it is important to keep these other
origins in mind as CLL cells may arise from different cell populations based on their BCR
repertoire.
Recently, a case report involving a 65y male with stage IV CLL identified a “Side
Population” of CLL cells identified through flow cytometry that were proposed to be precursors
to leukemic development [95]. Ablation of these cells through vaccination after CD40L
stimulation diminished the bulk of the disease 12months after treatment. The “side population”
of cells were CD5 and CD19 positive and thought to be similar to the cancer stem cell population
characterized in other types of tumor models [96]. True identification of this “side population”
would be of great benefit to determine if the likely B1 cells give rise to the malignant
counterpart.
1.2c B cell receptor and signaling
For normal B cells to be functionally active in an immune response, their BCR must
recognize a specific antigen for BCR cross-linking to occur and differentiation to antibody
secreting plasma cells or memory B cells [20]. With the millions of potential antigens that
initiate an immune response, the B cell must have a large repertoire of BCR sequences to
15

recognize most of the possible different epitopes. Each B cell clone that is generated has a
unique B cell receptor but the diversity between clones is spectacular. Diversity is generated
through somatic recombination of the variable gene segments, random recombination of VDJ
joining, and combination of light and heavy chains for maturation of the BCR followed by
somatic hypermutation during the course of the immune response [10]. The two different CLL
subsets, M-CLL and U-CLL, are defined by mutations found within the variable gene segments
that compose the Ig molecules that comprise up the B cell receptor.
The entire BCR complex is made of the surface Ig molecule and the signaling Igα
(CD79A) and Igβ (CD79B) heterodimer that conduct cytoplasmic downstream signaling and
other co-receptors like CD19 [97]. The BCR is critical for the survival of both normal and
malignant B cells despite their oncogenic transformation [21, 36, 98]. B cells can receive both
tonic (no external signal) and antigen dependent signaling that initiates phosphorylation of
ITAM motifs located on Igα/β heterodimer by the Src Family Kinase (SFK) Lyn. This creates a
scaffold for other kinases such as Syk (spleen tyrosine kinase) to become activated and promote
downstream signaling [99]. Syk then triggers activation of multiple kinases such as BTK (Bruton
tyrosine kinase), AKT (Protein Kinase B), PI3K (Phosphoinositide 3-kinase), other protein kinases
shown in Figure 1.4 as well as PLCγ2 (Phospholipase C 2), BLNK (B cell linker protein) that
promote NF-κB and MAPK signaling for survival and proliferation [100, 101].
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Figure 1.4: BCR signaling in CLL. Simplified model of the BCR signaling pathway in CLL
cells and key kinases involved in downstream pathways that promote survival and
proliferation. Adapted from Hallek, M. Blood. 2013 88(9): 803-816.
The two subsets of IGHV mutational status in CLL are also associated with varying levels
of BCR signaling, with U-CLL cells having higher levels of BCR activation compared to M-CLL
[102]. Mutational status has also been associated with ZAP-70 expression. ZAP-70, a protein
tyrosine kinase that is involved in signaling downstream of the T cell receptor, is more highly
expressed and is associated with enhanced signaling in U-CLL [35, 103]. The BCR pathway
provides the survival signals necessary for CLL but also provides multiple potential therapeutic
targets for disease treatment.
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Lyn:
The Src Family Kinases (SFK) play an important role in BCR signaling. These proteins
contain specific domains characterizing them as SFKs, including SH1, SH2, SH3, and SH4 motifs
[104]. Most important are the SH2 and the catalytic SH3 domains that regulate activation
through binding and phosphorylation of the ITAMs (immunoreceptor tyrosine based activation
motifs) on Igα/β of the BCR complex. Multiple members of the SFKs include Lyn, Fgr, Lck, Blk,
Fyn, Hck, Yes, and Src but Lyn is known to be the primary SFK in B cells [104]. There are two
alternately spliced forms of Lyn resulting in 53kDa and 56kDa protein isoforms [105]. Lyn is a
complex kinase known to have paradoxical roles as both a positive and negative regulator of
signaling [106]. In addition to recruitment and activation of Syk in BCR signaling, Lyn mediates
phosphorylation of the co-receptor, CD19, promotes activation of PI3K dependent signaling such
as AKT activation. Conversely, Lyn is also known to phosphorylate the co-receptor CD22 that
recruits SHP-1, a phosphatase that attenuates BCR signaling [104]. B cells from Lyn-/- mice are
found to be hyper-responsive and autoreactive suggesting the important role of Lyn in negative
regulation of B cells [101]. Lyn is also known to phosphorylate FCγR [107], CD5 [108], and other
negative regulators of BCR signaling [106].
In CLL, Lyn is found to be highly overexpressed at the protein level with increased basal
activity compared to normal B cells [109]. Contri and colleagues found that Lyn activition is not
increased with BCR cross-linking which is thought to be due to the increased basal activity of Lyn
present in the CLL cells. However, inhibition of Lyn decreased survival of leukemic cells. In 2013,
Wang et al investigated 92 patients with CLL to determine if expression levels of kinases
involved in the BCR signaling cascade correlated with patient prognosis, treatment response and
survival. Results suggested that mRNA levels of all the kinases involved in proximal BCR signaling
were elevated but Lyn expression was further increased in patients that were being treated and
resulted in decreased treatment free survival [110, 111]. The increased Lyn activity in CLL cases
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could be a contributing factor to the tonic BCR signaling in CLL cells as Lyn is the first kinase
immediately downstream of the BCR and also responsible for the prolonged survival of leukemic
cells as it inhibits apoptosis [37, 109]. Additionally, Lyn has been shown to provide survival
signals within the CLL microenvironment [112]. One study transferred CLL cells into mice that
are null for Lyn expression and found that disease developed at a slower rate compared to WT
animals. The lack of Lyn provided by macrophages in the microenvironment impaired CLL cell
expansion suggesting that this kinase has multiple functions in CLL [113]
Data indicating Lyn as a key proponent in CLL pathogenesis has led to the development
of targeted inhibitors. Drugs such as PP2 and SU6656 that target the activity of SFKs result in
down regulation of phospho-src and inhibition of Lyn expression in B cell lymphomas and CLL
[109, 114, 115]. Dasatinib, an approved FDA drug targeting the activity of all SFKs, has also
shown potential as a therapeutic option for CLL patients [116, 117].
Syk:
Spleen Tyrosine Kinase (Syk) is essential in BCR signaling, leading to intracellular calcium
flux and activation of downstream signaling cascades [118]. Animals that lack Syk exhibit
embryonic hemorrhage and perinatal lethality but also have impaired B cell development at the
pre- B cell level [101]. Syk is a 72kDa protein that can bind to phosphorylated ITAMs to provide a
scaffold for other kinases involved in the pathway and is also activated by the upstream kinase,
Lyn. Syk couples BCR activation to downstream signaling by activating BTK and PLCγ2. Activation
of these kinases enhances the survival of B-cells by promoting DAG, AKT and Mcl1 [118, 119].
Syk is also involved in pathways independent of the BCR in normal and malignant cells such as
cellular adhesion and vascular development [120, 121].
In CLL, Syk is found to have elevated constitutive activity that promotes cell survival
through the BCR pathway and is associated slightly more with unmutated status of the IGHV
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region [119]. Elevated Syk activation is also associated with CD38 positivity in CLL cells [122].
CD38 is a transmembrane glycoprotein that promotes intracellular calcium signaling and cell-cell
adhesion. Expression of CD38 on CLL cells is also a prognostic indicator of aggressive disease in
patients [35, 71]. Benkisser-Petersen et al. found that CD38 expressing cells had elevated Syk
activity and treatment with R406, a Syk inhibitor and active metabolite of Fostamatinib,
decreased CD38 mediated migration and CLL cell survival. Studies examining the regulation of
Syk activity in CLL cells after CD40L stimulation discovered that Syk inhibition prevented the
anti-apoptotic signals mediated through T helper cells via CD40L [123]. Syk inhibition has also
been found to block the cross-talk between CLL cells and stromal cells independent of BCR
signaling inhibition, making this kinase a promising therapeutic target [124]. Currently,
Fostamatinib is the only FDA approved drug targeting Syk in CLL and other B cell malignancies
and its objective response rate is a promising 55% [37].
BTK:
Bruton’s tyrosine kinase (BTK), a 77kDa protein that is a member of the Tec family of
kinases, is primarily expressed in B cells [125]. Patients with X-linked agammaglobulinemia lack
peripheral blood B cells due to a defect in BTK function, confirming the importance of this kinase
in B cell development and survival [37]. BTK is important in B cell development at the transition
between pre-B cell to immature B cell suggesting it may have a role in the signaling required for
Ig light chain arrangement [126]. BTK is also important in mature B cells as BCR activation
promotes PLCγ2 phosphorylation leading to calcium mobilization, NF-κB and MAPK signaling.
Additionally, BTK has also been found to amplify the PI3K/AKT pathway in B cells [127]. BTK
signaling has also been shown to promote B cell migration through chemokine receptors and
adhesion molecules playing an important role in tissue homing.
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In CLL, BTK is found to be over-expressed and shown to be a promising target for
therapy as it is involved in tonic BCR signaling [128]. Ibrutinib is the most notable inhibitor in
that it irreversibly binds to the active site of BTK and results in decreased NF-κB activity [101]. In
vivo, Ibrutinib treatment has been very successful with a 54% overall response rate. Ibrutinib
has been known to cause lymphocytosis of CLL cells or egress of cells from nodal compartments
suggesting that treatment also blocks the homing capacity of CLL cells [129]. Ibrutinib treatment
is the most promising FDA approved therapy for patients with aggressive disease, such as cases
with the 17p deletion that otherwise have no other treatment options [130]. However, Ibrutinib
also blocks TEC kinases family member, IEK, involved in T-cell activation. Currently small
molecules that target BTK, but not IEK, are being developed.
Other Kinases:
The PI3K/AKT pathway is known to contribute to BCR-induced survival [131]. As
described above, upstream activation of Lyn, Syk, and BTK leads to increased PI3K activity.
Idelalisib, which specifically inhibits the PI3Kδ isoform, is approved for treatment of patients
with CLL. Idelalisib inhibits both PI3K and ERK activation in malignant B cells and induces
apoptosis [101]. ERK signaling has been well defined and is critical for B cell development and
proliferation downstream of BCR activation and has also been well studied as a therapeutic
target in many cancers [132-134]. The RAF/MEK/ERK1/2 pathway is activated in CLL cells and
drugs such as Sorafenib that target Raf kinases lead to decreased CLL survival in vitro[135].
The mammalian target of rapamycin (mTOR) is another kinase that is known to be a key
regulator of downstream BCR signaling targets such as cell cycle proteins [136]. Treatment with
rapamycin has led to the prevention of CLL cells entering the cell cycle ex vivo and also induces
apoptosis in p53 mutated CLL cells.

21

Recent studies further investigating antigen-independent proliferation of CLL cells
through BCR independent pathways have found that CLL cells respond well to TLR-9 and CD40
stimulation. TLR-9 stimulation via CpG induces proliferation of CLL cells, but treatment with BCR
inhibitors such as Ibrutinib and entospletonib (α-Syk) led to reduced viability [137, 138].
Additionally, CD40L with IL-21 stimulation generates CLL proliferation through the MAPK axis
that leads to increased cyclin D2 expression via JAK/STAT signaling [138, 139]. Inhibition of BTK,
PI3K, and JAK kinases after CD40L stimulation led to reduced survival of CLL cells further
confirming that these kinases are critical for CLL survival independent of BCR.
1.2d CLL microenvironment
The original hallmarks of cancer proposed by Hannahan and Weinberg have been
expanded to include the tumor microenvironment that promotes growth of cancer cells by
avoiding apoptosis and evading immune suppression [7]. Both solid and hematologic tumors are
very heterogeneous and comprise of multiple different cell types such as stromal cells,
endothelial cells, tumor infiltrating macrophages and lymphocytes. These cells produce vascular
growth factors and various cytokines and chemokines that support cancer cells [140].
Compelling evidence exists that recognizes the importance of the BCR signaling pathway in the
survival of CLL, but microenvironment has emerged as another key factor in CLL survival. The
microenvironment is of interest in CLL as primary CLL cells do not proliferate or survive in longterm in vitro cultures alone, suggesting that other factors and/or cell types provide support. The
actual site of proliferation and the CLL microenvironment is still debated in the field. This could
be because CLL cells are found within the peripheral blood, bone marrow and other secondary
lymphoid organs in which the malignant cell comes into contact with a variety of accessory cells
depending on their location. Several studies have identified proliferation centers in the bone
marrow and lymph nodes. A study from the University of Nebraska performed extensive gene
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expression profiling of CLL cells derived from the peripheral blood (PB), bone marrow (BM) and
lymph nodes (LN) of patients. Results suggested that cells derived from the lymph node
expressed genes enriched for BCR signaling, BAFF/APRIL proliferation, NF-κB signaling and
immune suppression signatures compared to the PB and BM compartments [141]. These results
confirmed an earlier study that examined Ki67 staining in PB, LN, and BM samples from 24
patients which found that the LN contained CLL cells with a greater proliferative capacity [142].
Although studies in human samples find that the lymph node is the site of CLL proliferation;
questions are still raised based on the dramatic splenomegaly observed in mouse models [143,
144].
The CLL tumor microenvironment provides a physical location supporting the cross-talk
between malignant cells and accessory cells that inhibit apoptosis and also provide resistance to
drug treatment [145]. CLL is a slow progressing disease and was originally thought to simply be
an accumulation of cells with defective apoptosis, but recent studies using deuterium labeling
have determined that CLL cells proliferate at a rate of 0.1-1% per day suggesting that CLL is a
dynamic disease of proliferation [146]. Pseudofollicular proliferation centers that are found
throughout infiltrated tissues are the source of newly generated CLL cells [147]. Within this area,
CLL cells depend on stimulation through a functioning BCR receptor as discussed above. It is well
appreciated that CLL cells are activated through antigen independent and dependent manners
but the microenvironment may be the source of antigen/stimulus [148]. Theses antigens are not
specifically defined, but may include microbial antigens, natural antibodies, and auto antigens
expressed by dying cells.
The CLL microenvironment promotes cell to cell interactions with a variety of different
cell types. Direct interaction between B-CLL cells and T cells via CD40 on B-cells and CD40L on T
cells provides a proliferative stimulus. [149]. CD40 signaling in B cells induces expression of anti23

apoptotic molecules and proliferative signaling through AKT, ERK, TRAF, and NF-κB. T cells also
secrete cytokines such as IL-4, TNFα, and IL-2 that support CLL proliferation. Alternatively, the
CLL microenvironment also supports immune evasion allowing CLL cells to dampen the immune
function of cytotoxic T cells by secreting immunosuppressive cytokines like TGFβ and IL-10 [149].
Stromal cells derived from bone marrow or other secondary lymphoid tissues support
the survival and proliferation of CLL cells [150]. This interaction provides a bi-directional cross
talk that promotes the growth of both CLL and stromal cells. In cell culture, CLL cells actually
migrate beneath bone marrow mesenchymal cells, a process known as pseudoemperiopolesis,
suggesting that this interaction is dependent on cell contact in order for CLL cells to survive.
Cells known as Nurse-like cells can be found in the peripheral blood of patients that are derived
from monocytes and become adherent in culture systems [151]. These cells express stromal cell
derived factor – 1 (SDF-1) that binds to CXCR4 on CLL cells to prevent spontaneous apoptosis
and promotes resistance of CLL cells to chemotherapies. CXCL12 is also secreted by nurse-like
cells (NLCs) as well as mesenchymal derived stromal cells that attract CLL cells via CXCR4
towards proliferation centers within the secondary lymphoid compartments [48].
Tumor associated macrophages (TAMs) also play a key role in supporting the growth
and survival of CLL cells. Depletion of TAMs in CLL models by targeting CSF1 or by clodronate
treatment was found to decrease the engraftment of CLL resulting in leukemic cell death [152].
Reinart and colleagues found that plasma of CLL patients had increased levels of circulating MIF
(macrophage inhibitory factor). By crossing a mouse lacking MIF to the well-known CLL mouse
model, Eμ-Tcl1, this group discovered that decreased expression of MIF significantly delayed
disease development [153]. Absence of MIF decreased BCR signaling in CLL and rendered cells
more susceptible to apoptosis, further confirming the necessity of BCR signaling stimulation of
CLL cells in the microenvironment. In another mouse study examining the role of CXCR5 in the
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homing of CLL cells, Heinig et al discovered that access to follicular dendritic cells was critical for
disease proliferation [154].
Many additional cell types, chemokines and cytokines have been identified in the CLL
microenvironment that support CLL growth and survival (briefly summarized in Figure 1.5,
adapted from Kipps, 2017 Nature Primers [48]). The cross-talk between neoplastic CLL cells and
the surrounding tissue provides more options for therapeutic targets.

Figure 1.5: Interactions of the CLL cells with the surrounding microenvironment. CLL
cells require the support of multiple cell types and survival factors for persistence.
Neoplastic B cells interact with stromal cells, nurse-like cells, macrophages,
lymphocytes, endothelial cells, and many others through direct cell to cell contact via
receptor-ligand mediated interactions and through soluble mediators. Signals within the
microenvironment stimulate the CLL cell though the BCR signaling pathway to promote
survival and proliferation. Figure used with permission from Kipps, T. 2017 Nature
Disease Primers: Chronic Lymphocytic Leukemia 3(16096).
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1.2e Current Treatment for Chronic Lymphocytic Leukemia
Vast improvements have been made over the past few decades in discovering new
treatment modalities for patients with CLL as we learn more about the requirement of the BCR
signaling pathway and microenvironment. Small molecule inhibitors targeting kinases such as
SFKs, BTK, SYK, and PI3K as discussed earlier have proven successful in a number of cases in
addition to the standard regimen of chemotherapeutics + anti-CD20 antibodies [48].
Next generation sequencing (NGS) has revealed many complexities among CLL patients
and has enabled grouping of patients into prognostic categories. In addition to the IGHV
mutational status, mutations such as TP53, SF3B1, and NOTCH1 indicates more aggressive
disease triggering the need for more efficient treatment strategies [130]. FISH (fluorescence in
situ hybridization) analysis has also improved the detection of genomic aberrations leading to
worse prognosis of patients with 17p and 11q abnormalities [53]. These prognostic factors in
addition to patient age and fitness determine the dose of treatment. As mentioned before,
some patients do not require treatment and are only placed in the “watch and wait” category.
There is no evidence suggesting that early treatment of asymptomatic cases can improve the
overall survival of patients, therefore, preference is for monitoring of disease symptoms until
progression is evident for treatment to start. Treatment is required immediately for patients
classified as Stage III or IV, if they show signs of progressive bone marrow failure or have
autoimmune cytopenias [155].
Standard treatment for patients includes chemotherapy combinations of fludarabine
and cyclophosphamide with rituximab (FCR), but due to comorbidities or other exclusion
criteria, not all patients are able to tolerate chemotherapy [156]. Current chemotherapies used
for CLL treatment include purine analogues such as pentostatin and cladarbine in addition to
fludarabine. Other alkylating agents besides cyclophosphamide are chlorambucil or
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bendamustine [48]. Immunotherapy options are primarily monoclonal antibodies that target
CD20 surface receptors on the neoplastic B cells (rituximab, obintuzumab, and ofatumumab) as
well as Campath-1 antibodies (alemtuzumab) that target CD52 and otlertuzumab, which targets
CD37 [156]. Patients that are fit, have mutated IGHV status and no p53 mutation normally
respond well to FCR, but if a patient is older and more prone to infections, bendamustine and
rituximab are normally prescribed as they are more tolerable. Patients with unmutated IGHV
status do not respond as well to FCR with only a 32% overall survival rate compared to 65% for
M-CLL patients [42]. Patients that have p53 mutation have a worse response to standard
chemotherapy treatment and are often treated initially with ibrutinib, a BTK inhibitor. If these
17p deletion/p53 mutated patients do not respond to ibrutinib, they will receive a combination
of idealisib (PI3K inhibitor) and rituximab [130]. This combination is normally the last line of
defense as it is very harsh and exponentially increases the patient’s risk of infection. Patients
may also be considered for allogeneic hematopoietic cell transplantation if they are in good
physiological condition. Drugs targeting molecules involved in the apoptotic pathway have
proven very successful in the treatment of CLL. Venetoclax, or ABT-199, targets the function of
BCL-2 and prevents sequestration of Bim in order for the apoptotic cascade to proceed. This
drug treatment has been helpful in refractory or relapsed patients [48]. Other refractory
patients may receive a combination of chemoimmunotherapy options pending their last
treatment regimen. Salvage treatment options include combinations of standard
chemotherapies, immunotherapy, BCR inhibitors, and immunomodulatory drugs such as
lenalidomide as well as steroids.
Impressive results have been obtained with genetically modified T cells known as CAR-T
(chimeric antigen receptor) cell therapy that target hematological B-cell malignancies. These T
cell have been engineered to target known tumor antigens or in the case of B cells, CD19, and
27

are expanded in vitro before intravenous injection back to the patient. CD19-CAR-T cells have
led to long term disease free remission in multiple clinical trials [157].
Patients with CLL have about a 5-10% chance of developing Richter’s syndrome which
usually leads to a very poor prognosis with a median survival time of about 10 months [158].
Richter’s transformation is due to the development of lymphoma after being diagnosed with
CLL. Most patients present with hepatosplenomegaly and are primarily diagnosed with diffuse
large B cell lymphoma that is aggressive and difficult to treat as it varies from the de novo DLBCL
with known genetic abnormalities [48]. Retrospective studies have examined the incidence of
secondary cancers in CLL patients. There is a slight increase in melanoma, sarcoma, lung, renal,
and prostate cancer in patients with CLL [34, 159].
Therapy for Chronic Lymphocytic Leukemia has improved extensively over the past few
decades leading to better outcomes, but CLL still remains incurable. Further studies about the
role of BCR signaling and microenvironment in CLL are warranted to improve the current success
of these drugs and to design even more effective therapies that can lead to cures.
1.3 Prostate Apoptosis Response -4
One of the original hallmarks of cancer is to evade apoptosis and many cancers master
this skill by down regulating tumor suppressors and pro-apoptotic factors [6]. Prostate
Apoptosis Response-4 (Par-4) is a well-defined tumor suppressor that is found to be repressed
by promoter methylation in about 30% of all cancers including Acute Lymphoblastic Leukemia
(ALL) [160]. Par-4 was originally identified by Sells and colleagues by its upregulation during
ionomycin induced apoptosis of androgen independent and dependent prostate cancer cells in
1994 [161]. Shortly after, using a yeast two-hybrid assay and HEK-293 mammalian cells,
Johnstone et. al. discovered that Par-4 interacts with the Wilm’s Tumor-1 protein, a
transcriptional suppressor [162]. Additional early studies found that Par-4 also interacts
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physically with atypical protein kinase c (aPKC) and over expression of Par-4 in NIH 3T3
fibroblasts led to an apoptotic morphological change [163]. These initial studies defined Par-4 as
a pro-apoptotic factor and tumor suppressor.
The human Par-4 gene is located on chromosome 12q21 and contains 7 exons, encoding
a 340 amino acid, 43-47kDa protein [164, 165]. Par-4 is ubiquitously expressed in tissues of
different species and Johnstone et al. found that mouse Par-4 shows 83% and 91% identity to
human and rat Par-4 respectively [164]. Interestingly, the leucine zipper domains, carboxy
terminal region, and nuclear localization sequences (NLS) exhibit 100% conservation across
species [166]. The leucine zipper domain allows Par-4 to interact with other proteins as either a
homo- or heterodimer. The nuclear localization sequences suggest that Par-4’s function is
dependent on nuclear. However, in normal tissues, Par-4 is localized mostly to the cytoplasm
[167]. The NLS2 sequence is very interesting in Par-4 as it is sufficient to allow nuclear
translocation alone but it is also part of a domain that is necessary for the apoptosis-inducing
properties of Par-4, termed selective for apoptosis of cancer cell (SAC) domain [168]. SAC is a
core domain of 59 amino acids in length and includes a threonine residue that is the site of
phosphorylation via Protein Kinase A [169]. Activation of Par-4 through phosphorylation
indicates that its function is tightly regulated by post-translational modification. PKA, a broad
spectrum serine/threonine kinase regulated by cAMP signaling, is associated with cell
proliferation, and is frequently overexpressed in cancer cells. Par-4 is able to utilize the PKA
upregulation in cancer cells to specifically induce apoptosis of cancer but not normal cells [169].
This selective ability of Par-4 makes it an attractive therapeutic target. Additionally, Par-4 is
negatively regulated by AKT activity through phosphorylation at serine 249, which is located
between the SAC domain and leucine zipper region [165]. A simplified diagram of the Par-4
domains is found in Figure 1.6 (Adapted from Hebbar et al. 2012).
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Figure 1.6: Diagram of Par-4 domains. Par-4 contains two nuclear localization sequences
with NLS2 contained within the SAC domain. PKA phosphorylates Par-4 at threonine 155
for activation and is inhibited at serine 249 by Akt phosphorylation. A nuclear export
sequence is also found within the N-terminal region. Amino acid residue numbers
represent Rat Par-4, but domains are conserved across species.

Phosphorylation of Par-4 via AKT is required for cancer cell survival, as phosphorylation
of Par-4 by Akt leads to binding of the chaperone 14-3-3, retaining Par-4 in the cytoplasm [170].
Many studies have linked the pro-apoptotic activity of Par-4 to its ability to inhibit NF-κB
transcriptional activity. Activated Par-4 prevents ζPKC from phosphorylating IκB, which is
necessary for RelA translocation to the nucleus [163, 171, 172]. Another mechanism of NF-κB
inhibition is due to a direct repressive effect of Par-4 in the nucleus but the exact mechanism
still needs to be elucidated. A summary of Par-4 activation is shown in Figure 1.7 [169].
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Figure 1.7: Endogenous role of Par-4 in normal and cancer cells. As described by
Gurumurthy et al., Par-4 remains in the cytoplasm of normal cells. In cancer cells with
elevated PKA activation, Par-4 is phosphorylated at Thr155 and translocates to the
nucelus to inhibit NF-κB transcriptional activity. Figure modified from Gurumurthy,
Sushma, "MECHANISM OF CANCER SELECTIVE APOPTOSIS BY PAR-4" (2005).University
of Kentucky Doctoral Dissertations. 471.
1.3a Par-4 Tumor Suppressor
Par-4 has a dynamic relationship with Akt, a key survival kinase that is activated by the
second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3)[173]. Akt is also
phosphorylated by PDK1, which is activated by PIP3 at Thr308 and by TORC2 at Ser473, two
residues critical for Akt enzymatic activity [174, 175]. Akt phosphorylates a number of effector
proteins such as mTOR, IKK, and Mdm2 for activation and is found to inhibit other molecules
such as Bad, p27, p21, GSK3β, and transcription factors including Foxo3a [173, 176]. Akt is
inhibited by the tumor suppressor PTEN (phosphatase and tensin homolog) that converts PIP3
back to PIP2 to prevent Akt activation. Akt inhibits Par-4 activation through phosphorylation in
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many studies as mentioned earlier [170, 177]. Conversely, Par-4 has also been found to inhibit
Akt. In a mouse model of lung cancer, Joshi and colleagues show that lack of Par-4 led to
increased Akt as well as NF-κB activity leaving cells more sensitive to Ras induced oncogenesis
[178]. In Ras expressing lungs, the lack of Par-4 led to an increase in 75% of tumor tissue
compared to 12% in WT mice. Increased tumor burden was also correlated with increased NF-κB
signaling and thought to be regulated by the increased PKCζ activity that is normally suppressed
by Par-4 [163, 178]. Increased levels of Akt activity were confirmed by increased Ser473 and
Thr308 phosphorylation in the Par-4 KO lungs. Increase in Akt activation was not due to an
increase in PI3K activity and studies suggest that lack of Par-4 results in phosphorylation of Akt
at Ser124 via PKCζ which modulates Akt activation [178]. In another study, Gurumurthy et al.,
confirmed that Akt directly binds to Par-4 through immunoprecipitation assay and
phosphorylates Par-4 at Ser249 (rat) to inhibit its translocation to the nucleus [170].
Additionally, they found that Par-4 expression is necessary for PTEN inhibition of Akt and
apoptosis. Other studies have also noted that PTEN haploinsufficiency also led to a loss of Par-4
expression [179, 180].
In addition to the study by Joshi et al., other groups have noted the connection between
Par-4 and Ras. Ras has been shown to regulate Par-4 expression through the Raf-MEK-ERK
pathway [181]. In studies with immortalized fibroblast lines containing inducible Ras expression,
Qiu and colleagues discovered Ras expression downregulated Par-4 expression whereas
inhibition of the Raf-MEK-ERK pathway with the inhibitor PD98059 restored Par-4 levels. Par-4
was also found to inhibit expression and activation of ERK1/2 proteins which prevented the
oncogenic Ras-transformation, showing a full negative regulatory loop between Par-4 and Ras
[181].
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Par-4 has also been found to interact with topoisomerase 1 (TOP1) by binding directly
through its leucine zipper domain [182]. Topoisomerases relax DNA by making single strand
nicks in order for DNA replication, transcription, and recombination to occur [183]. TOP1 protein
levels are elevated in proliferating cells and also increased in several types of cancers. Goswami
and colleagues found that Par-4 binds to TOP1 to attenuate its DNA relaxation activity to
prevents cellular transformation [182].
Par-4 tumor suppressor function is also observed in vivo as Par-4 null animals are found
to have increased spontaneous tumors with 80% of females developing endometrial hyperplasia
and males developing prostatic lesions [172]. The par-4 gene was disrupted via homologous
recombination by inserting a neo cassette that eliminated exons 1 and 2 of the par-4 gene
completely abolishing Par-4 expression [184]. The absence of Par-4 in mouse embryonic
fibroblasts (MEFs) decreased sensitivity to TNFα and cyclohexamide mediated apoptosis, further
confirming that Par-4 is needed for the apoptotic response to these treatments. This result
mirrored in vitro studies showing that downregulation of endogenous Par-4 elevated TNFα
induced NF-κB activity [171]. Par-4 knockout MEFs also had reduced JNK and p38 activity after
TNFα stimulation [184]. Par-4 null mice also exhibited increased levels of apoptosis inhibitor
XIAP (X-chromosome linked inhibitor of apoptosis). XIAP is an E3 ubiquitin ligase and a known
inhibitor of caspase activation [185]. XIAP is also downstream of NF-κB and thought to be
increased in Par-4 null animals due to lack of Par-4 inhibition on the PKCζ-NFκB-XIAP pathway
[172, 184].
The average lifespan of Par-4 null mice is 18mo compared to 25mo for Par-4 WT animals
with an 87% propensity to develop tumors [172]. These mice also exhibited normal B and T cell
development but do have slight increase in total number of lymphocytes leading to an increased
spleen size [186]. The proportions of B and T cells were not changed in young mice lacking Par-4,
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but the proliferative response to BCR and TCR stimulants were increased compared to WT
animals. Additionally, the lack of Par-4 in these mice led to hyperactivation of atypical protein
kinases, blocking JNK signaling. Lack of JNK signaling in CD4+T cells resulted in increased IL-4
production and skewed the animal towards a Th2 response [186].
1.3b Par-4 and Apoptosis
Apoptosis is a process of programmed cell death that is vital for many processes and is
highly controlled [187]. There are two main pathways of apoptosis: the extrinsic or death
receptor pathway and the intrinsic or mitochondrial pathway. Inappropriate apoptotic signaling
can lead to different diseases, including cancer. Cancer avoids apoptosis by inhibiting apoptotic
signals and promoting cell survival proteins. Par-4 is found to be silenced in multiple cancers
including renal, neuroblastoma, endometrial, lung, prostate, and pancreatic mostly through
promoter hypermethylation [188]. Par-4 has been shown to inhibit NF-κB activity as discussed
earlier which results in an activation of the intrinsic apoptosis pathway and also plays a role in
activating the extrinsic pathway through Fas/FasL. Over expression of Par-4 has been found to
induce apoptosis in some sensitive cancer cell lines, but over expression of Par-4 in normal cells
only sensitizes them to additional apoptotic signals, making Par-4 a cancer selective target [189].
Par-4 has been found to interact with Bcl-2, an anti-apoptotic molecule. An initial study
investigating the levels of Par-4 in patients with ALL found that Par-4 expression was inversely
correlated with Bcl-2 expression; similar results were found in leukemic cell lines [190].
Additionally, overexpressing Par-4 in PC-3 and NIH 3T3 cells reduced Bcl-2 protein levels [191].
These observations led to other studies defining the mechanism specifically in lymphoid
malignancies as Bcl-2 overexpression is associated with DLBCL and follicular lymphoma
pathogenesis [192]. Overexpression studies of Par-4 in Jurkat T lymphocytes led to a disruption
in the mitochondrial membrane potential, downregulation of Bcl-2 and activation of caspase
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mediated apoptosis [193]. Bcl-2 expression has been shown to increase after radiation induced
insults via increased NF-κB activity in PC-3 cells, but enforced Par-4 expression prevented Bcl-2
induction [194].
Par-4 induces apoptosis by promoting the translocation of Fas and Fas Ligand (FasL) to
the plasma membrane to recruit FADD, which activates downstream caspase-8 pathway [195].
PC-3 cells that were transfected with Par-4 exhibited an increase in Fas/FasL at the cell
membrane and immunoprecipitation assay showed that Par-4 was bound to Fas and FADD,
further confirming its important role in initiating the death pathway [195]. Activation of this
pathway through Par-4 at normal levels is not sufficient to induce apoptosis alone, but Par-4’s
additional role in inhibiting NF-κB was also required for cell death. PKA phosphorylation of Par-4
at Thr155 is also essential for Par-4 induced trafficking of Fas/FasL to the membrane [169].
Activation of the Fas-FADD complex by Par-4 promotes caspase-8 dependent activation
that leads to downstream activation of executioner caspases including 3, 6, and 7. Par-4 has also
been found to be a substrate of caspase dependent cleavage by both caspase 8 and 3 [196, 197].
Studies utilizing cisplatin treatment resulted in decrease total Par-4 protein levels but a
reciprocal increase in a 25kDa fragment suggesting Par-4 is cleaved [196]. Caspase-3, in
particular, was found to cleave Par-4 at an unconventional site, leaving the fragment to
accumulate in the nucleus and inhibit NF-κB activity. Caspase-3 inhibitors prevented Par-4
cleavage and cells lacking caspase-3 such as MCF-7 cells did not express cleaved Par-4. Another
study found that UV-induced damage of HeLa cells resulted in a 17kDa and 28kDa fragments of
Par-4 [197]. Treatment with cyclohexamide and TNFα also induced Par-4 cleavage through
caspase-8 leading to nuclear accumulation of the c-terminal end of Par-4.
In addition to interacting with WT-1 (Wilm’s tumor-1), and PKCζ, Par-4 has also been
found to interact with other anti-apoptotic proteins such as Dlk (DAP-like kinase)[162, 163, 198].
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DAP Kinases are known to phosphorylate the regulatory myosin light chain II (MLC) that results
in membrane blebbing during cell death [198]. Par-4 and DlK interactions are thought to result
in cytoplasmic accumulation of the complex resulting in enhanced MLC phosphorylation and
reorganization of the actin filament cytoskeleton.
1.3c Secretion of Par-4
Seminal studies investigating Par-4 function led to the discovery that Par-4 is secreted
from all cell types and can induce apoptosis of neighboring cells [199]. PC-3 cells were
transfected with GFP labeled Par-4 as well as SAC domain-GFP to find that transfected cells
underwent apoptosis but also cells that were not expressing GFP were dying as measured
through caspase-3 activation. The Par-4 detected in the conditioned media was not due to dying
cells as experiments performed in Par-4 transfected BPH-1 cells that are not sensitive to Par-4
apoptosis also resulted in secreted Par-4. This indicated that Par-4 secretion is independent of
apoptosis. Par-4 secretion occurs through the classical ER-Golgi pathway as inhibition of the
network with brefeldin A (BFA) blocked secretion [165, 199]. Par-4 secretion is associated with
the ER stress response and was also found to associate with GRP78, a member of the heat shock
protein family 70 (HSP70) that works to facilitate proper protein folding, prevent intermediate
aggregates, target misfolded proteins for degradation, bind calcium, and serve as an ER stress
signal regulator [200]. Burikhanov et al. showed that Par-4 and the SAC domain bind and
associate with GRP78 at the plasma membrane in response to TRAIL (tumor necrosis factor
related apoptosis inducing ligand). TRAIL is a known ER stress inducing factor and treatment of
PC-3 cells with TRAIL led to increased GRP78/Par-4 at the cell surface and induced apoptosis
[201]. Intrinsic Par-4 expression is also required for GRP78 expression on the surface of the cell
but the lack of Par-4 does not alter total GRP78 protein levels [199]. BPH-1 cells that normally do
not respond to extracellular Par-4, transfected with GRP78 were sensitive to apoptosis induced
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by extracellular Par-4. Extracellular Par-4 is found to activate caspase-8 and caspase-3 through
FADD[199]. Initiation of extracellular Par-4 mediated apoptosis results in a feedback loop that
promotes more translocation of Par-4 and GRP78 to the surface of the cell. A simplified diagram
of Par-4 mediated apoptosis is shown in Figure 1.8.

Figure 1.8: Par-4 mediated apoptosis. Par-4 binds and inhibits PKCζ that prevents prosurvival
signaling of NF-κB and leads to apoptosis. Under cellular stress, Par-4 and its chaperone, GRP78
are translocated from the ER to the plasma membrane were Par-4 is secreted. Extracellular Par4 can bind to cell surface GRP78 that recruits FADD and initiates caspase-8 and caspase-3
activation. Cellular stress can then lead to increase in Par-4 secretion creating a robust feedback
loop. Diagram adapted from Shrestha-Bhattarai, T. Cancer-selective apoptotic effects of
extracellular and intracellular Par-4 Oncogene (2010) 29, 3873–3880.
1.3d Par-4 and Chronic Lymphocytic Leukemia
Several studies have examined Par-4 levels in CLL leading to prognostic predictions.
Chow et. al. found that CLL patients that express high Par-4 levels respond better to imatinib
treatment [202]. However, a 2011 study examining Par-4 levels in different CLL patient
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populations found that Par-4 expression was elevated in the CD38+ CLL subgroup and advanced
stage patients [203]. Boehrer et. al. found 30/30 human CLL patient samples expressed
detectable Par-4 protein levels but only 70% of acute lymphocytic leukemia samples expressed
detectable Par-4 protein suggesting that Par-4 is not as frequently expressed in less mature
lymphocytes [190]. Although Par-4 is expressed in CLL cells the mechanism of Par-4 regulation in
CLL is yet to be studied.
1.4 Study of Chronic Lymphocytic Leukemia
CLL is a difficult disease to study as the culturing of primary CLL cells results in apoptosis.
There is clear indication that the microenvironment is required for the survival and proliferation
of these malignant B cells. Cell culture conditions have yet to be optimized to mimic the tumor
microenvironment leaving in vivo models of CLL as the best way to study this cancer. Many
mouse models are available to study the disease that represent findings in the clinic such as
genomic aberrations (13q14 deletions) or overexpression of oncogenes such as Tcl1 [204]. Aged
New Zealand Black (NZB) mouse shows development of a CLL-like disease with an expansion of
IgM+CD5+ B cells, but serial passage of these cells results in lymphoma development in
recipients [205]. The NZB model did suggest that lack of miR15a/16-1 leads to the development
of CLL [206]. These two microRNAs are found at chromosome 13q14 which is commonly deleted
in CLL patients, and loss of miR15a/16-1 is found in 68% of CLL patients and leads to CLL
development in a mouse model [207]. Animals overexpressing APRIL, ROR1, and BCL2 also
develop a CLL like disease [208-210]. There are additional mouse models of CLL but none as
reliable as the Eμ-Tcl1 mouse that overexpresses the human Tcl1 oncogene [204, 211].
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1.4a T cell leukemia 1
The first transgenic mouse model to exhibit a CLL-like disease is the Eμ-Tcl1 mouse
developed in the early 2000’s and is still widely used today [144]. This mouse expresses the
human Tcl1 gene, T-cell leukemia 1, specifically in B cells through the Ig VH promoter and Eµ
enhancer. T cell leukemia 1 was first identified in a patient with ataxia telangiectasia that
developed a T-cell chronic lymphocytic leukemia with a chromosomal translocation at 14q32
[212]. Normally, Tcl1 is expressed during embryogenesis and in fetal tissues, and in lymphocytes
during the pro-B cell (CD34+CD19+) stage with peak expression found in the CD19hiIgM- naïve B
cell population [213]. Tcl1 is also detected in CD4-CD8-CD3- immature thymocytes but not in
mature T cells [213]. Narducci et al. found that Tcl1 was expressed in 75% of B-cell
lymphoblastic lymphomas and 60% of diffuse large B cell lymphomas. This oncoprotein is also
overexpressed in the majority of follicular and mantle cell lymphomas (Mino, Jeko cell lines),
and Burkitt’s lymphoma (Ramos, Daudi) which are all derived from germinal centers(GC) or postGC B cells that normally express low levels of Tcl1[213-216]. Tcl1 is found to augment Akt1
kinase activity by physically interacting with the pleckstrin homology domain of the prosurvival
protein [217]. It has been suggested that Tcl1 binding results in Akt1 oligimerization near the
plasma membrane to promote transphosphorylation or phosphorylation via other kinases such
as PDK1 at Thr308 residue and/or the mTOR complex at Ser473 [218]. Tcl1 also mediates the
nuclear translocation of Akt1 [217]. Tcl1 promotes the activation of NF-κB in a 4-fold greater
manner after treatment with wortmannin, a PI3K inhibitor, suggesting that it may interact with
NF-κB co-activators such as CREB [219]. Pekarsky et al. also indicated that Tcl1 inhibited
Activator Protein-1 complex (AP-1) dependent transcription by binding to cFos, cJun, and JunB
[219].
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A study at MD Anderson investigating the role of Tcl1 in human CLL cases found that
nearly 90% were Tcl1 positive [220, 221]. While Tcl1 expression was variable among tumors, it
was found to be closely associated with Zap-70 positivity and unmutated IGHV genes. Additional
studies also found that Tcl1 expression led to increased BCR signaling capacity in patients due to
elevated Lyn, Syk, Zap70, and PKC activity [222]. Herling and colleagues suggested that Tcl1 may
be a biomarker indicating CLL patients with elevated BCR signaling that may respond better to
kinase inhibitors. Because the Eμ-Tcl1 mouse expresses high levels of the human Tcl1 gene, it is
thought to be a representative model of U-CLL.
1.4b Eμ-Tcl1 Mouse
According to many different reviews, the Eμ-Tcl1 mouse model is the most
representative animal model of human CLL as these mice develop disease at late stages and
exhibit similar genomic characteristics [204, 211, 221, 223, 224]. The Tcl1 oncogene was initially
expressed in animals under the control of the lck promoter that led to T cell leukemia by the
Croce group [225]. Bichi et. al. then utilized the Tcl1 oncogene to be expressed under the VH
promoter and Eμ enhancer to be expressed specifically in B cells and develop a CLL-like disease
around the ages of 10-15 months (Figure 1.9)[144].

Figure 1.9: Tcl1 expression construct. The human Tcl1 350bp fragment was cloned and
inserted into a plasmid with the mouse VH promoter and Ig μ enhancer along with the
poly A site of the human β-globulin gene. Figure adapted from Bichi et. al. 2002 PNAS
99(10): 6955-6960. Human chronic lymphocytic leukemia modeled in mouse by targeted
TCL1 expression.
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Penetrance of B cell malignancies is 100% in some but not all mouse studies [204]. It is
important to note that at the same time the Eμ-Tcl1 mouse was developed, another mouse
expressing Tcl1 under the B29 promoter and μ enhancer was developed by the Teitell group
[226]. The B29-Tcl1 mouse developed malignancies in both the B and T cell compartments
including DLBCL, follicular lymphoma, T cell lymphoma, and some cases of B cell leukemia. The
Eμ-Tcl1 mouse begins to exhibit a clonal expansion of CD5+IgM+ B lymphocytes in the peritoneal
cavity at 2mo and the spleen and peripheral blood at the age of 3-4mo [144]. These mice
continue to develop and exhibit splenomegaly with distorted histology and continued increased
in the CD5+CD19+ population.
The Eμ-Tcl1 mouse is an excellent model to study human disease as they express a
similar BCR repertoire associated with aggressive disease [227], show similar response to
treatment [228], and show dysregulated T cell function [229, 230]. Recently, with the
development of the NSG (NOD/SCID gamma null) mouse, some groups have worked with
xenograft models of CLL by taking human peripheral blood B-CLL cells and injecting them into
immunodeficient animals for study but these cells exhibit minimal proliferation [231, 232].
While the Eμ-Tcl1 mouse represents a similar course of disease as in humans, it does
require time to develop. Due to this characteristic, we established an adoptive transfer model of
primary Eμ-Tcl1 splenic cells into syngeneic C56Bl/6 recipients without prior conditioning. We
are able to monitor the progress of these animals by submandibular bleeding, flow cytometry
and spleen palpation. We have compared the adoptive transfer cells to the primary Eμ-Tcl1 cells
by fluorescence-activated cell sorting (FACs) and found that they express similar cell surface
molecules. Similarity is also observed in functional tests of primary and adoptive transfer CLL
cells as well as spleen histology.
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1.4c Cell lines of CLL
While the in vivo models of CLL replicate disease, ex vivo culturing of primary Eμ-Tcl1
and adoptive transfer cells leads to apoptosis. Studies with ex vivo CLL cells are productive, but
long term culture is challenging. Therefore, cells lines have been developed in order to study the
biochemistry of this disease and define the mechanisms that promote CLL survival. The MEC-1
and MEC-2 cell lines were characterized in 1999 and were derived from the peripheral blood of
an EBV-seropositive CLL patient [233]. These cells are highly utilized in the field as they express
mature B cell markers and express VH4 Ig family that have not gone through somatic
hypermutation. These cells are negative for CD5 expression but have the capacity to grow in
vivo mouse models and MEC-1 cells also show other characteristics similar to ex vivo CLL cells
such as high expression of Ig molecules [234]. Another cell line that has been used to study CLL
is the OSU-CLL that was generated by EBV transformation of patient cells that expressed CD5
[235]. These cells were found to migrate similar to primary CLL cells and were also able to grow
in immunodeficient NOG mice. A new cell line known as MDA-BM5 was recently generated from
bone marrow of a CLL patient with the 17p and p53 deletion [236]. These cells are CD5+CD19+
and have undergone somatic hypermutation.
Cell lines have also been generated from mouse models, specifically the IgH.TEμ mouse
that expressed the SV40 T oncogene[237]. Cell lines EMC2, 4, and 6 express
CD5+CD43+IgM+CD19+ on their surface and are able to grow in Rag-/- mice [238]. Additionally,
these mouse cell lines express constitutively active BTK and AKT.
1.5 Premise of this study
Although CLL has been very well characterized and new therapies have been developed
to treat the disease, the cases of patient relapse are tremendous, warranting new pathways to
be discovered. Par-4 has been documented to be expressed in CLL and related for a few
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prognostic factors, but the actual role that Par-4 plays in CLL as well as it’s regulation has not
been defined. We investigated the levels of Par-4 expression in primary mouse CLL cells, cell
lines, and primary patient samples and found that these cells have elevated Par-4 expression
when compared to normal B cell counter parts. Previous studies from our lab have shown the
importance of BCR signaling in the survival of these cells and it is well known that CLL cells have
elevated BCR signaling that promotes their survival [36, 114, 239]. This led us to hypothesize
that constitutive BCR signaling could regulate Par-4 expression in CLL cells. Elevated levels of
Par-4 protein expression also raised the question of why CLL cells were not sensitive to Par-4
induced apoptosis. Our studies show novel regulation of Par-4 through BCR signaling, and Par-4
plays a pro-growth rather than pro-apoptotic role in CLL, further confirming that this apoptotic
pathway is dysregulated in CLL.
We made an additional observation about the importance of the spleen in the growth
and development of CLL through our adoptive transfer model. Studies in the laboratory of
injecting CLL cell through different routes (IV, IP, SQ) all led to severe splenomegaly. We were
able to track the growth of CLL cells through a human ROR1 marker that allowed us to suggest
that CLL cells home and grow primarily in the spleen. We hypothesized if removal of the spleen
would alter the growth and development of CLL. Splenectomy of adoptive transfer recipients
indeed prevented the growth of CLL after transfer in WT C57BL/6 mice. Splenectomy in the EμTcl1 mouse at early and late stages also improved the overall survival time and delayed CLL
development. But our surprising discovery was that splenectomy in the Par-4-/- mice enabled
growth of CLL 50% of the time. This indicates that Par-4 does play a role in preventing the
growth of CLL in secondary proliferation sites. Our studies show that intrinsic Par-4 works to
promote the growth of CLL while extracellular Par-4 may act to suppress CLL in different
microenvironments.
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CHAPTER 2
Materials and Methods
2a) Mice
Eμ-Tcl1 Mice and Par-4-/- mice were described previously and were bred in house [144, 184]. EμTcl1 mice were provided by Dr. John Byrd (Ohio State University) and Par-4-/- mice were
provided by Dr. Vivek Rangnekar (University of Kentucky). C57BL/6 and NOD-scid IL2Rgnull-IL3/GM-CSF (NSGS) and NOD-scid IL2Rgnull (NSG) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME) and bred in house. Eμ-Tcl1 and Par-4-/- mice were crossed for the
F1 generation and the F1 mice were intercrossed to generate Par4-/-Tcl1+ offspring. Mice were
confirmed for genotyping using primers listed in Table 2. The Tcl1 amplified fragment is 320bp,
Par-4 WT fragment is 213bp and Par-4 knockout fragment is 248bp in size.
Table 2: List of forward and reverse primers for PCR of genomic DNA of Par-4 and Tcl1. Primer
sequences were provided by collaborators at OSU (Tcl1) and the Rangnekar lab (Par-4).
Target Gene
Tcl1

Par-4 WT

Par-4 KO

Sequence (5’3’)
Forward

GCC GAG TGC CCG ACA CTC

Reverse

CAT CTG GCA GCA GCT CGA

Forward

GTG ATG ACG TCT TCT GAT TTC C

Reverse

GAG ACT CCA GAA CTT AGT TGC

Forward

CGT CTC GGA ATG GAG G

Reverse

GAG ACT CCA GAA CTT AGT TGC

Adoptive transfer models were carried out by injecting 4-10x106 Ficoll-paque purified
splenic Eμ-Tcl1 CLL cells in 150μl volume with sterile PBS intravenously via retro-orbital route
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while animals were under isoflurane anesthesia[240]. Animals were housed and maintained by
the Department of Laboratory Animal Resources at the University of Kentucky (Lexington, KY) in
specific pathogen free conditions in micro-isolator containers. All animal studies were approved
by the Institutional Animal Care and Use Committee (under protocol number 2011-0904) and
were carried out in accordance with the Animal Welfare Act. CLL development in Eμ-Tcl1, Par-4/-

EμTcl1 and adoptive transfer recipients was monitored through submandibular cheek bleeding

using sterile 5mm Goldenrod Animal lancets (Medipoint, Inc. Mineola, NY) collected in BD
microtainer tubes with K2EDTA (Becton-Dickinson and Company, Franklin Lakes, NJ) [241]. When
the percentage of CD5+CD19+ cells in the peripheral blood was >70%, EμTcl1 mice were
carefully monitored for moribund body conditions and euthanized according to the IACUC
standards. Body condition scores were generated by monitoring the weight of the mice and
level of activity as previously described in [242]. Cells were isolated from the spleen of Eμ-Tcl1
mice and confirmed for the CLL phenotype CD5+CD19+ by flow cytometry. Other characteristics
to confirm CLL in the mice were through analysis of spleen histology by showing lack of follicular
structures and expansion of proliferation centers with increased white pulp. Additionally, the
ability to transfer the primary mouse spleen CLL cells into recipient mice confirmed the
malignant qualities of the disease.
2b) Cells and Tissues
Primary Eμ-Tcl1 CLL single cell suspension was prepared by processing Eμ-Tcl1 spleens
through a 40μM cell strainer with the blunt end of a 5cc syringe in Hanks Buffered Salt Solution
(HBSS). Other tissues were collected and processed in a similar manner including lymph nodes,
liver, omental tissue, thymus, and any solid tumors. Tibiae and Femora were collected from
mice and marrow was isolated by flushing with a 26G syringe with HBSS. Peritoneal cells for
lysates and B cell subset sorting were obtained through peritoneal lavage with HBSS [15].
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Peripheral blood mononuclear cells were isolated from 200-300μl collection and treated with
RBC lysis buffer and HBSS washes. Cells were cultured in complete RPMI 1640 media (Corning
#10-040-CV, New York, NY) supplemented with 10% Fetal Bovine Serum (FBS), 50µM betamercaptoethanol (2-ME), 1mM Sodium Pyruvate, and 50,000 Units Penicillin/Streptomycin.
Mec-1 cells were cultured in IMDM (Iscove's Modified Dulbecco's Medium)
(ThermoFisher Scientific #12440061 Waltham, MA) supplemented with 10% FBS, 50μM 2-ME,
1mM Sodium Pyruvate, and 50,000 Units Gentamicin. OSU-CLL cells were cultured in completed
RPMI 1640. NCI-H460, PC-3, SudHL-6, RAMOS, and NIH-3T3 cell lines were cultured in complete
RPMI 1640 (H4-60, PC-3), IF-12 (SudHL-6, RAMOS), or DMEM (NIH-3T3) media.
2c) Patients
Human Patients with CLL were recruited from the University of Kentucky, Markey
Cancer Center Hematology and Oncology Clinic. Each patient gave informed consent approved
through the University of Kentucky Institutional Review Board, IRB #15-0697. Peripheral blood
CLL cells were purified through Ficoll-Paque density gradients (GE HealthCare #17-144-02,
Pittsburgh, PA) and confirmed for CLL phenotype by CD45+CD5+CD19+ staining via flow
cytometry. Healthy control donors were obtained from leukopack units purchased from the
Kentucky Blood Bank (Lexington, KY) after quality testing and white blood cells were isolated
through Ficoll-Paque density gradients. Human cells were cultured in completed RPMI 1640
described above.
2d) Reagents
Dasatinib (0003-0528-11) was manufactured by Bristol-Myers Squibb Company (Seattle,
WA). Syk inhibitor IV (Bay 61-3606) (57-471-42MG) was obtained from EMD Millipore
Calbiochem (Billerica, MA). Ibrutinib (A3001) and ERK1/2 inhibitor, SCH772984 (A3805), were
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obtained from ApexBio (Houston, TX). Dimethyl sulfoxide (DMSO) was obtained from Sigma
Aldrich (D2438) (St. Louis, MO).
2e) Flow Cytometry and Cell Sorting
Single cell suspensions of CLL cells and tissues from C57BL/6, EμTcl1 and Par4-/-EμTcl1
mice were analyzed for multicolor flow cytometry using the FACSCaliber and Becton Dickinson
LSRII Flow Cytometer (BD San Jose, CA) in the University of Kentucky Flow Cytometry and Cell
Sorting Facility. 1x106 cells were incubated to block Fcγ receptors using normal Rat Ig
(10μg/1x106 cells) for 15 minutes at room temperature and then stained for 30 minutes on ice
with fluorchrome-conjugated antibodies (all from BioLegend, San Diego, CA) towards CD5 (Cat #
100606 or 100608), CD19(Cat # 115520 or 115508 or 115512), CD45 (Cat# 103114 or 103110).
Peritoneal B cell subsets and spleen B cells were stained for CD19, CD5, and CD11b (Cat #
10121,) to distinguish B1a: CD5+CD19+CD11b+, B1b: CD5-CD19+CD11b+, and B2: CD5-CD19+
CD11b- populations and sorted on the iCyt Synergy sorter system from Sony Biotechnology (San
Jose, CA). Human CLL and normal peripheral blood samples were stained with antibodies
specific to human CD5 (Cat # 364022), CD19 (Cat # 302208) and CD45 (Cat # 368512) for 1 hour
on ice.
2f) Cell Survival and Proliferation Assays
Cell survival and proliferation was determined by the 3-(4,5-dimethylthiazole-2-yl)-2,5biphenyl tetrazolium bromide (MTT) assay[243]. Primary mouse and human CLL cells were
cultured at 2x105cells/well in 96 well flat-bottom microtiter plates in 200µl. Mec-1 and OSU-CLL
cells were cultured at 2x104 cells/well. The cells were treated with 0-40µM Dasatinib,
Fostamatinib, and Ibrutinib dissolved in DMSO for 48hr and then media was changed and
incubated with MTT (0.5mg/ml; Sigma Aldrich, M5655) for 4hr. The formazin crystals were
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solubilized in acidic isopropanol and optical density was measured at 560nm and 690nm. The
OD values (560-690nm) of cultures without the drugs were set to 100%. DMSO concentration
did not exceed 0.02% of culture medium and had no measurable effect on cell viability.
2g) Immunoblot Analysis
Cells were lysed in Cell Signaling lysis buffer (Cat # 9803, Danvers, MA) supplemented with 1X
protease inhibitor (Roche Cat # 5892953001, Indianapolis, IN), 1mM PMSF (Sigma#P7626), 2mM
NaF (Sigma #S-1504), 2mM freshly made Na3VO4 (Sigma #S-6508). Mec-1 shRNA cells were also
lysed with RIPA buffer made by 10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100 and 1X
protease inhibitor. Nuclear and Cytoplasmic fractions were isolated using NE-PER Extraction Kit
from ThermoScientific (#78833). Pierce BCA Assay was performed to detect the amount of
protein in each sample and the diluted in 4x sodium dodecyl sulfate (SDS) sample buffer
(100mM Tris-HCl, pH 6.8, 30% glycerol, 4% SDS, 5% 2-ME, and 0.01% weigh/volume
bromophenol blue) resulting in 1X concentration and then boiled for 10 minutes followed by
cooling on ice for 10 min. 30μg of protein was separated on an SDS polyacrylamide gel using the
BIO-RAD Mini Protean Tetra System (Bio-Rad Cat #1658001EDU). 7μl of Precision Plus Protein
dual color ladder (Bio-Rad Cat #1610394) ranging from 10-250kDa in size was used for each gel.
Gel separation was run in running buffer (25mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) at
90V/3A for 10minutes followed by 150V/3A for approximately 45 minutes or until the loading
dye reached the end of the gel. Gels were then transferred to polyvinylidene difluoride
membranes (EMD Millipore Cat #IPVH00010) in transfer buffer (25mM Tris, 192mM glycine,
20% methanol, pH 8.3) at 90V/3A for 1.5hr at 4°C. Each membrane was blocked at room
temperature for 1hr in 5% milk or 3% Bovine Serum Albumin (BSA) in 1X TBST (10X: 0.5M Tris,
1.5M NaCl, and 1% Tween-20). Membranes were then probed with respective primary
antibodies at 4°C overnight, washed and then probed with horseradish peroxidase-conjugated
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secondary antibodies for minimum 1hr at room temperature. Membranes were exposed to
HyGLO chemiluminescence reagent (Denville Scientific Cat #E2400) and developed on HyBlot CL
autoradiography film (Denville Scientific #E3012). Some difficult to detect proteins utilized
BioRad Clarity Western ECL Substrate (Bio-Rad Laboratories Cat # 170-5060). Intensities of
bands were quantified using the Gel Analysis method of the NIH Image J program. All band
intensities were normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression
or β-actin or corresponding non-phosphorylated proteins. Phospho specific antibodies against
Src (Y416) (#2101S), Akt (S473) (#9271L), Syk (Y525/526) (#2711), Btk (Y223) (#5082P), P-ERK
(#9101) were obtained from Cell Signaling Technologies (Danvers, MA). Antibodies against total
Akt (#9272S), Syk (#2712), Btk (#3533S), GAPDH (#2118S) were also obtained from Cell Signaling
Technologies. Antibodies against total Lyn (#SC-15), Par-4 (#SC-1807), Col1A (#SC-28657), Tcl1
(#SC-33550), p21 (F-5) (#SC-6246), ERK1/2 (#SC-94), Bcl2 (#SC-7382) and HDAC (Histone
Deacetylase, #sc-7872) were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA).
Peroxidase coupled secondary antibodies were also obtained from Santa Cruz Biotechnologies
(#SC-2004, SC-2005). Antibody against β-actin was obtained from Sigma Aldrich (Cat# A5441).
2h) Measurement of apoptosis induced by secreted Par-4
Primary Eμ-Tcl1 mouse CLL cells were cultured for 12-24hr in RPMI-1640 media and
then media was collected and applied (400μl) to H4-60 lung cancer cell line. Apoptotic nuclei
were defined by 6-diamidino-2-phenylindole (DAPI) staining (Cat #H-1200 Vector Laboratories,
Inc., Burlingame, CA) [170]. 100nM Recombinant thioredoxin (TXR) and TXR-Par-4 fusion
proteins were provided by Dr. Vivek Rangnekar (University of Kentucky) as a positive control and
antibody towards Par-4 was used to block Par-4 mediated apoptosis. This assay was performed
with the help of Dr. Nikhil Hebbar, University of Kentucky.
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Primary Eμ-Tcl1 mouse CLL cells and purified mouse splenic B cells were isolated via
complement dependent T cell depletion: 25x106 total spleen cells in 10ml total volume were
plated on 10cm petri dishes and incubated for 1hr at 37°C for macrophage depletion. Cells are
then collected and RBCs are lysed at 100x106 cells per 1ml of RBC Lysis Buffer (Sigma
Cat#R7757). Cells are then washed and re-suspended in antibody mix containing Thy1.2, Lyt2,
and L3T4 at a cell density of 25x106/ml and incubated for 40min on ice. 10ml of HBSS is then
added to the antibody mixture with cells and centrifuged to wash. Rabbit IgG complement is
then added at 1ml per 25x106 cells and incubated in 37°C water bath for 30 min. Cells were then
washed in HBSS. Isolated B cells were then stimulated with 5μg/ml LPS (Millipore Sigma-Aldrich,
St. Louis, MO) for 12 hrs in low serum (0.05%FBS) RPMI. Media was collected and concentrated
using Amicon Ultra-4 centrifugal filter concentrators (Cat #UFC801024, EMD Millipore, Billerica,
MA). The conditioned medium was probed for Par-4 and collagen (Col) 1A. Albumin was
detected by Coomasie blue stain. The cells were also collected and the lysates were used to
measure total cellular Par-4 levels.
2i) shRNA Lentiviral Infection
Mec-1 CLL cells were transduced with lentiviruses expressing Lyn shRNA and Par-4
shRNA. Lyn shRNA gene set prepared by the RNAi Consortium was purchased through
ThermoFisher Scientific (now with Dharmacon or open Biosystems) (Cat #RHS4533). We
observed the highest knockdowns with Lyn shRNA clones # TRCN0000010101 and
#TRCN0000010107, and hence were used in these studies. Par-4 shRNA constructs were cloned
into the pLKO.1 lentiviral vector. Lentiviruses were packaged in HEK-293-T cells by
cotransfection with pMD2.G (VSV G) envelope plasmid (Addgene Cat # 12259) and the Gag, Pol
expressing psPAX2 packaging plasmid (Addgene #12260). Lentiviral particles were collected
from the supernatants after 48hrs of transfection and then transduced in Mec-1 cells. 1.5x106
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Mec-1 cells were infected with the target shRNA lentivirus and 10μg/ml Polybrene (Cat #
SC134220, Santa Cruz), in 4ml of complete IMDM media by centrifugation for 90 min at
2800rpm at 10°C (spinoculation technique). Viruses and cells were incubated for 24hrs at 37°C
and then fresh media was replenished. Puromycin dose antibiotic selection began at day 3 and
remained in culture for the entire period of experimentation after proper titration. Limiting
dilution was performed earlier to determine that Mec-1 cells seeded at 0.5cells/well in 96 well
plate were capable to of growing. shRNA infected cells were then added to 96 wells and clones
were generated. Less than 15% of the wells generated knockdown clones that expanded. Gene
silencing efficiency was analyzed by immunoblot for respective proteins. Control shRNA and Par4 shRNA Mec-1 cell growth rate was monitored through counting and trypan blue exclusion
using a hemacytometer. Total cell numbers were recorded with each passage and extrapolated
total cell counts were calculated.
2j) Knocking out selected SFKs using CRISPR- Cas 9 techniques
R6-22 Lenti CRISPR V2 plasmid construct (Plasmid # 52961) included the Cas9
nickase and guide RNA and was obtained from Addgene (Cambridge, MA) along with R6-21
pCMV-VSV-G (Plasmid #8454) and R6-20 pLJM1-EGFP (Plasmid number 19319) for viral
constructs in bacterial stabs. Cultures were grown up and plasmids were isolated using Omega
EZNA Plasmid DNA Midi Kit (Omega Biotek Norcross, GA, Cat #D6915-03). Lenti CRISPR V2
plasmid was cut with Bsmb1 restriction enzyme (NEB Biolabs Ipswich, MA, Cat #R0580S) to
generate overhangs. Guide RNAs were designed using GeCKO (Genome scale CRISPR Knock-Out)
program in the Lentiviral CRISPR toolbox provided by Zhang Lab at Massachusetts Institute of
Technology (Cambridge, MA). NCBI RefSeq was used to confirm guide RNAs: Lyn NP_002341, Fgr
NP_001036212, and Lck NP_001036236. Oligonucleotide primer sequences of targets with
BsmB1 sites were designed and obtained from IDT (Integrated DNA Technologies Coralville, IA)
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(Table 3). Oligonucleotides were annealed and ends dephosphorylated before ligating oligo
duplexes into BsmB1 cut Lenti-CRISPR V2 plasmid. Complete plasmid with target guide RNA was
when ligated into NEB 10-beta Competent E. Coli (NEB Biolabs Cat # C3019H) and amplified in
culture. Plasmids were cut to confirm that the target sequence was inserted correctly with
SnaB1 restriction enzyme (NEB Biolabs Cat #R0130S) and also sequenced by ACGT Sequencing
Services. Plasmids with Lyn, Fgr, and Lck target sequences were confirmed and then sent to the
Genetic Technologies Core (GTC) at the University of Kentucky. Lentivirus titer was performed in
the GTC and 1.5x106 Mec-1 cells were infected with 1x106 infection units in 4ml of complete
IMDM media by centrifugation for 90 min at 2800rpm at 10°C. Cells were incubated with viruses
for 24hrs at 37°C and then fresh media was replenished. Puromycin antibiotic selection began at
day 3 and remained in culture for the entire period of experimentation after proper titration
(1.5μg/ml). Gene silencing efficiency was analyzed by immunoblot for respective proteins.
Table 3: Designed Guide RNA oligonucleotide sequences for CRISPR-Cas9 knockout studies.

Guide RNA
Lyn1a
Lyn4a
Fgr1
Fgr2
Lck1
Lck2

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5' → 3'
CACC GTT CTT TCA GTA TTA CGT AC
AAAC GTA CGT AAT ACT GAA AGA AC
CACCG TAA CCG CTC TGA CTC CCG TC
AAAC GAC GGG AGT CAG AGC GGT TA
CACC GGC GTG TCA GAG GCT ACC GC
AAAC GCG GTA GCC TCT GAC ACG CC
CACC GAA AAG CTA TAT AGA CGG TTA
AAAC TAA CCG TCT ATA TAG CTT TTC
CACC GTG GTG GCT ACG ACG GCG AA
AC TTC GCC GTC CTA CGG ACC AC
CACC GGT GGT GGC TAC GAC GGC GA
AAC TCG CCG TCG TAG CCA CCA CC
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2k) CD79 siRNA Knockdown Study
CD79 siRNA (Cat # SC-35025) and control siRNA (Cat # SC-37007) were obtained from
Santa Cruz Biotechnologies. Human CLL samples obtained from peripheral blood collection were
purified by Ficoll-paque density gradient. 20x106 CLL cells were then transferred in 200μl PBS to
a 0.4cm electrode gene pulser cuvette (Cat # 165-2008, BioRad, Richmond, CA) with 10μg of
control or targeted siRNA. The cells were then pulsed at 220mV or 250mV, 960μF, 0Ω and then
quickly transferred to 4ml RPMI (5x106 cells/ml) for 24hr incubation and then collected for
immunoblot analysis. Control siRNA was only pulsed at 250mV, 960μF, 0Ω.
2l) In vivo tumor study
Mec-1 CLL cells were transduced with lentiviruses expressing Par-4 shRNA or Control
(scrambled) shRNA. Cells expressing shRNA constructs were selected with puromycin treatment
for 26 days and knockdown was confirmed through immunoblot analysis. 2x106 shRNA
expressing cells were injected subcutaneously into flanks of NSGS mice with 1:1 ratio of matrigel
(#354234, BD Biosciences) in 100μl volume. Par-4 shRNA cells were injected on the right flank
and control shRNA cells were injected on the left flank with 6 mice for each group. Tumor
volumes were measured using electronic caliper and tumor volumes were calculated by length
(mm) x width2(mm). Significance was determined by student t-test for each day of
measurement.
2m) Cell Cycle Analysis
After selection and confirmed knockdown of Par-4, shRNA infected Mec-1 cells (5 x 105) were
cultured in 48 well plates in triplicate for 48hrs and then analyzed for cell cycle stage after fixing
with cold 70% ethanol for 1hr at 4°C and incubation with a mixture of 1µg/ml propidium iodide
(PI) (Sigma Aldrich, P1470) and 25µg/ml RNase A (Sigma Aldrich, R6513) at 37°C for 30 min. The
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level of PI fluorescence was measured with a FACSCaliber flow cytometer. Cell populations in G1,
S, G2/M phase were calculated using ModFit Software.
2n) Quantitative Real-time PCR (qRT-PCR)
Total RNA was isolated from different cell populations using TRI reagent (Sigma Aldrich
Cat #T9424) and quantified with ThermoScientific Nanodrop 1000 Spectrophotometer. A total of
0.5μg of RNA was then used to make cDNA with qScript cDNA SuperMix (Quanta Bioscience Cat
#95048-100, Gaithersburg, MD). iTaq Universal SYBR Green Supermix (BIO-RAD Cat #172-5121,
Hercules, CA) was used to carry out the RT-PCR reaction with indicated primers. Sequences are
provided in Table 4 and primers were obtained from IDT technologies (Coralville, IA). RT-PCR
was performed using BioRAD CFX96 Touch Real-time PCR Detection System.
Table 4: List of qRT-PCR primers

Target Gene
mPar-4
m18S
hPar-4
hp21
h18s

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

5' → 3'
GACTTGTGAGGCTGATGCAA
GCCCAACAACCTTCAAAAGA
CGCCGCTAGAGGTGAAATTCT
CGAACCTCCGACTTTCGTTCT
GAAGATGCAATTACACAACAGAACAC
TAGCAGATAGGAACTGCCTGGAT
CAGACCAGCATGACAGATTTC
TTAGGGCTTCCTCTTGGAGA
TTCGAACGTCTGCCCTATCAA
ATGGTAGGCACGGCGACTA

2o) Tissue Histology
Whole spleen tissues were collected from mice at the time of euthanasia and a
fragment was cut for tissue analysis. Pieced spleen was placed in a tissue cassette and fixed in
Buffered Formalde-Fresh 10% Formalin (Fisher Scientific Fair Lawn, NJ Cat #SF93-4). Tissues
54

were then processed and embedded in paraffin blocks by the Markey Cancer Center
Biospecimen Procurement and Translational Pathology Shared Resource Facility (MCC BPTP
SRF). Tissue blocks were cut and spleens were stained with Hematoxylin and Eosin staining.
Gross morphological changes were noted by expanded white pulp and loss of follicular
architecture within the tissue.
2p) Ultrasound Imaging
Mice were sedated with isoflurane using an anesthetic vaporizer with a dial setting of 23% in the induction chamber followed by maintenance at 1.5% oxygen carrier gas at 4 liters/min
at induction and at 1.5 to 2 liters/min as maintenance for a mouse weighing 300 grams. Mice
were placed on a heated platform (capable of monitoring Heart rate) and the areas to be
examined were shaved using a Wahl series 8900 cordless rechargeable animal trimmer and hair
is further removed using a depilatory (Nair, Church & Dwight Company), approximately 0.1-0.5
ounces is applied using Q tips on the region of abdomen or thorax that was to be imaged. The
depilatory was allowed to stay for 2-3 minutes and then wiped off with unscented baby wipes
(PDI nice or M233XT Quick medical), and the skin was allowed to dry. Pre-warmed ultrasonic gel
of about 0.5-2 ounces was applied. Mice were scanned using a solid-state transducer for the
measurement of enlargement of spleen and any irregularities in the spleen and other abdominal
organs if any. After scanning, the ultrasonic gel was removed/ wiped off and mice were placed
back in the cage on padding to recover while being observed. The ultrasound machine, probe,
nose cone, platform and surrounding areas were cleaned using a disinfectant (T-Spray II ® by
Pharmaceutical Innovations, Inc.) supplied by the manufacturer. The ultrasound machine (Vevo
2100), probes and equipment are manufactured by Visualsonics (FUJIFILM, Toronto, ON).
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2q) Splenectomy
Prior to surgery, the animal is assessed for normal activity and then the abdomen is
shaved using a Wahl series 8900 cordless rechargeable animal trimmer and hair is further
removed using a depilatory (Nair). Isoflurane (1-5% in O2) is inhaled through a nose cone at 1.5
to 2 liters/min. Artificial tear replacement ointment (Lacrilube) is placed on the eye of the
mouse to prevent dehydration. Behavioral cues and respiratory rate are monitored closely
during anesthesia. The animal is placed on a sterilized surgical pad on top of a heating pad to
maintain body temperature. The animal is placed on its right side and scissors are used to make
approximately a 2.0cm cut of the skin on the left side. Connective tissue is then gently moved
away from the abdominal wall to where you can visual the spleen through the peritoneum. A
1.5cm incision is then made in the peritoneal wall and the spleen is gently pulled to the exterior.
A 4-0 absorbable suture is used to look and tie off the splenic artery and the efferent venule.
After vessel ligation, the spleen is removed. The peritoneal wall is closed with one or two
absorbable sutures in a simple interrupted stitch. The skin is then closed with 9mm stainless
steel wound clips (AUTOCLIP, Clay Adams Brand, Cat# 427631). The animal is then given
sustained release bubrenorphine (Animalgesics Labs) at 3.25mg/kg, subcutaneously once at the
completion of surgery. Mice are then monitored daily for 3 days and checked twice weekly
following. The wound clips are removed after 10-14 days, with triple antibiotic cream applied.
2r) Statistical Analysis
Statistical analyses was performed using GraphPad Prism 7 (GraphPad Software, Inc., La
Jolla,CA). Statistical significance of differences between groups was evaluated by Student’s ttest, growth rates of cells were analyzed by linear regression analysis calculated through the
slope, and Kaplan-Meier curves were analyzed by Log-Rank test and Gehan-Breslow-Wilcoxin
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Test. Correlation statistics were tested by linear regression analysis. Experiments testing the
means overtime were analyzed by two-way ANOVA. P values < 0.05 were considered significant.

Copyright © Mary Kathryn McKenna 2017
57

CHAPTER 3
Eμ-Tcl1 CLL cells have elevated expression of Par-4
Prostate Apoptosis Response-4 (Par-4) is a known tumor suppressor that is down
regulated by promoter methylation in about 30% of cancers including renal cell carcinoma and
Acute Lymphoblastic Leukemia (ALL) [244, 245]. Par-4 was originally identified by its
upregulation during apoptosis of prostate cancer cells and later was shown to have a cancer
selective mechanism of inducing cell death through its specific SAC domain [168]. Par-4 has
been shown to be activated by Protein Kinase A (PKA) phosphorylation at
Thr155(rat)/Thr163(human) residue. This site is located in the SAC domain and allows Par-4 to
translocate to the nucleus and inhibit NF-κB activity in cancer cells but not normal cells [169].
This specificity for cancer cell death makes Par-4 an attractive therapeutic target in many
cancers that has resulted in clinical trials to enhance Par-4 mediated cell death in solid tumors
[246]. To date, only three studies have examined Par-4 expression in CLL and these have led to
some suggested prognostic indicators [190, 202, 203]. Initially, Boehrer et al. examined the
levels of Par-4 in normal and neoplastic lymphocytes and found that all patients with CLL (n=30)
expressed Par-4 protein levels, but only 63% were positive for Par-4 mRNA expression
suggesting that there may be a difference in Par-4 regulation in different types of leukemia
[190]. Previous studies had indicated that Par-4 and Bcl-2 are inversely correlated [191], but
there was no relationship found between the expression of Par-4 and Bcl-2 protein expression in
CLL patients. Next, Chow and colleagues found that CLL patients that lacked the Imatinib targets
BCR-ABL, C-Kit, PDGFR were still sensitive to Imatinib treatment and that the response
correlated with Par-4expression [202]. Additionally, this study confirmed Boehrer et al. finding
that there was no relationship between Par-4 expression and Bcl-2 in patients that did or did not
respond to Imatinib treatment. Par-4 was also downregulated in the course of the treatment
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with Imatinib when cells underwent apoptosis after caspase-8 and -3 activation [202]. Lastly,
Borjarska-Junak and colleagues assessed the expression of Par-4 in CLL B-cells and found a
positive correlation of Par-4 with Bcl-2, which is opposite of what is observed in nonhematopoietic cells. Par-4 was also positively correlated with DAXX (death associated protein),
and ZIPK (zipper interacting protein kinase) expression [203]. Additionally, Par-4 was found to
associate with LDH (lactate dehydrogenase) serum concentrations and was more highly
expressed in CD38+ CLL patients who have a more aggressive form of CLL disease [35, 71]. These
initial studies suggest that Par-4 in CLL may be regulated differently in this hematologic disease
and have other regulatory mechanisms. Therefore studies presented in this chapter investigated
the level of Par-4 expression in CLL cells from the Eμ-Tcl1 mouse model compared to normal B
cell subsets, specifically B1a cells, one of the suggested normal counterparts of CLL. We made
the surprising finding that Eμ-Tcl1 CLL cells express elevated levels of Par-4 that has been proven
to be functional by inducing apoptosis of solid tumors, but CLL cells themselves were not
sensitive to Par-4 mediated apoptosis. This observation also translated to human CLL samples
that over expressed Par-4 compared to normal donor peripheral blood cells. Studies presented
in this chapter also examined the expression of Par-4 in the primary CLL models as well as the
adoptive transfer model of murine CLL.
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Results
3a) Eμ-Tcl1 B-CLL spleen cells have elevated levels of Par-4 expression
Although increased constitutive Par-4 expression has been described in CLL cells, most
previous studies compared CLL cells to peripheral blood total B cells which are mostly made of
B-2 cells. Hence we isolated CLL cells from the spleens of Eμ-Tcl1 mice which were CD5+CD19+
(Figure 3.1A). B cell subsets were isolated from the peritoneum and spleens of C57BL/6 WT mice
and FACS sorted into specific populations of B1a: CD19+CD5+CD11b+, B1b: CD19+CD5-CD11b+,
and B2: CD19+CD5-CD11b- cells (Figure 3.1B) [15]. Immunoblot analysis indicated that Eμ-Tcl1
CLL cells expressed high levels of Par-4 protein compared to all the normal B cell subsets (Figure
3.1C). B1a cells expressed more Par-4 compared to the other B cell populations but only ~33% of
the observed levels in CLL. Par-4 mRNA expression was also elevated in CLL cells compared to B
cell subsets, mirroring the levels of Par-4 protein expression (Figure 3.1D). Because Eμ-Tcl1 CLL
cells overexpress the Tcl1oncogene, we questioned if the observed increase in Par-4 expression
was associated with Tcl1. We isolated different B cell subsets from 2mo old Eμ-Tcl1 mice that
had no detectable levels of CLL in the peripheral blood and measured Par-4 levels compared to
WT B cell subsets (Figure 3.1E). B1a Eμ-Tcl1 cells expressed higher Par-4 protein levels compared
to B1b and conventional B2 Eμ-Tcl1 cells. This finding was similar to what was observed in WT B
cell subsets. All the Eμ-Tcl1 B cell subsets express Tcl1 as indicated in Fig. 3.1E and shown in
reference [144], but Par-4 protein levels were not as highly expressed as compared to spleen
cells from Eμ-Tcl1 mice with >90% CD5+CD19+ CLL cells. This result led us to investigate if
increased Par-4 expression resulted from leukemic progression in Eμ-Tcl1 mice. As previously
observed, CD5+CD19+ B cell percentage increased with the age of the mice in the peripheral
blood and spleen (Figure 3.1F and[209]) and immunoblot analysis of whole spleen cells from the
different aged Eμ-Tcl1 mice indicated that Par-4 protein expression increased with CLL burden
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(Figure 3.1G). We confirmed this correlation by examining the relationship between the
percentage of CD5+CD19+ cells and Par-4 expression in the spleens of Eμ-Tcl1 mice. This
indicated a positive association between leukemic burden and Par-4 (r2=0.7495, p<0.0055)
(Figure 3.1H). On the other hand, Par-4 expression did not correlate with Tcl1 levels when both
proteins were normalized to β-actin (r2=0.003958, p =.8824) (Figure 3.1I). When comparing
multiple different CLL samples that arose in individual mice, we also saw some variation in levels
of Par-4 that also did not correlate with changes in Tcl1 expression (Figure 3.1J).
3b) Primary human CLL cells express elevated Par-4 levels
We wanted to see if this elevated Par-4 expression was just a mouse phenomenon or if
Par-4 was also highly expressed in human CLL. Primary human CLL peripheral blood samples
were obtained through consent and IRB approval and compared to normal human donors
summarized in Table 5. Such comparison to normal controls was not performed in previous
studies. CLL was confirmed through CD5+CD19+ staining by flow cytometry (Figure 3.2A) and
total protein was isolated and probed for Par-4 expression (Figure 3.2B). CLL samples expressed
significantly higher levels of Par-4 protein when compared to normal donors. The Par-4 gene has
been mapped to the middle portion of chromosome 12 that has also been implicated in CLL
pathology as it is associated with about 16% of diagnosed CLL cases [164, 247, 248]. According
to patient data indicated in Table 3.1, there does not appear to be a gene dosage effect of Par-4
expression in patients that express trisomy 12 (Figure 3.2C). For example, patients 11 and 14 are
indicated to have trisomy 12, but appear to have less Par-4 than others that are not indicated to
have cytogenetic abnormalities. With the help from our collaborators at Ohio State University,
we were able to test the levels of Par-4 in patients with U-CLL and M-CLL (Figure 3.2D)
(p=0.231). It appears that Par-4 expression is slightly higher in the more aggressive U-CLL form
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of CLL but it is not significantly different, p=0.231. However, more samples would be needed to
further confirm this result.
3c) Expression of Par-4 in adoptive transfer mouse model of CLL
We observed that Par-4 is highly expressed in the splenic B-CLL cells of the Eμ-Tcl1
primary mouse model compared to the normal counter part of B1a cells [79, 93]. We have
confirmed that the splenic CLL cells from the de novo primary Eμ-Tcl1 mouse and the adoptive
transfer CLL cells express almost identical cell surface molecules (Table 6), but we wanted to
confirm that these cells retain similar Par-4 expression after transfer. Initially, we showed that
the primary Eμ-Tcl1 spleen and adoptive transfer spleen yielded similar total WBC counts and
percent of CD5+CD19+ cells as shown in Figure 3.3A. Transfer of different primary Eμ-Tcl1 CLL
cells that arose de novo in individual mice may exhibit delayed or progressive variable growth
patterns, but on average, these mice tend to develop CLL like disease in about 3-8 weeks. A
representative growth curve of CLL in the peripheral blood is depicted in Figure 3.3B compared
to normal peripheral blood CD5+CD19+ cells in WT mice. We are able to monitor CLL growth in
recipient mice through submandibular cheek bleeding and FACs analysis over time. We isolated
tissues from the recipient mice after CLL development and found that CD5+CD19+ CLL cells were
present in the spleen, peripheral blood, lymph node, bone marrow, peritoneal cavity, liver, and
omental tissues (Figure 3.3C, left). This is a dramatic increase compared to normal spleen, lymph
node, and bone marrow tissues of a non-injected animal (Figure 3.3C, right). Additionally, we
probed for Par-4 and Tcl1 expression in these tissues of CLL injected mice compared to the
primary Eμ-Tcl1 CLL cells that arose de novo (Figure 3.3D). All tissues expressed Tcl1, confirming
the presence of CLL cells and there was high Par-4 expression as well.
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3d) Par-4 is secreted by CLL cells and is functional in inducing apoptosis
Par-4 is a known tumor suppressor in solid tumors and is able to induce apoptosis in an
intrinsic as well as an extracellular manner [165, 244]. Because we observed that CLL cells
expressed high levels of Par-4 but their survival is maintained, we questioned if Par-4 is able to
translocate to the nucleus where it is known to interact with NF-κB. Nuclear and cytoplasmic
compartments were isolated from multiple primary Eμ-Tcl1 CLL samples and Par-4 was detected
in both cellular locations (Figure 3.4A). Tcl1 expression was also located in both locations except
for CLL #1. Presently we do not know why Tcl1 was absent in the nucleus of this one CLL sample.
Additionally, the Mec-1 CLL cell line and primary human CLL samples were examined for Par-4
localization and the protein was also found within both compartments in these cells (Figure
3.4B).
Par-4 is also found to be secreted by many cells to induce apoptosis in an extracellular
manner [199]. We found that CLL cells do secrete high amounts of Par-4 compared to normal
and stimulated spleen B cells (Figure 3.4C). Because CLL cells undergo apoptosis quickly in
culture, we questioned if the secreted Par-4 that we detected was just due to apoptosis of the
cells. We cultured primary mouse Eμ-Tcl1 CLL cells with or without LPS or αIgM stimulation and
measured Par-4 secretion. Additionally, we probed for GAPDH in the conditioned medium as an
indicator of cell apoptosis and lysis because GAPDH is not supposed to be secreted (Figure
3.4D). GAPDH levels were very low in the concentrated medium in comparison to the cell
lysates, whereas Par-4 levels in conditioned medium were almost as high as observed in total
cell lysate.
Additionally, we adoptively transferred Eμ-Tcl1 CLL cells into syngeneic C57BL/6 WT
hosts and mice null for Par-4 [184] and detected similar levels of Par-4 in the plasma of WT and
Par4-/- mice 4 weeks after transfer via western blot (Figure 3.4E). This confirmed that Eμ-Tcl1 CLL
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cells secreted Par-4 in vivo. We also examined the spleens of these recipient mice after
termination to confirm that Par-4 and Tcl1 were expressed in the Par4-/- recipients to indicate
CLL engraftment.
We next tested if Par-4 secreted from CLL cells was functional in inducing apoptosis of
the Par-4 sensitive H460 lung cancer cell line. Conditioned medium from CLL cell culture applied
to the H460 cell line induced apoptosis which was reduced by inclusion of anti-Par-4 antibody
but not control IgG (Figure 3.4F). We also confirmed that human CLL samples secrete Par-4 with
or without stimulation (Figure 3.4G).
Extracellular Par-4 requires the receptor GRP78 to bind and induce extrinsic apoptosis
[199]. CLL cells have slightly lower levels of basal GRP78 protein compared to other cell lines and
may be one reason why CLL cells are not sensitive to the known pro-apoptotic effects of Par-4
(Figure 3.2H) but further studies examining the location of GRP78 are required.
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Figure 3.1A
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Figure 3.1B
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Figure 3.1C

Figure 3.1D
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Figure 3.1E

Figure 3.1F
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Figure 3.1G
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Figure 3.1H

Figure 3.1I
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Figure 3.1J

Figure 3.1: Eμ-Tcl1 B-CLL spleen cells have elevated levels of Par-4 expression
A) Spleens were collected from Eμ-Tcl1 and C57BL/6 mice at similar ages. Tissue was
processed and stained with H&E for histology analysis. Single cell suspensions from spleens
were stained for CD45, CD5, and CD19. A representative FACs profile for a diseased mouse
(10.1mo) is shown with 84.95% CD5+CD19+ cells compared to a normal 12.6mo WT mouse with
8.56% CD5+CD19+ cells. B) Peritoneal cavity cells were isolated from 20 WT 16 week mice and
pooled together. Cells were stained for CD19, CD11b and CD5 and gated into B cell subsets as
indicated and isolated by FACs sorting. C) Immunoblot analysis of peritoneal cavity B cell
subsets, Eμ-Tcl1 CLL spleen cells, and WT isolated B2 spleen cells probed for Par-4 and Tcl1.
Densitometry values are normalized to β-actin. D) Relative Par-4 mRNA expression measured in
Eμ-Tcl1 CLL cells and WT B cell subsets. Par-4 mRNA levels were normalized to mouse 18S mRNA
expression. These values were normalized to B1a Par-4 mRNA expression. Results show mean ±
SE of triplicate samples. E) Peritoneal Cavity cells were collected from both WT (n=20) and EµTcl1 mice (n=4) ranging in age of 2-3mo and sorted in to B cell subsets according to Fig 3.1b.
Total protein was isolated. Immunoblot analysis was performed to determine the expression of
Par-4 and Tcl1 proteins. F) Total percentage of CD5+CD19+ cells in the spleens of Eμ-Tcl1 mice
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increase with age and CLL disease development. P value = <0.001 determined by One way
ANOVA. G) Spleens were collected from mice at three different ages. Nine spleens collected
from 4/5mo and 8mo each and 2 spleens from 11mo Eμ-Tcl1 mice. Three spleens were pooled
together and total protein was isolated and probed for Par-4 and Tcl1. Par-4 protein expression
is normalized to β-actin. ** indicates p value = 0.0012 determine by student t test between
4/5mo and 11mo EµTcl1 mice. H) Correlation of Par-4 protein expression and percentage of
CD5+CD19+ cells EµTcl1 mice. I) Correlation of Par-4 protein expression and Tcl1expression in
the spleens of EµTcl1 mice at different ages. Each point represents an average of three mice. r2
value was determined by Pearson Coefficient test. p = 0.0055 (H) p =0.8824 (I) determined by
linear regression analysis. J) Immunoblot analysis of Par-4 and Tcl1 expression in multiple EμTcl1 CLL spleen samples compared to normal spleen. Lane 2 indicates gel loading ladder.
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Table 5: Human CLL Patient information.
Patient Number
hCLL Patient #1
hCLL Patient #2
hCLL Patient #3
hCLL Patient #4
hCLL Patient #6
hCLL Patient #7
hCLL Patient #8
hCLL Patient #9
hCLL Patient #10
hCLL Partient #11
hCLL Patient #13
hCLL Patient #14
hCLL Patient #15
hCLL Patient #16
hCLL Patient #17
hCLL Patient #18

Age
76
82
56
36
46
52
69
57
62
69
70
63
53
55
76
80

Treated
No
No
No
No
No
Yes
No
Yes
Yes
No
No
No
Yes
Yes
Yes
Yes

CD38+
Positive
Negative

Zap70+
Negative

Negative
Negative

Negative

Positive

Cytogenetics
Trisomy 12

13q deletion
13q deletion
Normal
11.7% 17p deleted cells
Trisomy 12, 13q deletion
Trisomy 12
13 q deletion

Positive

WBC (k/μl) %CD5+CD19+
19.8
87.66
20.7
90.54
82.35
38.3
88.08
41
44.01
15.2
81.37
29
83.88
40
50.33
83.7
10.55
30.2
95.71
17.4
80.45
34.8
96.97
12.1
84.73
6
13.64
36.6
37.23
142
97.73

Patient peripheral blood samples were obtained from the Markey Cancer Center
Hematology/Oncology Clinic through IRB consent. Total peripheral white blood cell (WBC)
counts at time of collection are indicated and the percent CD5+CD19+ cells were measured
through flow cytometry after collection. Cytogenetics, CD38+, Zap70+ are indicated if known
through previous diagnosis.
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Figure 3.2A
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Figure 3.2 Human CLL samples express elevated Par-4 protein levels
A) Representative FACS profiles of primary human peripheral blood samples diagnosed with BCLL stained with antibodies to CD5 and CD19 compared to two normal donors (ND#1 and ND#2)
B) Immunoblot analysis of Par-4 protein expression levels in primary hCLL samples compared to
a pooled whole peripheral blood lymphocyte lysate of two normal donors. Protein values were
normalized to β-actin. C) Primary patient samples were collected and total protein was isolated
from PBMC and analyzed by western blot to determine Par-4 expression. Densitometry was
determined by ImageJ analysis. Trisomy 12 levels were indicated from the patient’s medical
chart to subgroup patients. n=23 for non-trisomy 12 and n=7 for trisomy 12. p=0.879
determined by student t-test. D) Par-4 protein expression was determined by immunoblot
analysis in C) and IGHV status was measured by PCR. Patients were grouped into U-CLL if the
variable region was less than 2% different from the germline sequence. n= 16 for M-CLL and
n=14 for U-CLL. p=0.231 determined by student t-test.
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Figure 3.3 Expression of Par-4 in Adoptive Transfer Mouse Model of CLL
10 x106 EµTcl1 CLL cells were injected into C57BL/6 recipient mice which were monitored by
regular submandibular bleeding. A) Representative spleen sizes of C57BL/6, Eμ-Tcl1, and
adoptive transfer recipient after development of CLL. Total viable cell numbers were calculated
by hemacytomter using trypan blue exclusion and cells were stained for CD5, CD19 or IgM and
gated on CD45 positivity. B) Representative growth of CLL in adoptive transfer recipients (n=4)
measured through peripheral blood staining of CD5+CD19+ cells gated on CD45 compared to
PBS-injected C57BL/6 mice (n=2). Points represent mean + SEM. C) Percent CD45+CD5+CD19+
cells in the tissues of adoptive transfer recipient mice 48 days post injection (Right) compared to
normal C57Bl/6 mouse tissues (Left). D) Immunoblot analysis of Par-4 expression in tissues of
adoptive transfer recipient mice 48 days post injection compared to the primary Eμ-Tcl1 CLL
cells.
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Table 6: Comparison of WT, Eμ-Tcl1, and Adoptive Transfer recipient spleens.

Whole spleens were crushed and stained for immune cell markers and analyzed by flow
cytometry. Values represent percentage of cells in each population of total viable spleen cells.
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Figure 3.4A

Figure 3.4B
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Figure 3.4D
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Figure 3.4 Par-4 translocates to the nucleus, is secreted from CLL cells and is functional in
inducing apoptosis
A) Nuclear and cytoplasmic compartments were isolated from multiple primary Eμ-Tcl1 CLL
spleens, separated by SDS page, transferred to PVDF membrane and probed for Par-4, Tcl1,
HDAC, and GAPDH. Lane 5 is the protein ladder control marker. B) Nuclear and cytoplasmic
compartments were isolated from Mec-1, LY-10, and PC-3 CLL cell lines and Par-4 expression
was analyzed by immunoblot (top). None of these cell lines express Tcl1. Lane 4 is the protein
ladder marker. Primary human CLL nuclear and cytoplasmic fractions were probed for Par-4
(bottom). Lane 5 is the protein ladder marker. C) Conditioned medium (CM) was collected and
concentrated from WT splenic B cells alone or stimulated with 5μg/ml LPS and Eμ-Tcl1 CLL cells.
CM and total protein lysate from the cells were analyzed by immunoblot analysis for Par-4,
albumin, collagen 1A1, and GAPDH. D) Eμ-Tcl1 CLL cells were cultured with or without 25μg/ml
αIgM or 5μg/ml LPS for 12hrs and CM was collected, concentrated, and separated by SDS-Page,
and analyzed by immunoblot. CM Par-4 is normalized to Collagen 1A1 (Col1A1), a known
secreted protein, and Par-4 in the total cell lysate was normalized to GAPDH. E) Top: Plasma was
collected each week after adoptive transfer of Eμ-Tcl1 CLL cells into C56BL/6 WT mice and Par4-/animals. Plasma was diluted in 4X sample buffer and analyzed by immunoblot analysis for Par-4.
Mouse Embryonic Fibroblasts (MEFs) were used as positive control of Par-4. Week 4 sample for
Par4-/- plasma proteins are before week 3 due to loading error. Bottom: After 4 weeks of growth,
spleens were collected from WT and Par4-/- animals injected with CLL cells and lysates were
analyzed by immunoblot for Par-4 and Tcl1. Each lane represents one mouse. Par4+/+ recipient
#3 did not develop CLL. Densitometry values are normalized to β-actin. F) 400μl of conditioned
medium from Eμ-Tcl1 CLL cells was applied to H460 lung cancer cell line. H460 cells were treated
with control recombinant protein 100nM thioredoxin (Trx), 100nM recombinant TRX Par-4
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fusion protein, CLL CM, CLL CM with anti-Par-4 antibody, and isotype antibody for controls.
Apoptosis was measured by immunocytochemisty and DAPI morphology. Results are presented
as mean + SEM of triplicate determinations. G) Conditioned medium (CM) was collected and
concentrated from human peripheral blood CLL cells alone or stimulated with 25μg/ml αIgM.
CM and total protein lysate from the cells were analyzed by immunoblots which were probed
for Par-4. Lanes 1 and 2 represent duplicate samples. H) GRP78 expression in lysates from
indicated cell lines, de novo and adoptive transfer Eμ-Tcl1 CLL cells was determined by
immunoblot analysis. The blots were probed for β-actin as loading control.
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Summary
Originally we initiated this study to define the tumor suppressive role of Par-4 in CLL,
but made a surprising and exciting discovery that Par-4 is upregulated in both mouse and human
CLL cells. CLL is classified by CD5 and CD19 positivity so it is important to compare these cells to
the correct controls. Mouse B1a cells express both CD5 and CD19 making this subset of B cells a
likely comparison as suggested by many other groups [93, 249]. CLL cells overexpress Par-4
compared to normal B cells and the increased expression is not related to the increased
expression of the Tcl1 oncogene or the type of B cell subset. CLL cells and B1 cells express CD5
on the surface of their cells. In normal B1 cells, CD5 is thought to mitigate signaling through the
BCR to prevent activation from weak signals. We did not investigate if increased Par-4
expression is related to CD5 expression in B cells but is unlikely as the human Mec-1 CLL cells
also shows high levels of Par-4 but lack CD5 expression.
Our findings are consistent with studies presented by Boehrer and colleagues in that
most CLL samples have detectable Par-4 protein levels [190]. We also find detectable levels of
Par-4 mRNA in both mouse and human CLL samples. Our studies also showed that Par-4 in CLL is
able to translocate to the nucleus of CLL cells and is secreted. Further examination of the Par-4
protein must be done to determine if it is phosphorylated at the Thr155/163 residue which is
required for the known pro-apoptotic functions of Par-4 [169].
The ability of CLL cells to secrete Par-4 in vitro and in vivo is an interesting finding and
begs the question of what cells in the microenvironment are sensitive to Par-4 mediated
apoptosis. We show that CLL cells secrete Par-4 in vivo as detected in the plasma of Par-4
deficient mice injected with Eμ-Tcl1 CLL cells containing Par-4. We surmise that CLL secreted
Par-4 is not inducing an autocrine or paracrine apoptotic effect to other CLL cells as the tumor
burden continues to grow similarly in wild type and Par4-/- recipients injected with CLL cells.
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GRP78 expression is found to be slightly lower in CLL cells compared to other tumor cell lines
and could be the reason CLL cells are not sensitive to Par-4 mediated apoptosis. Additional
studies examining the location of GRP78 on CLL cells must be done to confirm this hypothesis.

Copyright © Mary Kathryn McKenna 2017
88

CHAPTER 4
Novel Regulation of Par-4 through BCR signaling in CLL
Although Par-4 is synthesized in many tumor cells, mechanisms that regulate its
expression have not been described thus far. Additionally, the function of Par-4 in normal cell
homeostasis has not been investigated as the majority of its effector functions have been
defined in cancer cells. Par-4 has been found to interact and bind to multiple proteins such as
PKCζ [163], WT1 [162], Akt [170], topoisomerase (TOP1) [182] and is downstream of ZIPK [198,
203]and Caspase-3 activation [196]. As shown in Chapter 3, CLL cells express high Par-4 levels
compared to normal B cells, leading us to investigate its regulation. Since CLL cells have been
shown to have elevated tonic BCR signaling [136, 227], we tested the hypothesis that Par-4
expression may be regulated by BCR signaling. The BCR pathway is required for the survival of
both normal and malignant B cells despite their oncogenic activation, making it a therapeutic
target in B cell malignancies [36, 99, 136]. Kinase inhibitors targeting SFK [250], Syk[124],
BTK[127], and PI3K [130] have all been proven effective in the treatment of CLL as each inhibits
required downstream survival signals. Anti-CD20 monoclonal antibodies such as rituximab have
also been proven efficient with combination of other chemotherapies [251]. We utilized FDA
approved therapies to target BCR signaling and examined the effects on Par-4 expression.
Studies in this chapter resulted in a surprising finding that inhibition of the BCR survival pathway
in CLL cells led to reduced Par-4expression.
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Results
4a) Constitutive BCR signaling in CLL cells
We first verified that EµTcl1 CLL cells have increased tonic BCR signaling by comparing pSFK levels in CLL to those in various normal B-cell subsets. Surprisingly such a comparison,
especially to normal B-1 cell subset has not been performed thus far either in human or mouse.
As shown in Figure 4.1A, EµTcl1 cells indeed have increased p-SFK compared to both B-2 as well
as B-1 cell subset in the WT and young Eμ-Tcl1 mice. Additionally, mouse CLL cells express
greater than two fold more total Lyn protein compared to other B cell subsets. We also
observed high levels of activated SFK in human CLL samples but could not detect a significant
difference compared to normal whole blood cells (Figure 4.1B). This could be because peripheral
blood cells from healthy adults have very few B cells (5-10%) but a large majority of T cells (7080%). T cells do have activated SFKs, which contributes to the SFK band seen in the normal
whole peripheral blood cells [252]. There are very few T cells in the blood of CLL patients with
the activated SFK coming primarily from neoplastic B cells.
4b) BCR inhibition leads to decreased Par-4 expression in mouse and human CLL cells
CLL cells have increased BCR signaling and elevated Par-4 expression; therefore we
hypothesized that kinases involved in the BCR signaling pathway may regulate Par-4 expression
(Figure 4.2A). Treatment with dasatinib (SFK inhibitor), fostamatinib (SYK inhibitor), and
ibrutinib (BTK inhibitor) all led to a decrease in EμTcl1 CLL survival measured through the MTT
assay (Figure 4.2B). We additionally confirmed that these inhibitors were effective in reducing
the survival of human CLL cells (Figure 4.2C). Immunoblot analysis shows that Eμ-Tcl1 CLL cells
treated with each kinase inhibitor led to reduced activation of its respective target (Figure 4.2DF). In agreement with our hypothesis, this inhibition was accompanied by a decrease in Par-4
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protein expression. We also observed decreased Par-4 mRNA levels after SFK and BTK inhibition,
suggesting regulation at the transcript level (Figure 4.2G). Par-4 protein down regulation was
replicated in primary human CLL samples after treatment with Dasatinib and Fostamatinib
indicating that this is not just a mouse phenomenon (Figure 4.2H). Although the kinase
inhibitors decrease CLL viability in 48 hour MTT assays, at 12-24 hours, when decrease in Par-4
levels could clearly be seen with the BCR signing inhibitors, the cell viability was still 70-80%.
Hence the decrease in Par-4 protein levels is unlikely due to nonspecific cell death.
4c) Lyn knockdown in CLL cells results in decreased Par-4 expression
We have observed that inhibition of BCR signaling in both mouse and human CLL cells
results in a novel downregulation of Par-4 expression at the protein and mRNA levels. As
mentioned before, primary CLL cells spontaneously undergo apoptosis in culture, making it
difficult to study mechanisms of regulation. Therefore, we utilized the human CLL cell lines,
Mec-1 and OSU-CLL for our studies. We first confirmed that these human cell lines were
sensitive to BCR signaling inhibition by treating cells with Dasatinib. Both Mec-1 and OSU-CLL
cells responded similarly to both primary mouse as well as human CLL cells (Figure 4.3A). The
cell lines were slightly less sensitive to drug treatment compared to primary cells, which could
be due to the background apoptosis occurring in primary CLL samples. Treatment of Mec-1 CLL
cell line with Dasatinib also reduced the activity of SFKs compared to total Lyn expression and
furthermore reduced Par-4 protein and mRNA expression (Figure 4.3B). Due to potential off
target effects with kinase inhibitors, we also used lentiviral mediated shRNA to target Lyn, as it
has been found to be important in the survival of B-CLL cells and required for BCR signaling [104,
106, 109]. Our first experiment led to a 60% knockdown of Lyn in the Mec-1 cell line and 50%
knockdown of Par-4 (Figure 4.3C, Left). We repeated our experiment and attained a 50%
knockdown of Lyn expression and a further reduction in Par-4 protein and mRNA expression
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(Figure 4.3C, Right). We also observed similar results in the diffuse large B cell lymphoma cell
line, LY-3, confirming that Lyn inhibition led to decreased Par-4 expression (Figure 4.3D).
We designed CRISPR-Cas9 constructs with guide RNAs targeting different SFKs
expressed in the Mec-1 cell line, cloned them into lentivirus, and infected the cells with these
viruses to knockout Lyn, Fgr, and Lck. Initial screening appeared to result in promising
knockdowns of these particular Src family kinases, but complete knockout was not achieved.
Attempts to single cell clone the knockouts were also made, but unfortunately, selection with
puromycin did not yield productive results. The initial knockdown of Lyn in the Mec-1 cells with
the CRISPR construct did reproduce the results with shRNA mediated knockdown that led to a
decrease in Par-4 expression (Figure 4.3E). Interestingly, at day 8 of puromycin selection, Fgr
levels were reduced by 72% which was maintained by day 13. Par-4 levels were down at day 8
but started to return by day 13. It is conceivable Fgr knockdown cells upregulate other SFKs such
as Lyn that may rescue Par-4 expression. The trend was similar for Lck but less obvious (Figure
4.3F). This may suggest that Lyn, the primary SFK in B cells, is able to compensate for loss of the
other SFKs or that other SFK members are not involved in Par-4 regulation.
For more specific targeting of BCR signaling, we used siRNA targeting CD79a (Igα), the
molecule required for BCR expression on the cell surface and downstream signaling in B cells
[36]. Inhibiting Igα expression prevents activation of non-receptor tyrosine kinases required for
BCR signaling and eliminates any pleiotropic effects of kinase inhibition with small molecules.
We observed a dramatic decrease in Par-4 expression with Igα silencing further confirming a
novel regulation of Par-4 through BCR signaling in one patient sample (Figure 4.3G, left). In
another patient sample, CD79a was difficult to detect, but we observed a slight down regulation
of Par-4 after silencing (Figure 4.3G, right).
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ERK signaling has been well defined to be critical for B cell development and
proliferation downstream of the BCR activation and has also been well studied to be a
therapeutic target in many cancers [132-134]. Because of its significance in B cell survival, we
inhibited ERK1/2 with SCH772984, a well characterized ERK2 inhibitor. There was a decrease in
Par-4 protein expression upon inhibition of ERK1/2 (Figure 4.3H)[253]. Interestingly, we did not
see a decrease in Par-4 expression in PC-3 cells after ERK inhibition suggesting that Par-4 is
downstream of a survival and proliferation pathway important in malignant B cells but not in
epithelial cancers such as prostate cancer.
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Figure 4.1A

Figure 4.1B
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Figure 4.1 Constitutive BCR signaling in CLL cells
A) Immunoblot analysis of peritoneal cavity B cell subsets, Eμ-Tcl1 CLL spleen cells, and WT
isolated B2 spleen cells probed for pSFK and total Lyn. pSFK levels are normalized to total Lyn
expression. Lyn, Par-4, and Tcl1 densitometry values are normalized to β-actin. B) Immunoblot
analysis of activated SFK and total Lyn protein levels in primary hCLL samples compared to Ficoll
purified peripheral blood lymphocyte lysate of four different normal donors (#1/2 pooled
together, #3, #4). Results from one of two experiments with similar results are shown.
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24

Figure 4.2 BCR inhibition leads to decreased Par-4 expression
A) Simplified diagram of BCR signaling indicating the kinases targeted with inhibitors: Lyn
(Dasatinib), Syk (Fostamatinib), and BTK (Ibrutinib). B) Eμ-Tcl1 CLL cells were treated with
different concentrations of Dasatinib, Fostamatinib, or Ibrutinib for 48 hrs. Cell viability was
measured through MTT Assay. Results represent an average of three experiments. C) Survival
curves of human CLL cells treated with BCR signaling inhibitors. Data shown represents one of
three experiments. D) Western blots of lysates of Eμ-Tcl1 CLL cells treated with 1μM Dasatinib,
E) 5μM Fostamatinib, and F) 5μM Ibrutinib. Phosphorylated SFK, P-Syk, and P-BTK were
normalized to respective total proteins which were normalized to β-actin. G) Treatment of EμTcl1 CLL cells with Dasatinib and Ibrutinib decreases Par-4 mRNA as measured by qRT-PCR. Par-4
mRNA is normalized to mouse 18S mRNA expression. H)Primary human peripheral blood B-CLL
cells (97.7% CD5+CD19+) cells were treated with 1μM Dasatinib (left) and 2μM Fostamatinib
(right). Phosphorylated SFK and Syk bands were normalized to total proteins respectively. Total
Lyn, Syk and Par-4 were normalized to β-actin. Results are representative of at least two
experiments.
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Figure 4.3 Specific knockdown of Lyn leads to reduced expression of Par-4 in CLL cell lines
A) Eμ-Tcl1 CLL cells, two human CLL cell lines (Mec-1, OSU-CLL), and primary human B-CLL cells
were treated with different concentrations of Dasatinib for 48hrs and viability was measured by
MTT assay. Values represent mean ±SE of triplicate cultures. Results represent a minimum of
three experiments. B) Mec-1 CLL cell line was treated with Dasatinib (10μM) and for different
time points. Total protein and mRNA were isolated. Levels of phosphorylated SFK and total Par-4
protein expression were analyzed by immunoblot analysis (left) and mRNA measured through
qRT-PCR (right). mRNA values represent mean ±SE in triplicates normalized to human 18s. C)
Mec-1 CLL cell line was infected with control or Lyn specific shRNA lentivirus and selected for
puromycin resistance. Viable cells were collected at Day 13 (Left, Experiment 1) and Day 17
(Middle, Experiment 2) and total protein and RNA was isolated. Left panel represents
immunoblot analysis of Lyn protein. Right panel shows levels of Par-4 mRNA expression
measured by qRT-PCR. D) Lentiviral mediated shRNA knockdown of Lyn on Par-4 expression in
LY-3 lymphoma cell line. Western blot of lysates of control and Lyn shRNA treated cells probed
for Lyn, Par-4 and β-actin is shown. (Provided by Dr. Sunil Noothi) E) Lyn targeting guide RNA
was cloned into lentiviral plasmid (Lenti-CRISPR V2) containing CRISPR/Cas9 and puromycin
resistance gene. Lentivirus was grown in HEK 293T cells. Mec-1 cells were infected with the
lentivirus expressing Lyn specific guide RNAs and selected with puromycin. Lysates of
puromycin resistant cells collected at day 8 or 13 after infection were analyzed by western blot
to determine the degree of Lyn knockdown and Par-4 levels. F) Lentiviruses expressing
CRISPR/Cas9 and guide RNAs targeting Fgr and Lck were used to infect Mec-1 cells. Lysates of
puromycin resistant cells were analyzed by Western blots which were probed for target SFK and
Par-4. Densitometry values were normalized to GAPDH. G) Human CLL cells were electroporated
with CD79a siRNA and incubated for 24hrs. Different voltages were used for electroporation,
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middle lane: 220mV, right lane: 250mV. Ctl siRNA voltage was 220mV. (Left: hCLL p#10, Right:
hCLL p#15). Total protein was analyzed by SDS-PAGE and Western blots, which were probed for
CD79a and Par-4. H) Par-4 expression is regulated through ERK signaling in Eμ-Tcl1CLL cells but
not PC-3 cancer cells. Western blots of lysates of Eµ-Tcl1 CLL cells and PC-3 prostate cancer cells
treated with ERK1/2 inhibitor, SCH772984, were probed for p-Erk, ERK1/2 and Par-4. pERK levels
are normalized to total ERK1/2 and Actin. Par-4 protein expression is normalized to Actin. Blots
represent one of three experiments.
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Summary
Our initial finding that CLL cells overexpress Par-4 compared to normal B cells led us to
investigate how Par-4 might be regulated in this cancer. Due to the well-known activity of BCR
signaling in CLL, we first focused on this pathway. Treatment of mouse and human primary CLL
cells with inhibitors to SFKs, Syk, and BTK, led to reduced cell survival and a decrease in Par-4
expression. It is interesting to note that Par-4 down regulation is not seen until after 6hrs of
treatment with BCR inhibitors with the greatest decrease in Par-4 expression at 12+hrs. Because
Par-4 has been shown to interact with many different proteins such as Akt, PKCζ, WT-1 and
others, these proteins could be providing stability after cytotoxic agents until a threshold is met
leading to Par-4 degradation. We and others saw reduced Akt activity and total protein after
dasatinib treatment in CLL [254] suggesting that a decrease in Akt may not be responsible for
immediate down regulation of Par-4 after BCR inhibition since Akt phosphorylation destabilizes
Par-4. We have not investigated if PKCζ or WT-1 are affected after BCR inhibition in CLL. Since
much of the currently known regulation of Par-4 is through post-translational interactions, there
could be other proteins that are bound to Par-4. Structural studies focusing on the regulatory
interaction of Par-4 indicate that heterodimer interactions through the leucine zipper domain of
Par-4 mediate more stable interactions [255]. Ternary structures and heterodimers of Par-4
could be responsible for the increased stability of Par-4 in B-CLL cells. One study proposed that
Par-4 is involved in a ternary complex with PKCζ and p62 to regulate NF-κB activation [256]. p62
is also known as the sequestosome (SQSTM1) which is important in autophagy and regulates
transport of proteins between the nucleus and cytoplasm for proteasomal degradation [257].
Par-4 is known to inhibit NF-κB by blocking the activity of PKCζ, but p62 has been found to
antagonize this effect and prevent Par-4 mediated inhibition [256]. Dasatinib treatment has
been found to result in autophagy-mediated cell death in ovarian cancer [258] and acute
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myeloid leukemia [259], and therefore, could increase activation of autophagy initially that leads
to increased p62 expression and further stability of Par-4 in CLL. Studies to confirm increase in
LC3 lipidation after dasatinib treatment and measuring p62 levels must be done to validate this
complex hypothesis but could explain why we do not see decreased Par-4 levels until later time
points after BCR inhibition.
Par-4 is also known to be a target of caspase-3 activation and since BCR inhibitor
treatment results in cell death, we questioned if down regulation of Par-4 is only through
caspase-3 cleavage [196]. Our studies with Par-4 down regulation after specific Lyn shRNA
knockdown in stably growing cells make this an unlikely possibility. We also observe Par-4 down
regulation after Igα silencing which leads us to suggest that BCR signaling inhibition through
kinase inhibitors must activate other pathways that could result in Par-4 stabilization as
discussed above.
This novel finding of Par-4 regulation by BCR signaling needs to be studied further to
define the mechanisms of this control. Par-4 protein and mRNA levels are reduced after BCR
signaling inhibition suggesting that Par-4 may be regulated at the transcriptional level in CLL.
Assays to transfect Mec-1 CLL cell line with Par-4-Luc promoter were attempted to see if BCR
inhibition led to reduced luciferase activity. Unfortunately, CLL cells were difficult to transfect
and we were not successful in definitively answering the question. Preliminary findings showed
that luciferase activity was slightly reduced after BCR inhibition treatment with dasatinib, but
were not statistically significant. There was success in infecting Mec-1 cells with lentivirus
carrying shRNA that targeted Lyn kinase. Down regulation of Lyn resulted in decreased Par-4
expression at both the protein and mRNA levels. Results targeting Igα confirmed that Par-4 is
downstream of BCR activation and regulated through this signaling pathway. Additional studies
investigating the levels of Par-4 after ERK inhibition in CLL cells showed that Par-4 is further
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downstream of the BCR signaling cascade. This result provides evidence that a well-defined
survival signaling pathway is regulating the expression of Par-4 specifically in B cells since we did
not see down regulation of Par-4 after ERK inhibition in PC-3 cells. Studies in Ras-transformed
fibroblasts that expressed constitutively active ERK2 showed a decrease in Par-4 expression
which is the opposite of what we observe in CLL cells [181]. While ERK1/2 are activated in PC-3
cells, we may not see an effect on Par-4 due to increased signaling upstream of ERK1/2 in PC-3
cells. Protein kinase c-alpha (PKCα) and EGFR (epidermal growth factor receptor) signaling have
both been found responsible for ERK1/2 signaling in PC-3 cells and could be masking the effect
of ERK inhibition on Par-4 [260]. PKC-α is found to be variably expressed in CLL cells and
potentially could not compensate for the inhibition of ERK1/2 signaling on Par-4 expression
[261].
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CHAPTER 5
Novel Role of Par-4 in regulating the Growth of CLL
We have shown that Par-4 expression is abnormal in CLL cells compared to its
expression in other cancer types. Novel regulation of Par-4 expression in malignant B cells
appears to be through the BCR signaling pathway. These observations have led us to question
the role Par-4 in CLL. Previous studies have suggested that Par-4 regulation may be different in
CLL cells as its mRNA levels did not match protein levels in patients [190]. Also, treatment of CLL
cells with Imatinib led to reduced Par-4 expression and cell death [202]. Along with our findings,
these two studies suggest that intrinsic Par-4 may not be playing its well-defined role as a tumor
suppressor in CLL.
The original paper that identified Par-4 to be upregulated in response to calcium
mobilization in prostate cancer cells also identified the entire family of prostate apoptosis
response genes (Par-1, Par-3, Par-4, and Par-5) [161]. They discovered the genes involved in cell
death mechanisms were divided into two components: specific apoptosis response genes (par4) and genes induced by growth regulatory factors (par-1, par-3, and par-5). AT-3 cells (prostate
carcinoma) starved from serum and then stimulated with serum resulted in an induction of par1, par-3, and par-5 but not par-4. Sells and colleagues found that Par-4 was specific to apoptosis
response, but also indicated that other family members are involved in growth regulation [161].
We investigated how Par-4 may contribute to CLL pathogenesis and growth by knocking
down the expression of Par-4 in the Mec-1 CLL cell line. Additionally, we crossed the Eμ-Tcl1
mice to a Par4-/- animal to examine the role of Par-4 in the development of CLL. Our results lead
us to hypothesize that intrinsic Par-4 is not a pro-apoptotic factor in the context of CLL but
rather may be a growth factor that is a potential therapeutic target.
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Results
5a) Knockdown of Par-4 leads to reduced CLL growth
We sought to determine the role of Par-4 in CLL growth by knocking down Par-4
expression in the human Mec-1 CLL line. There was a decrease in Par-4 protein and mRNA levels
after lentiviral shRNA mediated knockdown in Mec-1 cells (Figure 5.1A). Cell Signaling lysis
buffer and RIPA buffer were used to lyse Mec-1 cells treated with control and Par-4 shRNA to
confirm knockdown. Par-4 is known to inhibit Akt phosphorylation and reduce Bcl2 levels, which
were increased in Par-4 knockdown Mec-1 cells, confirming specific Par-4 knockdown (Figure
5.1A) [178, 190]. We repeated the knockdown experiment and generated several clones from a
single infection with two different Par-4 shRNA constructs (Figure 5.1B). After we confirmed Par4 knockdown, we tested the importance of Par-4 for CLL growth by culturing cells with
continuous puromycin selection for 14 days and counting total cell numbers to generate a
growth curve with four clones of control shRNA and five clones of hPar-4 shRNA (Figure 5.1C).
Surprisingly, Par-4 knockdown resulted in an overall reduction in the growth of Mec-1 cells in
vitro (Figure 5.1D, p = 0.0024).
Subcutaneous injection of control shRNA and Par-4 shRNA knockdown cells into left and right
flanks of NSGS mice induced tumors which were followed for a period of 3 weeks, at which time
they had to be euthanized as per IACUC protocol (Figure 5.1E). Par-4 knockdown Mec-1 cells
grew more slowly in vivo, mimicking the in vitro results (Figure 5.1F). Injected tumors retained
their knockdown of Par-4 expression in vivo as shown through immunoblot analysis (Figure
5.1G).
5b) Par-4 knockdown leads to increased p21 expression
The unexpected result of Par-4 knockdown reducing the growth rate of Mec-1 CLL cells
(Figure 5.1) and an increase in known pro-survival and anti-apoptotic proteins of phospho-Akt
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and Bcl2, led us to investigate if Par-4 knockdown affected the cell cycle in CLL cells.
Interestingly, Par-4 knockdown Mec-1 cells had fewer cells entering S phase but more cells in G1
phase suggesting a halt in the G1 to S transition (Figure 5.2A). We initially probed a panel of cell
cycle regulators and kinases in the Par-4 knockdown cells and made an interesting discovery
that p21 expression is increased in cells with reduced Par-4 (Figure 5.2B). We did not observe
significant changes in CDK1 expression, but did find a slight increase in CDK4 expression. CDK4 is
found to be prominent in the G1 phase while CDK2 is active in the G1 to S phase transition
followed by CDK1 which is active in G2/M phase [262]. Cell cycle analysis indicates that a greater
number of Par-4 knockdown cells are present in the G1 phase supporting the increase in CDK4
expression. Slightly less CDK2 expression is consistent with the proposal that the Mec-1 cells are
remaining in G1 and not able to proceed through the cell cycle. There was no significant change
in p27 levels between control and Par-4 knockdown. We additionally probed for Hsp90 as many
cell cycle regulators are clients of Hsp90 chaperone activity to confirm that changes are not due
to cell stress. Hsp70 is an excellent indicator of loss of Hsp90 function and we did not see
changes in that expression of either protein. p21 is involved in different phases of the cell cycle,
but primarily works to control the transition from G1 to S [263]. Increase in p21 levels is likely to
responsible for the G1/S halt observed in Par-4 knockdown cells. Clones generated from a
second shRNA infection reproduced the results of increased p21 expression. An average of three
control shRNA clones and 7 Par-4 shRNA clones are represented in the histogram. Elevated
levels of Par-4 expression in the control shRNA levels result in decreased p21 levels with
reciprocal results shown in the Par-4 shRNA knockdown cells (Figure 5.2C). We then examined
Par-4 and p21 mRNA levels in cells knocked down with the human Par-4 shRNA construct. mRNA
levels mirrored results observed at the protein level with increased p21 expression in cells with
reduced Par-4 (Figure 5.2D,E).
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5c) Loss of Par-4 delays development of CLL in vivo
To determine the effect of Par-4 in the development of CLL, we crossed Eμ-Tcl1 mice
with mice deficient for Par-4 (Figure 5.3A). We tested several tissues including, spleen,
peripheral blood, peritoneal cavity, lymph nodes, bone marrow cells, and liver in the Par-4-/EμTcl1 mice and confirmed that they were deficient for Par-4, but positive for Tcl1 expression
(Figure 5.3B). We monitored CLL progression in the Par-4+/+EμTcl1 and Par-4-/-EμTcl1 by periodic
submandibular bleeding and measuring the percentage of CD5+CD19+ CLL cells in the blood by
flow cytometry. Mice were considered to be CLL if there was a distinct population of
CD5+CD19+ (>15-20%) cells defined on the FACS profile. Figure 5.3C shows that CLL
development is significantly delayed in Par-4-/- mice compared to wild type mice (p<0.0003).
Figure 5.3D represents the survival analysis for Par-4+/+EμTcl1 and Par-4-/-EμTcl1 mice. The
average age of death of Par-4+/+EμTcl1 was 8.9mo versus the 11.97mo for Par-4-/-EμTcl1 mice
(p<0.05). Par-4-/-EμTcl1 mice still developed CLL like disease as indicated by CD5+CD19+ staining
and gross pathology of the disease indicated by splenomegaly (Figure 5.3E). The total spleen cell
number was similar in Par-4-/-EμTcl1, Par-4+/+EμTcl1, and the adoptive transfer recipient spleen
of Par-4+/+EμTcl1 cells. Adoptive transfer of 7.6x106 Par-4-/-EμTcl1 CLL cells into WT and Par4 null
recipients resulted in similar rates of growth measured through submandibular bleeding (Figure
5.3F). This indicated that Par-4 was not required in the microenvironment for the growth of CLL,
but loss of Par-4 in the de novo mouse model delays disease development supporting a cell
intrinsic role for Par-4.
We discovered that Par-4-/-EμTcl1 spleen cells expressed higher p21 protein levels
compared to Par-4+/+EμTcl1 spleen cells providing in vivo confirmation of p21 upregulation
observed in vitro using Par-4 knockdown cell lines (Figure 5.4A). Additional comparison showed
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that p21 is present in spleens of Par-4+/+EμTcl1mice but the majority of Par-4-/-EμTcl1spleens
express 2-23 fold more p21 (Figure 5.4B). In order for p21 to execute its function to block the
cell cycle from G1 to S phase, p21 must be found in the nucleus of the cell [264]. Therefore we
looked at nuclear and cytoplasmic fractions of Par-4+/+EμTcl1 and Par-4-/-EμTcl1 spleen cells and
found that Par-4-/-EμTcl1 cells had greater nuclear p21 levels compared to Par-4+/+EμTcl1 cells,
further confirming that Par-4 knockout led to increased levels of functional p21 (Figure 5.4C).
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Figure 5.1A

Figure 5.1B
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Figure 5.1 Knockdown of Par-4 in vitro leads to reduced CLL growth
A) Left panel: Western blot of proteins in the lysates of Mec-1 cells expressing human Par-4
specific shRNA or control shRNA, which was probed for Par-4, pAkt , Akt, Bcl-2, and ß-actin Par-4
protein band intensities were normalized to Actin. Lanes 1 &2 are cells lysed with Cell signaling
lysis buffer and lanes 3 &4 are cells lysed with RIPA buffer. Right panel: Quantification of Par-4
mRNA in Mec-1 cells expressing Par-4 shRNA compared to those expressing a control shRNA by
qRT-PCR. Par-4 mRNA expression was normalized to human 18S RNA. B) Multiple clones of Par-4
knockdown Mec-1 cells were obtained by limiting dilution cloning in the presence of puromycin.
Lysates of these clones were analyzed for Par-4 expression by Western blot. Par-4 protein band
intensities were normalized to ß-Actin. C) Growth curves of several clones of Mec-1 cells
(indicated by letter and number) expressing control or human Par-4 specific shRNA in the
presence of puromycin (1.5µg/ml). Cell counts were determined by trypan blue exclusion. D)
Growth curve of Mec-1 cells expressing control or Par-4 specific shRNA, with each representing
mean and SE for four clones for control shRNA and five clones for Par-4shRNA expressing clones.
Slopes of the curves are different (P= 0.0024) as calculated by linear regression analysis. E) Mec1 cells (2x106) expressing control or Par-4 specific shRNA were engrafted into NSGS mice
subcutaneously with matrigel. Pictures show tumors on flanks after 35 days of growth. F) Tumor
volumes were calculated by measuring the length and the width with a caliper. Tumor volumes
are plotted as a function of time. Difference between the slopes of the two lines is found to be
statistically significant (P ≤ 0.001) by linear regression analysis. G) After 35 days of growth the
tumors were excised and Western blot analysis was performed on tumor cell lysates to confirm
tumors retained Par-4 knockdown in each mouse throughout the experiment. Lane 2 in each
blot is the protein ladder control marker.
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Figure 5.2 Par-4 knockdown leads to G1 cell cycle arrest and increased p21 expression
A) Mec-1 cells infected with control or Par-4 specific shRNA lentivirus were collected and stained
with propidium iodide. Cell cycle analysis was performed by flow cytometry. Histograms
represent mean + SE of four control shRNA clones and 5 Par-4 shRNA clones. B) Cell lysates from
control and Par-4 shRNA expressing Mec-1 cell clones were analyzed by immunoblot for
proteins involved in cell cycle. Lanes 1 &2 are cells lysed with Cell signaling lysis buffer and lanes
3 &4 are cells lysed with RIPA buffer. Protein values are expression normalized to β-actin. C)
Mean + SE of band intensities of Par-4 and p21 expression normalized to β-actin in 3 control
shRNA and 7Par-4 shRNA clones. Densitometry values determine by Image J analysis. P value =
0.00003 for Par-4 expression and p= 0.05 for p21 expression determined by student t-test. D)
Control and Par-4 shRNA expressing Mec-1 clones were collected and RNA was isolated. Par-4
mRNA (left) and p21 mRNA (right) were quantified by qRT-PCR and were normalized to human
18S RNA expression. E) Immunoblots of proteins from Par-4 and control shRNA infected Mec-1
clones (indicated by letter followed by a number) used for QRT-PCR assays in panel D.
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Figure 5.3A

Figure 5.3B
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Figure 5.3 Loss of Par-4 delays development of CLL in vivo
A) Breeding scheme of the Eμ-Tcl1 CLL mice crossed with animals deficient for Par-4, both on
C57BL/6 background. F1 generation was then intercrossed to get complete Par-4 knockout with
the expression of the human Tcl1 gene in B cells. B) Tissues from Par4-/-Tcl1 mice (Mouse 2057,
Age 13mo, 18days) were harvested and expression of Par-4 and Tcl1 was determined by
Western blot analysis. C) Percent of Par-4+/+ Eµ-Tcl1 and Par-4-/-EµTcl1 cohorts that developed
CLL over time. P value = 0.0002 determined by Log-Rank test. (n=16 Eμ-Tcl1, n=10 Par4-/-Tcl1).
Mice were defined as CLL positive if they have > 15-20% of CD5+CD19+ cells in their peripheral
blood. D) Effect of Par-4 loss on the survival of EµTcl1 mice. Survival curve represents a total of
17 Eμ-Tcl1 Par-4+/+ mice and 9 EµTcl1Par4-/- mice. P value = 0.0472 determined by Log-Rank test.
Mice were euthanized according to their body condition score. E) Comparison of spleens sizes
and total cell number in C57BL/6 WT (13.1mo), Par-4-/-EµTcl1 (11.9mo), and adoptive transfer
recipient injected with EµTcl1 cells. F) Kinetics of CLL development in WT and Par4 null mice
injected with Par-4-/-EµTcl1 CLL cells obtained from the cohort described in previous panels. n =
6/group. There was no statistically significant difference in the % of CLL cells in the two groups
of recipients at all time points tested.

126

Figure 5.4A

Figure 5.4B
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Figure 5.4C

Figure 5.4 Par-4-/- Eµ-Tcl1spleen CLL cells have increased levels of p21 expression
A) Spleens from multiple Par-4+/+ Eμ-Tcl1 and Par4-/-Tcl1 mice (individual mice numbered 1
through 6) were harvested, total protein was isolated and analyzed by SDS PAGE followed by
Western blots. . Immunoblots were probed for Par-4 and p21. Protein expression was
normalized to β-Actin. B) Spleen cell lysates from Eμ-Tcl1 mice and Par4-/-Tcl1 mice were
analyzed by immunoblots, which were probed for Par-4, p21, and Tcl1. C) Proteins from nuclear
and cytoplasmic fractions of cell lysates from Par-4+/+ EμTcl1 and Par-4-/- EμTcl1 CLL cells were
analyzed by Western blots, which were probed for p21 expression. Nuclear (N) loading control is
HDAC and cytoplasmic (C) control is GAPDH. p21 densitometry values were normalized to
respective controls.
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Summary
A valuable way to verify the importance of a gene product in molecular biology is to
knock out the gene and determine if there is an effect on the phenomenon of interest. Hence,
we knocked down Par-4 in the Mec-1 cell line. We found that Par-4 is not critical for the survival
of CLL cells, as Mec-1 cells persisted with a dramatic down regulation of Par-4 protein and mRNA
expression. Additionally, Par-4 is not required for the development and growth of CLL cells as
animals lacking Par-4 with the Tcl1 oncogene continued to develop a CLL like disease.
Loss of Par-4 did result in a decrease in growth suggesting that it is involved in CLL cell
proliferation. Decreased Par-4 levels resulted in a reduction in the G1 to S phase transition of
the cell cycle with a reciprocal induction of p21 expression. This is a novel finding as CLL cells in
the periphery of patients are in a quiescent state. The knockdown studies are done in a
transformed cell line that proliferates, which could be responsible for the retardation in cell
cycle, as infection with a scrambled shRNA construct did not change the growth pattern of the
Mec-1 CLL cells. While a proliferative cell line may not be the best model of quiescent CLL cells,
it does allow us to establish mechanisms in which these cells avoid apoptosis. It would be
interesting to investigate the cell cycle status of cells in spleens of Par4-/-Eμ-Tcl1 and Par4+/+EμTcl1 mice at similar stages of disease to see if Par4-/-Eμ-Tcl1 CLL exhibit a reduced G1 to S
transition to confirm our cell line data. Results were comparable in the Mec-1 Par-4 shRNA
knockdown cells and the spleens of Par4-/-Eμ-Tcl1 mice that showed delayed CLL development
and increased p21 expression. This is a clinically relevant finding as a study investigating the
expression of p21 in CLL cases and patients with Richter’s syndrome found that 80% of CLL cases
did not express detectable levels of p21 [265]. 43% of patients with Richter’s syndrome did
express detectable levels of p21. Cobo et al. analyzed the sequence of p21 in three CLL cases
and 6 Richter’s syndrome to find a germline configuration in all of them indicating that it was
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not mutated. We did not sequence the p21 gene in our Par-4 knockdown and knockout cells to
confirm that it was not mutated, but our observed increase in nuclear p21 levels in Par4-/-EμTcl1 CLL cells suggests that it is still able to translocate to the nucleus and function in the
regulation of the cell cycle that occurs in the nucleus.
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CHAPTER 6
Splenic microenvironment and Par-4 expression is important for the
development of CLL in the mouse
B cell receptor signaling has been proven to be critical for the survival of CLL. The
microenvironment was found to support CLL B cell activation and provide a proliferative niche
for malignant cells to expand [9, 154, 266]. CLL cells that circulate within the peripheral blood
are characterized to be quiescent and resistant to apoptosis. A small population of CLL cells
exists that is actively proliferating, but the site of new growth is currently being debated [148]. A
recent study in CLL patients has provided direct in vivo evidence that the lymph node
microenvironment is the site of new cells with higher Ki67 staining expression compared to the
peripheral blood and bone marrow [143]. Other studies examining gene expression profiles
have suggested that the lymph node shows elevated BCR signaling gene signatures [142] and
may have enhanced immune suppressive markers [141]. In human patients, the spleen has not
been examined carefully as a site of CLL growth during early stages of CLL disease nor in most of
the molecular analyses, due to the difficulty of accessing spleen tissue. This limitation can be
overcome in an animal model. In the Eμ-Tcl1 transgenic mouse model, some studies utilized
intravital imaging to visualize sites to which CLL cells home for their clonal expansion [154].
Heinig et al. suggest that CLL cells travel to splenic B cell follicles to interact with follicular
dendritic cells (FDCs) to accelerate disease progression. Other studies have indicated that EμTcl1 CLL cells require interaction with macrophages in order to survive and proliferate, but the
site of interaction was not well defined [152, 153]. Further characterization of the CLL
microenvironment is essential to understand how CLL cells avoid apoptosis, become resistant to
cytotoxic therapies, and progress towards a more aggressive disease. Our initial studies to
establish an adoptive transfer model with Eμ-Tcl1 cells led us to question where the CLL cells
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home for their in vivo growth. Severe splenomegaly is a well-defined marker of CLL progression
in the Eμ-Tcl1 de novo and adoptive transfer models, suggesting that this splenic
microenvironment needs to be investigated further.
We have shown that CLL cells overexpress Par-4 compared to levels in normal B cell
subsets. Additionally, CLL cells secrete Par-4 that can induce apoptosis of other cancer cell lines.
Hence we investigated if Par-4 secreted from CLL cells is able to manipulate the
microenvironment’s ability to promote or delay CLL growth. Studies in this chapter investigate
the role of spleen and Par-4 in the splenic microenvironment using primary and adoptive
transfer models.
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Results
6a) Spleen is the primary site of CLL growth in mouse models
The Eμ-Tcl1 mouse is an excellent model to study CLL as these mice progressively
develop an accumulation of CD5+CD19+ cells within the peripheral blood, spleen, lymph nodes,
and bone marrow [144]. The Eμ-Tcl1 mouse exhibits splenomegaly, hepatomegaly, enlarged
lymph nodes, and anemia as disease progresses. We monitored the growth of the spleen in the
Eμ-Tcl1 mouse over time through ultrasonographic analysis and found that the spleen size
increases with age and disease progression (Figure 6.1A). Representative ultrasound images are
shown in Figure 6.1B. Staining of the peripheral blood and spleen cells from EµTcl1 mice
euthanized at different ages indicates that the spleen has a slightly higher percentage of
CD5+CD19+ cells compared to the blood (Figure 6.1C). In terms of absolute numbers spleen has
more CLL cells than any other tissue (data not shown).
We also utilized the adoptive transfer model to monitor the growth of CLL cells in the
peripheral blood and spleen (Figure 6.2A). Ultrasound imaging of the recipient mouse after CLL
injection shows an increase in spleen size. Total volume of the spleen is calculated by 3-D
imaging and tracing with the Vevo 2100 software (Figure 6.2B). We compared the change in
spleen size to the peripheral blood CD5+CD19+ staining and detected a notable increase in
spleen size at day 7 while we were able to detect CD5+CD19+ population in the blood only at
day 21 (Figure 6.2C). This result indicates that the CLL cells grow first in spleen before they
egress to the periphery. We also noted that recipient mice developed CLL with tumor burden
primarily in the spleen irrespective of the route of injection (IV, IP, or SQ) (Figure 6.2D).
To determine if the spleen is a preferred site of CLL growth we measured the
localization and the growth of CLL cells in various lymphoid organs after adoptive transfer. In
order to monitor the homing and growth of injected CLL cells, we utilized EµTcl1 CLL cells that
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expressed the human ROR1 cell surface molecule (C57BL/6 background) to differentiate injected
cells from resident CD5+CD19+ cells. Spleen, peritoneal cavity, bone marrow, and lymph node
tissues were collected after adoptive transfer of 10x106 hROR1+CD5+CD19+ cells into WT
recipients (Figure 6.3A). Total hROR1+CD5+CD19+ numbers were calculated by hemocytometer
trypan blue counts and percentage of hROR1 positive cells through flow cytometry (Figure 6.3B).
After 24hrs, CLL cells were found within the spleen but were not detected in the peritoneal
cavity until day 6 and bone marrow, liver, and lymph nodes until day 30 or longer (Figure 6.3C).
Spleen histology at each time point indicates an expansion of the white pulp and loss of
follicular structure as time progresses post- adoptive transfer (Figure 6.3D).
We also performed xenograft studies with primary human peripheral blood samples
injected into NSG mice. After 5 days of growth, we were able to detect human CLL cells in the
peripheral blood and spleen of NSG mice (Figure 6.4A). The spleen contained the greatest
number of human CLL cells (p#11: 3.1x105; p#14: 3.3x105) further confirming that the adoptively
transferred cells home to the spleen for proliferation and survival (Figure 6.4B).

6b) Splenectomy delays CLL development
Results indicate that the spleen is the primary site of CLL growth in the Eμ-Tcl1 de novo
and adoptive transfer models. To further confirm that this site is important in the growth and
development of CLL we surgically removed the spleens of Eμ-Tcl1 mice to measure its
importance for CLL (Figure 6.5A). Splenectomy of Eμ-Tcl1 mice at both 4mo and 8mo of age
delayed the development and/or progression of CLL as indicated by peripheral blood
CD5+CD19+ staining (Figure 6.5B). The overall survival of Eμ-Tcl1 mice splenectomized at both
ages was significantly increased with a median survival age increasing to 12.06mo compared to
9.68mo of animals with a spleen (Figure 6.5C, p value = 0.024 determined by Log-Rank test).
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Breakdown of animal survival that were splenectomized at each age is depicted in Figure 6.5D.
Mice splenectomized at 4mo had an average median survival age of 12.33mo (p value = 0.068
Log-Rank test, p=0.0103 Gehan-Breslow-Wilcoxon test) and mice splenecotmized at 8mo
resulted in a median survival age of 11.81mo (p value = 0.043 Log-Rank test, p = 0.0192 GehanBreslow-Wilcoxon test). We detected CD5+CD19+ cells within different compartments of the
body including the peripheral blood, peritoneal cavity, bone marrow, lymph nodes, liver,
thymus, and omental tissue (Figure 6.5E). The majority of the tumor burden in splenectomized
Eμ-Tcl1 mice was located in the peritoneal cavity and liver (Figure 6.5F).
Animals were euthanized when their body condition score diminished or showed
elevated CD5+CD19+ peripheral blood staining. A majority of the splenectomized mice still
showed signs of CLL with positive staining in the blood and other tissues at the time of sacrifice.
However, there were some specific cases (6/18) where the splenectomized mice did not develop
CLL (absence of detectable numbers of CD5+CD19+ cells) suggesting that splenectomy
potentially cured the disease (Table 6.1). These mice developed poor body condition,
presumably due to secondary effects of splenectomy (bowel obstruction etc.). Because some
mice still developed CLL, splenectomy does not cure, but does delay the progression. We also
tested the effect of removing the spleen in the adoptive transfer model. We splenectomized six
recipient mice and after recovery, injected CLL cells intravenously. We monitored CLL
development through peripheral blood staining over time and found that removal of the spleen
resulted in a highly significant delay in CLL growth, such that none of the splenectomized mice
developed disease even at day 200, whereas the eusplenic mice in the cohort developed disease
by day 25 (Figure 6.6A). Mice were euthanized at day 200 to determine if there was CLL in
internal organs even though no CLL cells were detected in the blood. An additional experiment
replicated the results of delayed CLL growth in splenectomized recipients and we were only able
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to detect a clean CD5+CD19+ stain in 2/10 mice as compared to ≈90% of eusplenic recipients
that developed disease (Figure 6.6B). We performed additional splenectomy experiments on WT
mice to determine if spleen removal altered the population of B1 cells without CLL injection. We
did not observe a change in the total population resident CD5+CD19+ B cells in any tissues.

6c) CLL cells do not require B, T, and NK cells present in the microenvironment
Splenectomy of both the de novo Eμ-Tcl1 and adoptive transfer models of CLL led to a
dramatic delay in CLL growth and development. We next tried to determine what cell types
present in the spleen are supporting the growth of CLL. We utilized the NSG (NOD-scid
IL2RΥnull) mouse strain that is lacking B, T and NK cells as the adoptive transfer recipients. The
NSG mice adoptively transferred with Eμ-Tcl1 CLL cells all developed CLL like disease at a slightly
quicker rate than WT C57BL/6 recipients (Figure 6.7A; p value = 0.026 determined by linear
regression analysis). This indicates that B, T, and NK cells are not required to support the growth
of CLL cells, but may suggest the occurrence of an immune response that slows the growth of
CLL cells in WT mice (Alhakeem, S. 2017 Dissertation). Additionally, we adoptively transferred
CLL cells into splenectomized NSG mice to determine if the requirement for spleen for CLL
growth will hold true in the absence of the adaptive immune system. (Figure 6.7B). As in BL/6
mice splenectomy considerably delayed CLL growth in Spx NSG mice. However, CLL cells grew
faster in the splenectomized NSG background compared to the splenectomized WT
background. CLL cells were isolated consistently from the peritoneal cavity, liver, and peripheral
blood of splenectomized NSG mice (Figure 6.7C). Two of three mice showed positive staining of
CLL cells within the bone marrow compartment and lymph node, but were absent from the
third, though all the mice had CLL cells in the blood, peritoneal cavity and liver. This suggests
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that the lack of B, T, and NK cells in other organs allowed the growth of CLL cells, suggesting a
role for adaptive immunity in controlling the spread of disease to other lymphoid organs.

6d) Splenectomy of Par-4-/- mice results in delayed CLL growth
We have shown that Par-4 is secreted by CLL cells and that the secreted Par-4 is
effective in inducing apoptosis of other cancer cell lines (Figure 3.4C, 3.4F). We were therefore
curious to test if Par-4 in the microenvironment played a role in the growth of CLL cells. Par4-/Eμ-Tcl1 mice lack Par-4 in CLL cells themselves as well as Par-4 that is sourced from other cell
types in the microenvironment. As shown in chapter 5, Par4-/-Eμ-Tcl mice still developed CLL but
at a delayed rate compared to Par4+/+Eμ-Tcl1 mice (Figure 5.3C). Par4-/-Eμ-Tcl1 mice also had an
improved lifespan compared to Par4+/+Eμ-Tcl1 suggesting that the lack of Par-4 intrinsically
and/or extracellularly reduced the aggressiveness of the disease.
We first wanted to determine if Par4+/+Eμ-Tcl1 CLL cells grow at similar rates within the
Par4-/- background versus C57BL/6 background. Initial experiments were promising showing that
the lack of Par-4 in recipient mice led to more rapid growth of CLL, but results could not be
repeated. An average of all three adoptive transfer experiments in Par4 null and WT recipients is
shown in Figure 6.8A. There was no significant difference in the growth rate of CLL cells between
the two recipient backgrounds (p value = 0.3441). Next we transferred the Par4-/-Eμ-Tcl1 cells
into WT and Par4-/- animals and measured their expansion overtime, allowing us to see if Par-4
in the microenvironment affected the growth rate of CLL cells lacking endogenous Par-4. We did
not observe a change in the rate of CLL growth between the Par-4 null and WT recipients (Figure
6.8B). There is variability in the growth rate of CLL samples derived from de novo mouse models
that may be contributing to this result, further experiments using different Par4-/-Eμ-Tcl1 CLL
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samples are required to confirm these results as these particular primary CLL cells could have
been more aggressive than others.
Due to the significant difference in CLL development between the Par4-/-Eμ-Tcl1 and
Par4+/+Eμ-Tcl1 mice, we further investigated the effect of Par-4 on CLL growth. Since elimination
of the primary site of CLL growth with splenectomy results in delayed CLL development, we
splenectomized Par4-/- mice to see if the lack of spleen and Par-4 may contribute to changes in
CLL growth. Interestingly, we find that absence of the spleen in the Par-4 null background allows
for faster growth of CLL cells in the Spx environment (Figure 6.9A). Repeated experiments found
that the lack of Par-4 in splenectomized animals results in CLL growth in 50% of recipients,
whereas only 20% of Par-4+/+ Spx mice develop CLL (Figure 6.9B). This result suggests that Par-4
present in the WT splenectomized animals is preventing the growth of CLL in other tissue
microenvironments. Further studies must be completed to determine how Par-4 is preventing
growth, but appears that it may be acting as a tumor suppressor in the secondary CLL
microenvironments.
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Figure 6.1: Spleen is the primary site of CLL growth in CLL in the EµTcl1 mouse model
A) Spleen volumes were measured through ultrasound imaging of Eμ-Tcl1 mice at different ages.
Each point represents an average of three spleens. Wildtype 3mo C57BL/6 mice have a spleen
size of 96.6mm3. B) Representative ultrasound images of Eμ-Tcl1 mouse spleens at each age. C)
Percentage of peripheral blood and spleen CD5+CD19+ cells in Eμ-Tcl1 mice at the indicated
ages. Values represent mean + SD of three mice, p = 0.567 determined by 2 way ANOVA
comparing the spleen and peripheral blood at different ages.
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Figure 6.2 Growth of CLL in spleen in the adoptive transfer model
A) Scheme of adoptive transfer for CLL development. 10x106 Emu-Tcl1 CLL cells were
injected into eusplenic or splenctomized C57BL/6 mice. B) Ultrasound imaging of spleen in an
adoptive transfer recipient after CLL injection at different times after CLL injection. Splenic
volumes are calculated after 3-D imaging and trace modeling using the Vevo 2100 ultrasound
system and software (Right). C) Comparison of peripheral blood CD5+CD19+ staining and spleen
volume in the adoptive transfer model. Average values of two mice are shown for each group
except the splenic volume of the PBS injection represents one mouse. D) 10x106 CLL cells were
injected intravenously (IV, n=1), intraperitoneal (IP, n=2), and subcutaneously (SQ, n=3). CLL
growth was monitored by submandibular cheek bleeding and flow cytometry analysis of
CD45+CD5+CD19+ staining. Mean + SD values are graphed
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Figure 6.3 Injection of hROR1+CLL cells to monitor localization of CLL in the adoptive transfer
model
A) Scheme of the experiment. C57BL/6.hROR1+ve CLL cells (10x106) were injected intravenously
into C57BL/6 recipients. Three mice per group with an additional noninjected WT mouse were
euthanized at each time point to detect CLL in different lymphoid organs. B) Total number of
hROR1+CD5+CD19+ cells detected by FACs analysis in each tissue at different times after CLL
transfer are shown. C) Total number of CLL cells in each tissue at day 30 post injection. D) H&E
staining of spleen tissues at each time point of euthanasia. All image magnifications were at 10x.
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6.4 Human xenograft in NSG mice
A) 20x106 human peripheral blood CLL cells (p#11 and p#14) were injected into two recipient
NSG mice. After 5 days of growth, tissues were collected and stained for human CD45+ cells. The
numbers refer to individual patients. Numbers 226 to 230 refer to individual NSG mouse
recipients. B) Total numbers of viable cells were calculated by hemocytometer counts and the
percentage of human CD45+ cells were used to calculate the total number of cells present in the
spleen (top) and bone marrow (bottom).
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Figure 6.5 Splenectomy delays the development and growth of CLL
A) Schematic diagram of the effect of splenectomy on CLL development in the Eμ-Tcl1 mouse
model. B) Percentage of CD45+CD5+CD19+ cells in the peripheral blood of Eμ-Tcl1 CLL cells over
time with and without splenectomy. Left: animals splenectomized at 4mo, Right: animals
splenectomized at 8mo. Values represent mean + SE . SpX n=9, Eusplenic n=13C) Overall survival
of Eμ-Tcl1 mice with (n=13) and without spleen (n=18). P value = 0.02 determined by Log-Rank
test. D) Breakdown of overall survival of animals splenectomized at 4mo (left) and 8mo (right) to
Eμ-Tcl1 mice with spleens. Nine animals in each age group are included compared to 13 animals
with spleen. 4mo p value = 0.06, 8mo p value = 0.043 determined by Log-Rank test. E)
CD45+CD5+CD19+ cells within the tissues of a representative splenectomized Eμ-Tcl1 mouse. F)
Tumor burden of CLL cells within different tissues of a representative splenectomized mouse.
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Table 7: Summary of splenectomized Eμ-Tcl1 mice.
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Figure 6.6A

Percent CD5+CD19+ Cells
in P. Blood

100

EuSplenic
Splenectomized

80
60
40
20
0
0

50

100

150

200

250

Days Post Injection

% CD5+CD19+ Lymphocytes

Figure 6.6B

100
80
60
40
20
0
WT SpX

WT

Figure 6.6 Splenectomy in the adoptive transfer model results in delayed CLL growth
A) Peripheral blood was monitored for CD5+CD19+ cells at various times after injection of
10x106 CLL cells in 6 recipient splenectomized mice and two eusplenic mice. B) Combination of
two experiments showing endpoint CLL cells in the peripheral blood of splenectomized adoptive
transfer recipient mice and WT with spleens. All recipients were euthanized at day 125 or
earlier when CLL developed.
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Figure 6.7C

Figure 6.7 CLL cells do not require B, T, or NK cells in the microenvironment niche
A) 5.0x106 Eμ-Tcl1 CLL cells were adoptively transferred into BL/6 or NSGS mice (n=4
each) and the recipients were monitored for CD5+CD19+ cells in the blood at various times after
CLL cell injection. The differences in the slopes of two lines of CLL kinetics in the two groups of
recipients are statistically significant (p value= 0.026 as determined by linear regression
analysis). B) Experiment described in panel A is repeated with Spx BL/6 and NSGS (figure legend
says NSGS) mice. C) Tissues from three Spx NSG mice were collected once CLL was detected in
the blood. Values represent the % of CD5+CD19+ cells gated on CD45+ in the peripheral blood,
peritoneal cavity, bone marrow, lymph node, and liver. Each bar represents one mouse.
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Figure 6.8 Adoptive transfer of CLL cells into Par4-/- vs Par4+/+ recipient mice
A) 10x106 Par4+/+EμTcl1 CLL cells were injected (i.v.) into WT BL/6 and BL/6.Par4-/recipients. Values represent mean + SEM of results from three experiments with a total of n=12
recipients per group. P value = 0.3441 determined by linear regression analysis. B) Par4-/-EμTcl1
CLL cells (10x106) were adoptively transferred (i.v. route) into WT and Par4-/- recipients. n=
5/group. P value = 0.79 determined by linear regression analysis. Graphs show the change in %
CD45+CD5+CD19+ cells in blood as a function of time.
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Figure 6.9 CLL develops faster in splenectomized Par-4-/- recipients
Par4+/+EμTcl1 CLL cells (7.8x106) were transferred into splenectomized Par4-/- and WT recipients
via the i.v. route. 3/6 of Par-4-/- splenectomized animals, but only 1/6 WT SpX mice developed
CLL 70 days after transfer. B) Endpoint percent CD5+CD19+ cells in peripheral blood of all
adoptive transfer studies to Par-4-/- and WT splenectomized recipients. 50% of splenectomized
Par-4-/- recipients developed CLL compared to 20% of WT splenectomized recipients.
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Summary
Defining the CLL microenvironment is critical in order to understand how leukemic cells
evade apoptosis and continue to proliferate. The spontaneous apoptosis of primary CLL cells
observed in tissue culture provides evidence for the necessity of supportive stromal cells and
other factors required to promote survival. Due to the difficulty in culturing CLL cells, mouse
models have proven to be an excellent tool to study the growth regulatory mechanisms of CLL.
We and others have shown that the Eμ-Tcl1 mouse model develops CLL-like disease
characterized by an accumulation of CD5+CD19+ lymphocytes in secondary lymphoid organs,
including the spleen as it progresses with age [144, 211]. The expansion of leukemic cells is
consistently reproduced in the adoptive transfer model which we have now characterized by
ultrasound imaging. CLL cells are first detected within the spleen and not in other lymphoid
tissues or liver until later time points after adoptive transfer. Utilizing the human ROR1expressing CLL cells, we confirmed that the spleen is the initial site for CLL homing after transfer.
This phenomenon is also not dependent on the route of injection as studies in the laboratory
have found that CLL cells are prominent in the spleen of recipient mice after intravenous,
intraperitoneal, and subcutaneous injections of mouse CLL cells. This observation is also made
when transferring primary human peripheral blood cells into NSG mice. Five days after transfer,
human cells are detected primarily within the spleen.
Splenectomy of both the de novo Eμ-Tcl1 and adoptive transfer recipients dramatically
delayed the development of CLL. In healthy hosts, the spleen stores more than a quarter of the
entire lymphocyte population and can expand to hold more red blood cells or WBCs when
needed during an immune response. The spleen’s ability to expand contributes to the gross
pathology that is observed in mouse models. Therefore, removal of the spleen initially relieves
the animal of the bulk of the tumor load. The surprising finding in the de novo Eμ-Tcl1 model
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after splenectomy is that some mice never developed CLL and were essentially cured of
leukemia. This was not true for all cases, but further studies to determine why CLL progression
occurs in some, but not all mice after splenectomy would be of interest.
Initial removal of the spleen before adoptive transfer of CLL cells dramatically prevents
CLL growth in C57Bl/6 WT mice. This is thought to be due to the loss of the primary site of
growth and CLL cells cannot establish another site for proliferation. To further support our
observations, it would be of interest to adoptively transfer CLL cells to recipient mice and to
perform splenectomy after CLL cells are established in the spleen for 2-3 days. This would more
closely represent what is seen in many patients that are likely to have CLL in the spleen before
disease is detected in peripheral blood.
CLL growth was detected in 50% of splenectomized Par-4 deficient animals as compared
to 20% of CLL growth observed in splenectomized C57Bl/6 animals. This is a surprising finding as
our preceding studies have indicated that intrinsic Par-4 does not act as a tumor suppressor in
the context of CLL. The lack of Par-4 in secondary sites of proliferation allows for the growth of
CLL which suggests that intrinsic and extracellular Par-4 may play different roles in CLL. The
studies presented here investigating the role of Par-4 in the microenvironment are preliminary
and primarily observational. Studies to define the mechanism by which Par-4 prevents CLL
growth in sites other than the spleen are underway.
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CHAPTER 7
Discussion
Par-4 is a well-known tumor suppressor that is down regulated in several cancers and
can selectively induce and sensitize cancer cells to apoptosis[267]. This quality has made Par-4
an attractive therapeutic target in a variety of cancers, yet there are very few studies
investigating its regulation. However, there are several studies that have investigated Par-4
expression in CLL. Human peripheral blood CLL samples express Par-4 but these studies did not
confirm if it is functional. Chow et al. suggested that Par-4 could be responsible for a patient’s
ability to respond to imatinib treatment but did not confirm if Par-4 was functionally inducing
apoptosis of neoplastic cells after treatment [202]. Other studies indicate that Par-4’s
interactions with other proteins such as Bcl-2 is not consistent in CLL as it is in solid tumors [190,
203]. These results suggest that Par-4 is regulated differently in CLL than what is currently
known from other tumor studies. This proposed difference could potentially contribute to one
of the many defects in the apoptotic pathway that is found to characterize CLL. In this study, I
originally aimed to define the tumor suppressive role of Par-4 in CLL, but made an unexpected
and exciting discovery that intrinsic Par-4 rather promotes CLL growth. My studies found that
BCR signaling pathway plays a surprising role in regulating Par-4 expression in CLL cells. I have
shown that Par-4 secreted from CLL cells is functional in inducing apoptosis of other cancer cells
leading to question why a pro-survival pathway is regulating the expression of a pro-apoptotic
factor. My studies knocking down intrinsic Par-4 expression in CLL cells suggest Par-4 has a novel
role in regulating cell growth mechanisms that include induction of p21 expression. Additionally,
I found that Par-4 in the secondary CLL microenvironments may act to prevent the growth of
CLL. These findings imply that Par-4 has pleiotropic roles within the context of CLL making it an
interesting protein to investigate.
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In this thesis I characterized the expression of Par-4 in CLL. This is the first investigation
of the role of Par-4 in CLL using the Eμ-Tcl1 mouse model to compare levels of expression in
malignant CLL cells against normal B1a cells. I have identified a novel regulation of Par-4 through
the BCR signaling pathway that was previously unknown. I have also confirmed much of our
findings in the mouse model with primary human CLL samples allowing my results to be
translated to patients.
7.1 Increased expression of Par-4 in CLL and novel regulation through BCR signaling
Both mouse Eμ-Tcl1 CLL cells and primary human CLL cells express high levels of Par-4
compared to normal B cell subsets and whole peripheral blood samples. Increased expression
levels led to concerns if Par-4 expressed in CLL cells was mutated, but I confirmed that Par-4 was
found in both the cytoplasm and the nucleus of CLL cells and that secreted Par-4 functionally
induced apoptosis of other cancer cell lines. Additionally, knockdown studies of Par-4 in the
Mec-1 CLL cell line confirmed that Par-4 was functionally interacting with well-defined targets
such as activated AKT and regulated Bcl2 expression [178, 193]. This was an interesting finding
since Par-4 knockdown cells were growing more slowly in culture than the control shRNA
infected cells leading me to hypothesize about how Par-4 may support growth in CLL. Previous
studies in CLL could not replicate the inverse relationship between Par-4 and Bcl2 that have
initially been proposed in transformed fibroblasts and PC-3 cells [190, 191]. More specifically,
one study found a positive correlation between expression of Par-4 and Bcl-2 in CLL patient
samples (R=0.7) [203]. Cheema and colleagues discovered that Par-4, along with WT-1 (Wilm’s
tumor suppressor-1) binds to the Bcl-2 promoter to prevent its expression and pro-survival
activity [268]. Ectopic expression of Par-4 in androgen-independent prostate cell lines resulted
in decreased Bcl-2 protein and transcript levels along with an increase in WT-1 expression. Par-4
has previously been shown to interact with the WT-1 promoter [162]. WT-1 is an interesting
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protein as it has been classified as both a tumor suppressor and oncogene [269]. WT-1 is found
to be required for normal development but when mutated, is associated with development of
kidney tumors and urogenital disease. Conversely, high WT-1 expression has been found in
nearly 74% of AML and 66% of ALL patients and is associated with a worse prognosis and poor
response to therapy. Cosialls and colleagues concluded that the WT-1 promoter region is
silenced by hypermethylation in 78.4% of CLL cases [270]. Consistent with this, another study
screening for tumor associated antigens in CLL did not detect WT-1 mRNA in 43 human CLL
cases [271]. The lack of WT-1 expression detected in CLL cases could be responsible for the
discrepancy of the Par-4-Bcl-2 relationship in human CLL cases. Without the co-interaction of
WT-1 in CLL, Par-4 may not be able to downregulate Bcl-2 expression as shown in studies by
Boehrer and Borjarska-Junak [190, 203]. With those points in mind, I still observed an increase in
Bcl-2 expression in Par-4 shRNA mediated knockdown in Mec-1 cells (Figure 5.1B). It would be of
interest to determine the status of WT-1 in the Mec-1 cell line to determine if the requirement
of WT-1 is essential for Bcl-2 regulation by Par-4 in CLL cells. We are currently investigating if
Bcl-2 expression is changed in the Par4-/-Eμ-Tcl1 versus Par4+/+Eμ-Tcl1 cells to be certain that the
inverse expression is not specific to Mec-1 cells.
We are currently sequencing Par-4 to confirm that it is not mutated in CLL. As noted
previously, our studies indicate that Par-4 is functional by its ability to localize within the
cytoplasm and nucleus. Detection of phosphorylation at Thr155 (rat) or Thr163 (human) would
confirm that the PKA phosphorylation site is intact which is required for Par-4 mediated
apoptosis [169]. The Par-4 nuclear location sequence 2 (NLS2) enables Par-4 to translocate to
the nucleus, but NF-κB inhibition is only observed after Thr163 phosphorylation. PKA is known
to be active in CLL cells and it would be ideal to determine that the threonine site is still intact in
CLL Par-4 [272].
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Additionally, I have utilized the online database CBioPortal for cancer genomics to
investigate if there are known mutations of the Par-4 gene in banked CLL patient samples.
CBioPortal provides exploration of multi-dimensional cancer genomic data sets to determine
mutation status of particular genes within individual patients [273, 274]. This program classifies
a gene alteration in a patient if it is mutated, deleted, amplified, or if its expression deviates
from the user-defined normal threshold [273]. I analyzed the status of the PAWR gene within
two available data sets: Chronic Lymphocytic Leukemia, Broad Cell 2013 that consisted of 160
samples and IUOPA Nature 2015 consisting of 506 samples [275, 276]. No PAWR gene
alterations were detected in these two studies. I confirmed that the program could indeed
identify PAWR gene alterations in known tumor models by investigating its status in the PanLung Cancer TCGA Nature Genetics 2016 study comprised of 1144 samples which indicated a
combination of mutations, deletions, and amplifications of PAWR [277]. This brief analysis
suggests that the PAWR gene is currently not found to be mutated in human CLL patients but
our current studies are will further confirm this conclusion.
It is well accepted that CLL cells contain activated Akt which is pivotal in maintaining cell
survival [278]. Akt is also known to phosphorylate Par-4 at Ser249 (rat)/ Ser230 (human) that
prevents nuclear translocation and Par-4 mediated apoptosis [170]. We do observe activated
levels of Akt in primary mouse Eμ-Tcl1 CLL cells consistent with what has been published
previously [228]. Tcl1 is a known co-activator of Akt and is a contributing factor in Akt activity in
the Eμ-Tcl1 mouse model [217]. Tcl1 has been found to interact with Akt through the pleckstrin
homology domain of Akt which alters the cellular localization of the kinase. Tcl1 helps facilitate
Akt phosphorylation at both Thr308 and Ser473 sites by translocating it to the cell membrane
for PI3K signaling [279]. Transfection of cells with Akt and Tcl1 also results in Akt translocation to
the nucleus [217]. Akt nuclear localization has recently been described to inhibit chromatin
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condensation, regulate cell cycle progression, cell survival and double stranded DNA break
repair [280]. We observed elevated levels of Tcl1 expression in the mouse Eμ-Tcl1 CLL cells and
activated levels of Akt suggesting that this may be another level of regulation of Par-4. As
mentioned earlier, Akt and Par-4 act on each other to regulate their functions in many different
solid tumor models. We have not investigated the interaction of Akt and Par-4 in the Eμ-Tcl1
mouse, but because of the interactions described with Tcl1-Akt and Akt-Par-4, it is possible that
Par-4 could be regulated by this pathway as well. We do see Par-4 is within the nucleus of CLL
cells, but we do not know the mechanism of action. According to Pekarsky and colleagues, Tcl1
complexes with Akt to translocate to the nucleus and one possibility is that Par-4 could be found
within this complex as well. Immunoprecipitation studies could determine if all three of these
proteins are interacting. CLL survival does not appear to depend on Par-4 nuclear location,
suggesting that Par-4 may not be inhibiting NF-κB. A tripartite complex of Tcl1-Akt-Par-4 may
prevent Par-4 mediated NF-κB inhibition. However, this hypothesis is not supported by the
observation that Mec-1 cells do not express high levels of Tcl1 and neither does every human
CLL clone, despite increased expression of Par-4.
The Tcl1 oncogene has been found to interact directly with de novo DNA
methyltransferases DNMT3a and DNMT3b in CLL [281]. DNA methyltransferases are enzymes
that methylate CpG islands that result in silencing of a target gene. Some hematological cancers
have mutations that inactivate DNA methyltransferases leading to over expression of driver
genes that promote disease [282]. Studies utilizing the Eμ-Tcl1 mouse found a two to four fold
increase in hypomethylated CpG islands and promoter regions in B cells expressing Tcl1
compared to WT mouse B cells [281]. These results suggest that overexpression of Tcl1 blocks
DNMT3a enzyme activity and therefore promotes expression of other genes. Interestingly, Par-4
promoter methylation and silencing has been detected in 30% of endometrial cancers [283].
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Other studies have found Par-4 promoter hypermethylation in Ras-tranformed cells which is
attributed to an upregulation in DNMT3a expression and activity [284]. It is possible that the
Par-4 upregulation that I observed in Eμ-Tcl1 cells is due to the lack of DNMT3a activity. I do not
have consistent results suggesting the Tcl1 is regulated through BCR signaling so it is not likely
that the promoter hypomethylation observed in Eμ-Tcl1 CLL cells is due to BCR signaling
regulation. It would be interesting to first confirm if Par-4 promoter is regulated by DNMT3a
mehthylation in CLL and then to measure protein levels in Tcl1+ and Tcl1- CLL cells to see if there
is a change in Par-4.
Immunoblot analysis indicated that Eμ-Tcl1 CLL cells expressed high levels of Par-4
compared to normal B cell subsets. Normal B1a cells that express CD5+CD19+ markers
expressed the highest level of Par-4 and had slightly higher basal levels of phosphorylated SFK
and Lyn compared to B1b and B2 cells, but less than CLL cells. We are the first group to compare
CLL BCR signaling and Par-4 expression with the correct B cell subset controls. I conclude that
increased Par-4 levels are not caused by Tcl1 expression as discussed earlier. B1a cells have
increased Par-4 expression compared to other B cell subsets and also differ in expression of CD5
uniquely. Is CD5 expression related to Par-4? I did not study this closely but could examine the
effect of anti-CD5 antibody treatment to CLL cells or siRNA targeting CD5 to determine the
effect on Par-4 expression. CD5 has been shown to negatively regulate BCR signaling by
recruiting SHP-1(Src homology 2 containing phosphatase 1) to the BCR signaling complex [75].
Similarly in CLL, studies have found that Lyn is able to phosphorylate CD5 leading to the
recruitment of SHP-1 to inhibit BCR signaling [108]. Lyn is known to be involved in both
activation and inhibition of B cells. My studies link Lyn expression and Par-4 in CLL and
regulation of Par-4 expression through CD5 could be a potential mechanism that requires
further study.
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Based on my findings and the importance of BCR signaling in the survival of CLL, this was
a likely pathway to be involved in Par-4 regulation [48, 127, 250]. Inhibitors of kinases involved
in BCR signaling and shRNA mediated knockdown of Lyn kinase in the Mec-1 cell line as well as
in the B cell lymphoma line, LY-3 (Figure 4.3D) clearly demonstrate regulation of Par-4
expression through the BCR signaling pathway. Studies utilizing siRNA targeting CD79a (Igα)
further confirm that Par-4 expression is regulated by the BCR signaling pathway avoiding the off
target effects of kinase inhibitors (Figure 4.3G).
We also investigated if BCR signaling inhibition led to a decrease in Tcl1 oncogene
expression to determine if it’s down regulation was a contributing factor to CLL cell death. We
did not observe consistent down regulation of Tcl1 after BCR inhibition until very late time
points when most of the cells were dead (≥ 48hrs). Hence it is unlikely that Par-4 down
regulation involves the effect of BCR signaling on Tcl1 expression. However, as discussed briefly
in Chapter 4, the delayed downregulation of Par-4 observed after BCR kinase inhibition may
result from Par-4 being bound in a tripartite complex of proteins. The potential interactions of
Par-4 and Akt as well as Akt-Tcl1 in primary CLL could create a ternary complex that provides
stability of protein expression after cytotoxic treatment with BCR inhibitors.
Immunoprecipitation assays of Par-4 would be required to see if Akt and Tcl1 are both bound to
further develop this hypothesis.
When BCR signaling is engaged, Src family and Syk protein kinases are activated which
triggers activation of complex downstream signaling networks that include phospholipase Cγ to
PI3-K pathway and Ras-MAPK (ERK) pathway [132]. My finding that targeting ERK1/2 in Eμ-Tcl1
CLL cells results in a decrease in Par-4 expression further confirms that Par-4 is regulated by
survival signaling in malignant CLL cells. This is an interesting finding compared to studies
investigating Par-4 regulation via Ras in fibroblasts where it was shown that Par-4 works to block
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ERK2 expression in order to prevent oncogenic transformation [181]. In my studies it is
conceivable that Par-4 is regulated directly by SFKs and/or Akt. Thus, the difference in Par-4/ERK
regulation in CLL B cells and fibroblasts could be due to tissue specific effects.
Kline et al. previously reported that c-Src and Par-4 interact independently of Akt1 [285].
Treatment of HT29 colon cancer cells with PP2, an SFK inhibitor, and 5-FU (5-fluoruracil) a
chemotherapeutic agent, led to increased Par-4 activation by preventing the negative regulation
of Par-4 by Akt1 and 14-3-3σ. Direct inhibition of c-Src reduced interactions of Par-4 with Src
which was predicted to be through three tyrosine residues on Par-4. This suggests a novel
regulation of Par-4 in colon cancer cells. Oncogenic SFKs as well as activated Akt are well
established in CLL, suggesting that these interactions could be responsible for Par-4 regulation
[109, 278, 286]. Studies to observe the effect of AKT inhibition in CLL on Par-4 expression would
be of interest to confirm the novel regulation of Par-4 through survival pathways in CLL.
A recent study investigating the mechanism of Par-4 regulation in pancreatic cancer
suggests that Par-4 is negatively regulated by TRIM21(Ro52) [287]. TRIM21 is an E3 ubiquitin
ligase that functions to ubiquitinate protein substrates, targeting them to proteosomal
degradation. In response to cisplatin treatment, TRIM21 downregulated Par-4 expression in a
pancreatic cancer cell line. TRIM21has also been identified as a target of autoantibodies in
Srogren’s Syndrome and Systemic Lupus Erythematous (SLE) where increased levels of TRIM21
resulted in increased apoptosis of B cells [288]. Of the tripartite motif (TRIM) family members,
currently TRIM13 (also known as Leu5) has been associated with CLL, as it is contained in the
chromosome 13q14 region deleted in many CLL cases. Hence it will be interesting to investigate
TRIM21 expression and the effect of BCR signaling on TRIM21 in CLL [289].
Another potential mechanism of Par-4 regulation in CLL is through Casein Kinase 2
(CK2). CK2 is a serine/threonine kinase that has been found to phosphorylate Par-4 at Ser231,
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which inhibits its pro-apoptotic activity in prostate cancer cells [290]. CK2 has also been found to
be hyper-activated and overexpressed in CLL cells [291]. Investigating Par-4 phosphorylation at
Ser231 could also explain why we do not observe the pro-apoptotic actions of intrinsic Par-4.
7.2 Role of p21 in pro-growth function of Par-4 in CLL
Knockdown studies targeting Par-4 in CLL generated a novel phenotype of delayed CLL
growth in vitro and in vivo, which led us to investigate roles of Par-4 other than its tumor
suppressor function. Because I observed an increase in pro-survival (pAkt) and anti-apoptotic
factors (Bcl-2), my first hypothesis was cell cycle regulation. I initially looked at cell cycle
inhibitors and indeed found an increase in p21 expression (Figure 5.2B). I also probed for p27
expression, and while there may be a slight increase in expression, it is not as significant as for
p21. Studies in human CLL patient samples have looked for expression of p21 and p27. 80% of
CLL cases were negative for basal levels of p21 expression while the majority of CLL cases
expressed high p27 levels [265]. The low levels of p21 in CLL could potentially be due to
increased levels of Par-4 in CLL. Along with in vitro studies using Par-4 knockdown Mec-1 cells
we crossed Par-4-/- animals with the de novo Eμ-Tcl1 mouse model of CLL to determine the role
of Par-4 in the development of CLL in vivo. The Par-4 deficiency delayed CLL development in the
EµTcl1 mice and also prolonged their survival compared to Par-4+/+ EµTcl1 mice. The Par-4-/- CLL
cells also exhibited an increase in p21 expression.
Recently, cyclin dependent kinase inhibitors are being investigated for the treatment of
leukemia due to their success in solid tumors [292]. Dinaciclib, a CDK1, CDK2, CDK4 and CDK5
inhibitor, reduced survival of CLL cells by inhibiting key oncogenic pathways vital for CLL survival
[293]. Our studies identify Par-4 as a factor involved in the cell cycle through connection with
p21 in CLL cells as reduced expression of Par-4 led to a halt in the G1/S transition of the cell
cycle and a reciprocal induction of p21 expression. Interestingly, Igawa et al. observed that CLL
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cells in the proliferation centers located in the lymph node highly expressed cyclin D2 which is
involved in the transition between G0/G1, a stage at which p21 activity is down regulated in
cycling cells [294, 295]. Studies investigating the interaction of Par-4 and Cyclin D2 are
warranted to elucidate the potential role that Par-4 is playing in promoting growth of CLL cells.
P21 expression is regulated by p53 in most cases, although p53 independent p21 expression has
been observed [296, 297]. Since p53 is mutated in Mec-1 cells, p21 expression in Par-4
knockdown and knockout cells may be using alternate pathways [298].
Another recent study investigated the relationship between Par-4 and p21 after
inducing ER stress with the treatment of a natural compound derivative 3-AWA (3-Azido
withaferin A) [299]. Depending on the dose of 3-AWA administered, induction of ER stress in
prostate and colon cancer cells led to an increase in Par-4 expression and down regulation of
p21. The authors suggested that the loss of activated Akt allowed for increased Par-4 expression
which then promoted apoptosis. The reduced expression of p21 after treatment was found to
be mediated by pro-apoptotic JNK (Jun N-terminal kinase) activation. JNK has been found to be
a key player in stress induced cell death in both normal cells and solid tumor cancers [300].
Conversely our lab has discovered that JNK is required for survival and proliferation of malignant
B lymphoma cells suggesting a dual role for the kinase in solid versus hematological cancers
[301]. The pro-survival role of JNK in B cell lymphoma was further confirmed in two recent
studies that examined CARD11 and DUSP4 deficiencies in B cell lymphoma [302, 303]. The
diverse roles that JNK potentially has in CLL versus endothelial based tumors may be
contributing to the pro-growth function of Par-4 in CLL via p21 suppression. The AKT/Par4/JNK/p21 axis defined by Rasool et. al. provides direction to investigate this pathway further in
CLL due to the pro-growth roles we have found for JNK and Par-4 in B cell malignancies.
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7.3 Par-4 in the tumor microenvironment
Introducing the Par-4 knockout allele into Eμ-Tcl1 mice delayed progression of CLL and
prolonged mouse survival compared to Par-4+/+EµTcl1 mice. Par-4-/-EµTcl1 mice are deficient for
Par-4 in all tissues, not specifically in B cells (Figure 5.3B). My finding that CLL cells are able to
secrete functional Par-4 introduces a level of complexity within the in vivo tumor
microenvironment. I do not know if Par-4 secreted from the CLL cells is manipulating the
microenvironment to further enhance the growth in Par-4+/+ EµTcl1. In order to test, one could
treat the Par-4+/+ EµTcl1 mouse with an anti-Par-4 antibody to see if extracellular Par-4 in the
mouse model is promoting or preventing the growth of CLL. In my splenectomy studies, the lack
of Par-4 in the secondary tumor microenvironments appears to allow the growth of CLL
suggesting that the presence of Par-4 is acting to prevent CLL growth in the sites which fits with
its known tumor suppressor function. But this is only observed in splenectomized mice. This is
important since I have shown spleen to be the primary niche where the CLL cells grow (Figure
6.1). While CLL cells do not appear to be sensitive to Par-4 sourced from an autocrine fashion, I
do not know if Par-4 sourced from other cells results in CLL apoptosis. Studies investigating EμTcl1 CLL cells treated with secreted Par-4 from other cancer cell lines or recombinant Par-4 have
been performed by our collaborators. Results show that human CLL cells are not sensitive to
recombinant Par-4 mediated apoptosis. Additionally, I observed slightly lower levels of total
GRP78 expressed in CLL cells compared to other cancer cells. Experiments with antibody
towards cell surface GRP78 must be performed to confirm that extracellular Par-4 is able to
functionally bind its receptor and induce apoptosis in the proposed FADD dependent manner.
Injection of CLL cells into splenectomized C57BL/6 and Par-4 null mice resulted in a
surprising finding that the lack of Par-4 enhanced the growth of CLL. This is a dramatic difference
compared to WT mice where very few splenectomized recipients developed disease as opposed
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to 50% of the Par-4 null mice that develop CLL. It is important to note that of the
splenectomized Par-4-/- mice that did develop CLL, all recipients were females. This is an
interesting finding as both female and male mice lacking Par-4 leads to the development of
endometrial or prostate hyperplasia respectively [172]. 56% of males develop prostate
hyperplasia while 36% of females develop endometrial tumors, suggesting that Par-4-/- males
actually have a greater likelihood to develop tumors. Because of the gender difference in
splenectomized mice, we question if hormone levels play a role in regulating the development
of CLL. Could elevated testosterone levels in male mice prevent CLL growth in the Par-4-/background? This can be tested by castrating male Par-4-/- mice, followed by splenectomy and
injection of CLL to see if changes in hormone level result in differential CLL growth rate. Or could
ovariectomy in female mice lead to reduced development of CLL in splenectomized recipients?
Interestingly, a 2005 study found the oestradiol injection into mice resulted in decreased Par-4
levels suggesting that estradiol regulates Par-4 [172]. Additionally estradiol has been found to
promote NOTCH signaling which can promote VEGF and tumor development [304-306]. The
elevated levels of estradiol in female mice could be promoting the growth of CLL cells when
lacking Par-4. CLL is more prevalent in men than women, suggesting a gender bias and it would
be curious to see if Par-4 is regulating this effect [307].
My findings suggest that the spleen is the primary site of growth in the CLL mouse
model. In the clinic, physicians currently rely primarily on peripheral blood, lymph node and
bone marrow involvement to evaluate patient status. Because I find that the majority of CLL
cells are located within the spleen of mice in early stages of disease, physicians could be
overlooking an initial proliferative setting with important prognostic implications. More
importantly, if we are able to identify the cell types found within the mouse splenic
microenvironment that are required for the growth of CLL we could also identify them in the
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human for potential therapeutic targets. I have established a splenic stromal cell line derived
from the Eμ-Tcl1 mouse spleen. Preliminary studies suggest that co-culture of splenic stromal
cells with CLL improves in vitro proliferation of CLL. This new stromal cell line could be of great
use to help mimic the in vivo tumor microenvironment. These stromal cells are more effective
than bone marrow stromal cell line or fibroblast cell line. Currently we are making efforts to
establish a Par4-/- splenic stromal cell line.
7.4 Summary
My study of BCR signaling in CLL has provided important insights in CLL growth and led to
development of new promising therapeutics [37]. Findings from our laboratory suggest that B
cell lymphomas and other B cell malignancies are reliant on the BCR signaling pathway and
therefore provides multiple targets for therapy [36]. I have used approved inhibitors to target
kinases within the BCR pathway to find that BCR signaling regulates Par-4 expression, a welldefined tumor suppressor. Unlike the down regulation that is observed in many solid tumors
including prostate, lung, breast, and pancreatic, Par-4 is highly expressed in CLL. This finding
markedly suggested that Par-4 regulation is altered in CLL and indeed, we find its expression is
reliant on the BCR survival pathway in CLL. My studies showed that endogenous Par-4 is
regulating the growth of CLL cells and loss of expression delays CLL development. Upregulated
p21 expression is likely responsible for reduced growth in Par-4 knockdown cells. Additionally, I
find that Par-4 plays a role in secondary microenvironments of CLL by preventing CLL growth in
splenectomy models (summarized in Figure 7.1). This initial study is the first to closely examine
Par-4 and its regulation in CLL and its contribution to the complexity of the disease.
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Figure 7.1 Summary of the Role of Par-4 in B-cell Chronic Lymphocytic Leukemia

Par-4 has pleotropic roles within CLL. BCR signaling regulates Par-4 expression in CLL. Inhibition
of BCR signaling results in CLL cell death and therefore prevents growth. Par-4 inhibits the
expression of p21 which is known to block cell cycle progression. The inhibition of p21 by Par-4
leads to enhanced cell cycle progression and cell growth. Additionally, Par-4 has been found to
be secreted from cells. The absence of spleen, the primary microenvironment of CLL, leads to
reduced CLL growth and development.
Par-4 has been defined as a tumor suppressor and pro-apoptotic factor in many solid
tumors but we propose a different role for intrinsic Par-4 in this hematologic disease. This is
unconventional, but not the first case in which a molecule has variable roles in different
diseases, especially between solid and hematological-based tumors. As mentioned earlier, JNK
was defined as a pro-apoptotic factor that is activated in response to UV damage and stress
leading to apoptosis in fibroblasts, prostate cancer, and neuronal cells [301]. Other studies then
found that JNK is involved in survival signaling of BCR/ABL transformed leukemic cells leading to
increased B cell transformation [308]. The dual role in apoptotic and survival signaling makes the
function of JNK complex and dependent on the cellular context [301]. The additional role of Par-
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4 in CLL also makes it a complex protein and potentially provides another target for CLL-specific
therapy.
Additionally, this study is important as I have identified intrinsic Par-4 as a pro growth
factor in CLL which could have implications since Par-4 is currently a target of a clinical trial
[246]. Studies have found that the treatment of normal mouse and human cells with the antimalarial drug, chloroquine, induces Par-4 secretion [309]. Induced paracrine secreted Par-4
triggered apoptosis of cancer cells in a mouse lung tumor model. These results led to a clinical
trial where patients will receive hydroxychloroquine orally every day after tumor resection for
90 days. This clinical trial is still in the phase of recruiting patients and we are eager to see the
promising outcomes of Par-4 secretion for the treatment of solid tumors. I find that loss of Par-4
in the secondary microenvironments allows for CLL growth which would further support the
need for the clinical trial to prevent cancer growth. Also, the SAC transgenic animals that over
express the cancer specific pro-apoptotic domain of Par-4 do not show any signs of developing
leukemia [310]. Although this study did not quantify levels of the SAC domain in the plasma of
the animals, it is known that the SAC domain is secreted from normal cells [199]. Because my
studies prove only intrinsic Par-4 is responsible for promoting cell growth and I do not have
evidence to suggest that extracellular Par-4 is taken up by CLL cells to further promote
transformation or growth, I do not think inducing Par-4 secretion in the clinical trial would
increase that patient’s chance to develop CLL.
I find that Par-4 promotes the growth of CLL in the EμTcl1 mouse model and human
Mec-1 cell line. It would be interesting to identify an inhibitor of Par-4 directly to see if a
chemical modulator specific to this protein would result in decreased CLL progression in vivo as
well. BCR inhibition has been proven effective in the treatment of CLL, but combination
treatment towards other molecules that promote CLL growth could result in an improved
177

response. If inhibitors towards Par-4 could enhance the effectiveness of BCR inhibition, lower
doses would be necessary and therefore minimize any adverse side effects. Continued work to
identify other potential targets is critical to help patients fight CLL.
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